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Cognitive Function and Symptoms
Hypoglycaemia and Hyperglycaemia
Approx 32 000 (main text)
During
In the first chapter, the definitions, frequency, causes and consequences of clinical
hypoglycaemia are discussed. Previous research on the cognitive effects of acute
hypoglycaemia is reviewed in the second chapter. Four studies of the effects of blood
glucose manipulation on cognitive function are then described.
In Study 1, the effect of acute hypoglycaemia on memory consolidation was studied in
non-diabetic subjects. Functional brain imaging was used to identify regions with
altered metabolism following hypoglycaemia. No effect of hypoglycaemia was seen on
memory or brain imaging results, suggesting that acute hypoglycaemia does not affect
previously-formed memories, though other possibilities are discussed.
In study 2, the effects of acute hypoglycaemia on learning and recall were studied, and a
novel test of prospective memory, mimicking memory in real life, was developed.
Subjects had type 1 diabetes and either normal or impaired awareness of hypoglycaemia.
Both learning and recall were impaired during hypoglycaemia. Prospective memory was
impaired to a similar degree, reinforcing the ecological validity of laboratory cognitive
function testing. No statistically significant differences between normal- and impaired-
awareness subjects were seen, but this may have been due to lack of statistical power.
A previous study had unexpectedly reported that high-level cognitive functions were
unaffected by hypoglycaemia. Study 3 re-addressed this issue using a more difficult
cognitive test to exclude the possibility of a ceding effect, and impairment by
hypoglycaemia was confirmed. A separate task, intended to indicate which of speed and
accuracy of cognitive processing is primarily affected, yielded no significant results.
In study 4, the symptoms of hyperglycaemia reported by 400 people with insulin-treated
diabetes were examined using factor analysis. Four categories were identified, and
labelled as 'osmotic', 'neurological', 'mental agitation' and 'malaise'. Substantial overlap
with hypoglycaemia symptoms was noted. The mean blood glucose level for symptom
onset was 15 mmol/1, with a tendency for less intense symptoms and a higher symptom
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Chapter 1
Clinical and Biochemical Aspects of
Hypoglycaemia
1.1 Introduction
In type 1 diabetes there is total, or near-total, loss of insulin secretory function by the
pancreas; a principal feature of the condition is an elevated blood glucose level, or
hyperglycaemia. Insulin was isolated and used as therapy for type 1 diabetes in the
1920s by the Toronto pioneers Frederick Banting, Charles Best, James Collip and John
Macleod. Insulin was confirmed to lower the blood glucose level, but in large doses it
caused a new phenomenon: low blood glucose, or hypoglycaemia. Rabbits injected with
large doses of insulin were seen to become wildly hungry, then comatose, and then to
die. Similar (but less drastic) side effects were seen when the new substance was first
used in humans [1]. Insulin therapy has undergone numerous refinements, both
revolutionary and incremental, since then, which have permitted more precise control of
blood glucose levels. Despite these advances, hypoglycaemia remains a common and
feared side effect [2,3,4], At best, hypoglycaemia causes unpleasant symptoms that
require the person with diabetes to treat themselves to correct the condition. At worst,
hypoglycaemia can cause confusion or collapse, creating a risk of physical injury,
especially during potentially risky activities such as driving. More pervasively, the fear of
possible hypoglycaemia can engender a state of perpetual anxiety that may be a barrier
to a normal working or domestic life, and a barrier to achievement of the good
glycaemic control that is needed to prevent diabetes-related complications.
In part, hypoglycaemia persists as a clinical problem because the targets for glycaemic
control are continually being adjusted. The Diabetes Control and Complications Trial
showed that lowering blood glucose with intensive insulin therapy reduces the incidence
and progression of microvascular and macrovascular diabetes complications, at the
expense of an increased frequency of hypoglycaemia [5,6]. Advances in insulin therapy
and monitoring have permitted people with diabetes to achieve more physiological
insulin profiles. These improvements might be used to achieve a reduction in
hypoglycaemia for a similar level of glycaemic control, but it is arguably more important
that glycaemic control should improve for a similar (or slightly reduced) frequency of
hypoglycaemia. Thus, until insulin therapy is perfected (in the sense that blood glucose
can be contained entirely within the non-diabetic range), further improvements in
insulin therapy will not eradicate hypoglycaemia but will continue to offer the
opportunity to diminish the burden of either hypoglycaemia or hyperglycaemia.
It is hard to overstate the importance of hypoglycaemia in insulin-treated diabetes.
Were it not for the fact that an excess of insulin causes hypoglycaemia, it would be
possible to avoid all the complications of diabetes by simply increasing doses of insulin
to abolish hyperglycaemia. Since hypoglycaemia appears to be a significant but
necessary evil in the management of diabetes mellitus with insulin, it is important that
we should understand its causes and effects. An enormous body of research has
developed on the topic, some ofwhich is discussed in this chapter and the next.
1.2 Definitions of Hypoglycaemia
Although the definition of hypoglycaemia as 'a low blood glucose level' is simple, the
type of blood in which glucose is measured is important. Arterial blood supplies
glucose to tissues, and so the arterial plasma glucose concentration is the gold standard
measurement. However, arterial sampling is invasive and can be painful, so venous or
capillary measurements are more often used in clinical practice. It is important to
remember that under conditions such as cold (when peripheral blood flow is reduced)
or vigorous exercise (when peripheral glucose uptake is increased), venous or capillary
glucose measurement may be a poor index of 'glycaemia' [7]. Also, clinical laboratory
measurements are in plasma glucose, to remove the confounding effect of a variable
haematocrit. Near-patient measurements and measurements in many research studies
are in whole blood, which typically yields results that are 10-20% lower than the
equivalent plasma glucose concentration [8].
1.2.1 Biochemical definitions by population norms
In theory, a biochemical definition of hypoglycaemia may be derived by reference to the
normal range of blood glucose in healthy people. Service, in a generally excellent review
article, stated that healthy people will usually maintain venous plasma glucose between
3.3 and 5.6 mmol/1, except in the immediate post-prandial period. He also stated that
"normal persons may have plasma glucose levels well below 50 mg per deciliter [2.8
mmol/1] while fasting" and recommended that a plasma glucose below 45 mg/dl (2.5
mmol/1) be required to diagnose a hypoglycaemic disorder [9].
Closer consideration of the issue shows that it is impossible to create a single
biochemical definition of hypoglycaemia. It is not uncommon for apparently healthy
people to experience frequent symptoms suggestive of a low blood glucose level, often
shortly after eating a meal. In earlier decades, 'functional' or 'post-prandial'
hypoglycaemia had been fashionable diagnoses, the investigation of which had occupied
considerable resources for little appreciable benefit [10,11]. Service appears to have
been promoting a pragmatic approach, so that a disease label is attached only to
conditions that without treatment are likely to progress to cause other, more serious,
morbidities — such as insulinomas, liver disease, adrenal failure and metabolic storage
disorders. However, the same evidence showing that profoundly low blood glucose
levels are very rare in 'functional hypoglycaemia' also shows both that symptoms are
more common when capillary blood glucose is below 3.3 mmol/1, and that blood
glucose levels below 3.3 mmol/1 are more common in people with symptoms [12].
More prosaically, personal experience relates that almost everyone experiences milder
versions of the classical symptoms of hypoglycaemia after exercise or fasting. As will be
discussed later, these symptoms prompt the ingestion of food, and are part of the
body's homeostatic mechanisms for glucose. The fact that very low glucose levels may
be seen in healthy people during a prolonged period of intentional food avoidance (e.g.
the 72-hour fast) does not mean that these are 'normal'.
Thus, the population does not categorize neatly into 'unhealthy' and 'healthy' people
who do and do not suffer hypoglycaemia, and a biochemical definition based on the
population distribution of blood glucose levels is unsatisfactory. Hypoglycaemia is
better defined with reference to its effects.
1.2.2 Biochemical definitions of hypoglycaemia by its effects
Progressive, experimentally-induced hypoglycaemia produces a hierarchy of responses
which are summarized in Figure 1.1 (derived from Schwartz et al [13] and Mitrakou et al
[14]). The earliest response is the release of epinephrine, glucagon and growth
hormone, which tend to slow or reverse the fall in blood glucose. This
counterregulatory response begins at an arterial blood glucose level of approximately 3.8
mmol/1, and may be taken as evidence that the body 'perceives' an abnormality.
Alternatively, the onset of symptoms at around 3.0 mmol/1 may be considered more
important. However, other conditions such as anxiety or alcohol intoxication may
produce the same symptoms or behaviours. A definition of hypoglycaemia based on
symptoms alone would be extremely unreliable, and such definitions are only rarely used










Figure 1.1. Glycaemic thresholds for initiation of various hypoglycaemic
responses. Based on data from Schwartz et al [13] (light bars) and Mitrakou et
al [14] (dark bars).
An important consideration is that the level of blood glucose at which a statistically
significant change is first detected is not necessarily the level at which the hypoglycaemic
response begins. Mild hypoglycaemia may cause only a small increase in symptom
scores which fails to achieve statistical significance. In both Schwartz et al [13] and
Mitrakou et al [14], 10 subjects were studied, which may not provide much statistical
power. Thus, it is more accurate to say that the evidence shows that hormonal
counterregulation begins somewhere above, but close to, 3.8 mmol/1, and that
symptoms begin somewhere above, but close to, 3.0 mmol/1. This appears to be more
compatible with anecdotal reports of simple hunger and tiredness at blood glucose
levels between 3 and 4 mmol/1 in both non-diabetic people and people with diabetes.
In diabetes, as will be discussed later, glycaemic thresholds for counterregulation,
symptoms and cognitive function appear adapt to prevailing blood glucose levels (which
may be very high or very low) in diabetes. Thus, it is possible for a person with diabetes
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to have a blood glucose level of 2.5 mmol/1 and to feel normal, with no detectable
cognitive impairment or counterregulatory activity. However, it is sensible to consider
these episodes as hypoglycaemia, since the adaptation is itself a consequence of a
metabolic disorder and, as will also be discussed later, is not entirely benign.
People with diabetes with chronically elevated blood glucose levels may experience
symptoms of low blood glucose at blood glucose levels above 4.0 mmol/1. As will be
discussed later, this acute state is probably benign (though the chronic hyperglycaemia is
not), but it is clinically relevant because the sensation of hypoglycaemia affects the
person's management of their diabetes.
1.2.3 Definition of severity of hypoglycaemia
It is almost universally accepted that the most useful distinction in terms of severity is
between those episodes of hypoglycaemia that are self-treated, and those for which
assistance is required. Thus, 'mild' hypoglycaemia is self-treated and 'severe'
hypoglycaemia requires third party assistance.
This definition remains a little subjective, as whether assistance is given depends on
whether it is available, and on the beliefs and attitudes of the victim and any third
parties. It is possible that a person with diabetes may eventually, and with difficulty,
self-treat an episode of hypoglycaemia (labelled mild) for which they would have wished
assistance had they been in company (labelled severe). The nature of assistance given
(e.g. encouragement to eat, buccal glucose administration or parenteral therapy) is highly
dependent upon individual circumstances, and therefore not a guide to severity.
1.2.4 Conclusions regarding hypoglycaemia definitions
There can be no single definition of hypoglycaemia. One reasonable biochemical
definition would be a blood glucose level below 3.0 mmol/1, in the sense that it in
healthy people it rarely occurs, and when induced experimentally is associated with
symptoms, hormonal responses and adverse effects on cognition. This definition is
specific but not sensitive: it may misclassify milder episodes that nonetheless cause
recognisable symptoms, and if caused by insulin therapy, may progress to cause harm if
left untreated.
A reasonable clinical definition would be a modification of Whipple's triad: a
combination of typical symptoms, a blood glucose low that is subjectively low for that
person, and relief of symptoms when blood glucose is raised [15]. However, this
definition fails to include asymptomatic hypoglycaemia in persons with impaired
awareness of hypoglycaemia. Such episodes are important, as they can be markers for a
condition that is not benign (see sections 1.6 and 2.5).
In clinical practice, people with diabetes are often advised to consider a blood glucose
level below 4.0 mmol/1 as hypoglycaemic, and Diabetes UK (the principal charity for
people with diabetes in this country) make this recommendation [16]. It includes a
sensible margin of safety, allowing for the possibility that the blood glucose level may be
falling, for measurement error and for individual differences in glycaemic thresholds.
1.3 Frequency of hypoglycaemia in insulin-treated
diabetes
1.3.1 Frequency of hypoglycaemia and glycaemic control
Insulin-treated diabetes is characterized by erratic rises and falls in blood glucose. Not
every fall will result in blood glucose dipping into the hypoglycaemic range; the
frequency with which this occurs is also dependent on the prevailing level of blood
glucose. This is illustrated in Figure 1.2, which shows the same hypothetical glucose
excursion at two levels of glycaemic control. It is apparent that the frequency of
hypoglycaemia will be increased in people with diabetes who achieve low average blood
glucose levels ('strict glycaemic control').
Figure 1.2. The same glucose excursion results in more hypoglycaemia when
glycaemic control is strict (diagonal hatching) than when glycaemic control is
relaxed (cross hatching).
This is borne out in results from surveys and clinical trials. Frequency of hypoglycaemia
increased as median blood glucose concentration decreased in a study by Thorsteinsson
et al [17]. The frequency of mild and severe hypoglycaemia was increased roughly two-
to threefold in patients with type 1 diabetes allocated to intensive glycaemic control in
the Diabetes Control and Complications Trial [5|. In the United Kingdom Prospective
Diabetes Study of type 2 diabetes, both minor and major hypoglycaemic episodes
occurred approximately twice as often in the intensively-treated group as in the
conventionally-treated group (based on intention-to-treat analysis; there was
considerable crossover between treatment types within groups) [18]. Thus, estimates of
hypoglycemia frequency in diabetic patients as a whole conceal a wide individual
variation in rates of hypoglycaemia.
1.3.2 Frequency of mild hypoglycaemia
The average frequency of mild hypoglycaemia in type 1 diabetes has been reported as
about once to twice per week [3,4]. However, this probably underestimates the rate of
biochemical hypoglycaemia, which can only be detected if symptoms are generated and
identified, or by chance on routine testing. The use of continuous glucose monitoring
systems (CGMS) has demonstrated that asymptomatic hypoglycaemia is extremely
common. Bode et al reported an average of 2.1 episodes of biochemical hypoglycaemia
(defined as blood glucose <3.9 mmol/1) per day in patients with type 1 diabetes, with
patients being hypoglycaemic for 8% of the monitoring period [19]. Chico et al also
detected frequent asymptomatic events with CGMS [20], and in both studies
hypoglycaemia was especially frequent during the night. These may be overestimates, as
CGMS devices have only been shown to have good accuracy when a more stringent
definition of hypoglycaemia is used (< 2.2 mmol/1), but the frequency of asymptomatic
nocturnal hypoglycaemia has also been clearly demonstrated in earlier laboratory-based
studies [21,22].
In type 2 diabetes, frequency estimates are lower overall, but more variable, ranging
from approximately five to 30 episodes per person per year. This is likely to reflect the
different treatment options (oral medication or insulin) and the progression of the
condition from milder insulin resistance or deficiency to an increasingly insulin-deficient
state resembling type 1 diabetes [23].
1.3.3 Frequency of severe hypoglycaemia
In population surveys, estimates of the incidence of severe hypoglycaemia in type 1
diabetes range from 1.0 to 1.7 episodes per person per year, with annual prevalences of
30 to 40% [4,24,25,26]. The Diabetes Control and Complications Trial reported lower
frequencies of 0.19 (conventional treatment group) and 0.62 (intensive) episodes per
year, which must be at least partly due to the highly selected patient group [5]. Patients
with two or more episodes of severe hypoglycaemia in the preceding two years were
excluded from the DCCT, based on a pilot feasibility study which had shown that such
patients were at high risk for recurrent severe hypoglycaemia with intensive treatment.
For type 2 diabetes, population surveys have reported incidences ranging between 0.07
and 0.73 episodes per year per person [23]. The incidence is again lower in clinical trials:
the United Kingdom Prospective Diabetes Study reported incidence rates of
approximately 0.02 episodes per person per year in the intensively-treated group [18].
1.4 Causes of hypoglycaemia in insulin-treated
diabetes
In diabetes, all episodes of hypoglycaemia result from a mismatch between insulin
activity and insulin requirement. This is often considered to mean the balance between
insulin dosing and food intake. Failure to reduce insulin doses when meals are reduced
or omitted is probably to blame for many episodes of hypoglycaemia, but there are
many other factors which affect the balance between insulin activity and requirement.
These may be divided into those which occur daily as a result of inherent difficulties
with subcutaneous insulin, and those which arise in special circumstances.
1.4.1 Common causes of hypoglycaemia
Insulin activity profile. In non-diabetic humans, the rise in blood insulin levels following a
standard meal lasts in the region of 2 hours [27]. By contrast, soluble human insulin
(e.g. Actrapid, Humulin S) given by subcutaneous injection peaks at 2-4 hours and has a
total duration of action of 8-10 hours. The modern insulin analogues lispro and aspart
peak earlier at 1-2 hours and have a shorter duration of action of around 5-8 hours
[28,29], although they still do not quite match non-diabetic post-prandial insulin
secretion. A dose of insulin that is adequate to control post-prandial hyperglycaemia
will therefore tend to cause hypoglycaemia around 3-4 hours after a meal. In practice,
people with insulin-treated diabetes must choose insulin doses that are a compromise
between control of hyperglycaemia and avoidance of hypoglycaemia. Similar problems
exist with the longer-acting isophane, lente and ultralente preparations of human insulin,
which are often used to provide overnight insulin, but peak around 2-6 hours after
injection and therefore tend to cause nocturnal hypoglycaemia.
Insulin absorption. Under laboratory conditions, the coefficient of variation for the
activity of a given dose of insulin may be as high as 60% [30]. In other words, the same
dose of insulin given on different days may have markedly different effects on blood
glucose, even when other factors are controlled.
Infrequent blood glucose testing. Many people with insulin-treated diabetes find blood
glucose measurement uncomfortable and inconvenient, and do not measure blood
glucose frequently. However, estimation of blood glucose levels on the basis of
symptoms is unreliable [31,32,33]. The effects of recurrent hypoglycaemia on symptom
generation will be discussed later in section 1.6.
Meal constitution. For a given amount of total carbohydrate, a starchy meal will release
monosaccharides more slowly than a meal containing simple sugars, and thus will cause
a smaller but more prolonged rise in blood glucose levels. This is reflected in the
concept of glycaemic index (GI). The rate of absorption of a meal also varies with its
fat and liquid content [34,35],
1.4.2 Special circumstances that may contribute to hypoglycaemia
Exercise. Glucose is utilized by muscles during exercise, independent of circulating
insulin levels, and hypoglycaemia may occur during or following exercise if appropriate
corrective action is not taken. Less obviously, there is a delayed risk of hypoglycaemia
after exercise has ceased; this may last up to 24 hours, with nocturnal hypoglycaemia
being particularly likely without corrective action [36].
Stress. Both physical and emotional stress can cause release of adrenaline, Cortisol and
other hormones that tend to cause hyperglycaemia. This leads to a fluctuating increase
in insulin requirements, with erratic blood glucose levels as a result, and hence an
increased risk of hypoglycaemia.
Gastroparesis. Abnormal gastro-intestinal motility, believed to be a consequence of
autonomic neuropathy, results in delayed and less predictable absorption of food
following meals [37].
Illness. Illness may cause hypoglycaemia through reduced enteric carbohydrate
absorption (anorexia, vomiting, and malabsorptive disorders such as coeliac disease).
Hypoadrenalism predisposes to hypoglycaemia. Renal failure reduces insulin clearance
and hence increases insulin activity for a given dose.
Drugs and toxins. Alcohol suppresses hepatic glucose output, with the result that the risk
of nocturnal hypoglycaemia is increased following evening alcohol intake. Some drugs,
including ACE inhibitors and disopyramide, appear to increase insulin sensitivity
[38,39]. Withdrawal of drugs that cause insulin resistance (e.g. systemic corticosteroids)
also results in a relative increase in insulin sensitivity.
1.5 Effects of hypoglycaemia
At the head of any such list should be the potential effects of hypoglycaemia on the
home, educational and working life, and emotional wellbeing of the person with
diabetes. These psychosocial aspects of hypoglycaemia have been reviewed extensively
elsewhere, but are outwith the scope of this thesis, the subjects of which are primarily
the symptoms and cognitive effects of altered glucose metabolism.
1.5.1 Hormonal responses to hypoglycaemia
The effects of different levels of hypoglycaemia in healthy humans have been defined by
experiments in which progressive hypoglycaemia was induced. These have been
summarized in Figure 1.1, and begin with the release of counterregulatory hormones,
including glucagon, adrenaline, Cortisol and growth hormone at blood glucose levels of
approximately 3.8 mmol/1. The hormonal responses are counterregulatory, triggering a
corrective rise in blood glucose.
1.5.2 Symptom responses to hypoglycaemia
The symptoms of hypoglycaemia begin at, or a little above, a blood glucose level of 3.0
mmol/1 (also summarized in Figure 1.1). The symptoms of hypoglycaemia have been
studied using factor analysis, a statistical technique that identifies separate groups of
symptoms that correlate strongly [40,41]. The value of this approach rests on the
probability that symptoms that occur together are caused by the same underlying
physiological process. The two main groups have been interpreted as representing the
autonomic (or adrenergic) effects of hypoglycaemia, and neuroglycopenia (confusion
and other manifestations of cerebral dysfunction) (Table 1.1). Symptoms attributed to
the hormonal and adrenergic nervous system reactions include tremor, sweating,
increases in heart rate and reduced salivation. Symptoms attributable to tissue
glycopenia (specifically affecting the brain, i.e. neuroglycopenia) include confusion, loss
of coordination and drowsiness.
Of the symptoms in Table 1.1, hunger can be considered one of the counterregulatory
mechanisms because it triggers corrective behaviour (ingestion of food). In factor
analysis, hunger co-segregated with the autonomic symptoms, although other evidence
indicates that hunger is generated in brain regions that are directly triggered by other
glucose-sensing brain region(s) rather than via adrenergic mediators [42,431. It should
be noted that applying factor analysis to symptom scores will identify symptoms that
tend to occur together, rather than necessarily sharing the same physiological cause.
The 'autonomic' symptoms show significant adaptation to recurrent hypoglycaemia,
whereas cognitive adaptation appears to occur to a limited extent only (discussed in
more detail in sections 1.6 and 2.5). An alternative interpretation of the factors in Table
1.1 is: (1) typical symptoms triggered by cerebral glucose sensing — may become
significantly diminished or lost; (2) typical symptoms directly due to cerebral glucose
privation — may adapt a little; (3) non-specific physical symptoms.





Shaking Odd behaviour Headache
Hunger Speech difficulty
Incoordination
Table 1.1. Symptoms of hypoglycaemia grouped by factor analysis.
Based on [40,41].
1.5.3 Cognitive effects of hypoglycaemia
Measurable cognitive dysfunction may begin at a slightly lower blood glucose level
(around 2.8 mmol/1 in non-diabetic humans) than is required for the onset of
symptoms. Subsequently more severe cognitive dysfunction develops, and loss of
consciousness, convulsion, coma, and ultimately brain damage and death occur as blood
glucose levels fall below about 1.5 mmol/1. Cognition during hypoglycaemia is
discussed in detail in Chapter 2.
1.6 Adaptation to hypoglycaemia and impaired
awareness of hypoglycaemia
In insulin-treated diabetes of long duration, a lower blood glucose level may be required
for generation of hypoglycaemic symptoms, and the intensity of symptoms felt at a
given level of hypoglycaemia may be diminished. This phenomenon has been referred
to as impaired hypoglycaemia awareness; 'hypoglycaemia unawareness' is less
appropriate, as it is rare that no symptoms are experienced at all. When a person with
diabetes has diminished warning symptoms for hypoglycaemia, their ability to take
appropriate action to avoid severe hypoglycaemia is limited. The frequency of severe
hypoglycaemia has been shown to be increased in patients who report impaired
hypoglycaemia awareness (44,45,46].
Experimental research has demonstrated that counterregulatory failure is associated with
impaired hypoglycaemia awareness. As detailed above in section 1.5, release of
hormones including glucagon, adrenaline (epinephrine), Cortisol and growth hormone
occurs in the early stages of hypoglycaemia in non-diabetic humans. All of these
hormones have a hyperglycaemic effect, though glucagon and adrenaline are the most
potent. In type 1 diabetes, the adrenaline (epinephrine) response to hypoglycaemia
becomes attenuated, although does not disappear entirely [47,48]. The glucagon
response is diminished early in the course of type 1 diabetes, and within a few years
becomes negligible or non-existent. It has long been known that patients who do not
mount a glucagon response to hypoglycaemia can secrete glucagon in response to
arginine infusion [47]. This paradox appears to have been explained recently by the
'intra-islet hypothesis', which postulates that glucagon release in response to
hypoglycaemia also requires a fall in intra-islet insulin concentration, and hence a
reduction in tonic a-cell inhibition [49]. In type 1 diabetes, intra-islet insulin
concentrations are close to zero at all times and no such fall is possible. Support for this
hypothesis is given by studies in non-diabetic humans: when islet insulin secretion is
prevented from falling by administration of sulphonylurea [50], or suppressed in
advance of hypoglycaemia by administration of diazoxide or somatostatin [51,52], the
glucagon response to hypoglycaemia is diminished.
The relative importance of these endocrine responses in the prevention of severe
hypoglycemia has been reviewed by Cryer, based on studies in healthy adults in whom
secretion of glucagon and growth hormone was inhibited by infusion of somatostatin
and adrenergic effects were inhibited by combined a- and p-blockade, and in adults
with bilateral adrenalectomy [53]. Hypoglycaemia was induced by bolus insulin
injection, and the time taken for the blood glucose level to recover was determined for
various combinations of hormonal suppression and replacement. These studies show
persuasively that, in the absence of food ingestion, (i) sole adrenaline deficiency or
blockade has little effect on recovery from hypoglycaemia; (ii) sole glucagon deficiency
slows but does not abolish recovery from hypoglycaemia; (iii) combined glucagon and
adrenaline deficiency/blockade abolishes recovery from hypoglycaemia. As described
earlier, it seems that the glucagon response must inevitably be lost in type 1 diabetes.
Recovery from hypoglycaemia therefore depends on (i) the adrenaline response, which
diminishes with time; and (ii) symptom detection.
The symptoms of hypoglycaemia are diminished, and occur at lower blood glucose
levels, both in diabetes of long duration by comparison with shorter duration [3,44,54]
and in strict glycaemic control by comparison with poor glycaemic control [55,56].
Strict glycaemic control is also associated with attenuated catecholamine responses to
hypoglycaemia [57]. An obvious possible mechanism is adaptation to hypoglycaemia, as
patients who have strict glycaemic control and/or long duration of diabetes will have
had greater cumulative exposure to hypoglycaemia. Confirmation of this is given by
studies of the effects of antecedent hypoglycaemia on responses to hypoglycaemia in
non-diabetic [58] and type 1 diabetic humans [59,60]. In each of these studies, a
preceding period of hypoglycaemia resulted in attenuated symptoms and hormonal
counterregulation during a hypoglycaemic clamp. In people with type 1 diabetes, careful
avoidance of hypoglycaemia through meticulous insulin control has been shown to
partially reverse this adaptation with respect to symptoms and adrenaline release;
glucagon secretion remained negligible, as would be predicted by the intra-islet
hypothesis [61,62,63],
In summary, impaired hypoglycaemia awareness is a common complication of insulin-
treated diabetes, and appears to be a maladaptive response to recurrent episodes of
iatrogenic hypoglycaemia. The principle defences against hypoglycaemia are secretion
of glucagon and adrenaline, and ingestion of food prompted by symptom detection.
The first defence (glucagon) is abolished in type 1 diabetes, and the second (adrenaline)
and third (symptoms) become impaired, but this would be of little consequence were it
not for the cognitive effects of hypoglycaemia. If hypoglycaemia had no effect on
cognitive function, then a diabetic person with impaired hypoglycaemia awareness
would simply treat themselves when they detected symptoms at a lower blood glucose
level. However, cognitive impairment does occur, which both prevents self-treatment
and can cause dangerous or inappropriate behaviour. Therefore, continuing the
argument of section 1.1, it can be argued that it is not hypoglycaemia per se but its effects
on cognitive function that prevent people with diabetes simply increasing insulin doses
until hyperglycaemia is abolished. Hypoglycaemic cognitive function is clearly a critical
issue, and will be discussed in the next chapter.
1.7 Hyperglycaemia
Hyperglycemia is the hallmark of diabetes, but its symptoms and effects on cognition
have received less research attention than have the effects of hypoglycaemia. This is
doubtless because hypoglycaemia is an acute state that can cause dramatic symptoms
and endanger physical safety, whereas the symptoms and consequences of
hyperglycemia are more insidious or chronic. Nonetheless, there is potential value in
researching acute hyperglycaemia:
i. Acute hyperglycaemia may have acute effects on mental or physical performance
that have not been recognised or well described.
ii. Awareness of hyperglycemic symptoms may allow individuals to take action to
correct hyperglycaemia, diminishing any acute effects, and helping to improve
chronic glycaemic control.
1.7.1 Effects of Hyperglycaemia on Cognition and Mood
A number of studies have examined cognitive function during acute hyperglycaemia.
Cox et al assessed this in the field, by issuing patients with type 1 diabetes with hand¬
held computers containing electronic versions of cognitive function tests [64]. Patients
were instructed to perform these tests immediately before routine blood glucose testing;
cognitive performance was then analysed in five categories of blood glucose. Their
results appear to show that a blood glucose >15 mmol/L is associated with impaired
verbal fluency, arithmetical ability and simple reaction time. However, the statistical test
(an ANOVA comparing all five categories) was inappropriate for this purpose.
In glycaemic clamp studies, Pais et al found no effect of mild hyperglycaemia (10.5
mmol/L) on memory and attention tasks in subjects with type 2 diabetes [65], and
Gschwend et al found no effect of marked hyperglycaemia (20 mmol/L) on reaction
time or Trail Making B performance in children with type 1 diabetes aged 9-19 years
[66]. However, in a comprehensive study from Edinburgh, Sommerfield et al found that
performance on Digit Symbol Substitution, Trail Making B, choice reaction time, and
some aspects of working memory and attention were significantly impaired at 16.5
mmol/L in subjects with type 2 diabetes [67]. Furthermore, Sommerfield et al also
found an effect of hyperglycaemia on mood: in specific questionnaires, subjects
indicated reduced levels of happiness and alertness, and more agitation.
1.7.2 Symptoms of Hyperglycaemia
Clinical experience tells us that the symptoms of hyperglycaemia include thirst, polyuria
and dryness of mucous membranes [68]. Although the value of clinical experience and
anecdotal evidence should not be underestimated, only a few research studies have
attempted to corroborate this.
Pennebaker et al and Cox et al, in studies from the same centre, asked patients with type
1 diabetes to rate the intensity of certain symptoms before blood glucose testing, both in
hospital and in the community [69,70]. Symptom intensity could then be paired with
blood glucose result, to identify symptoms of hypo- and hyperglycaemia. The only
symptom that was clearly associated with hyperglycaemia was "Dry eyes, nose or
mouth", though "Sweet taste" and "Salivation" also had some endorsement. The
studies were rather odd, in that other obvious symptoms of hyperglycaemia such as
thirst and polyuria were not included, and hyperglycaemia appeared to be defined as a
blood glucose level >110mg/dL (6.1 mmol/L). The same group have developed an
educational programme, "Blood Glucose Awareness Training" (BGAT), based m part
on teaching people with diabetes to recognise the symptoms of hypo- and
hyperglycaemia. One randomized, controlled trial showed no benefit of BGAT for
either hypoglycaemia frequency or HbAlc [71], A later trial showed a reduction in
frequency of severe hypoglycaemia, and improved detection of both hypoglycaemia and
hyperglycaemia, though again without benefit to HbAlc [72].
Overall, the symptoms of hyperglycaemia have not received detailed assessment. Unlike
hypoglycemic symptoms, the usual sensations that are experienced by people with
diabetes have not been clearly described, and their physiological causes are not
understood beyond an assumption that osmotic fluid shift is important. Although the
main focus of this thesis is cognition during hypoglycaemia, Chapter 7 describes a study
of hyperglycaemic symptoms in people with diabetes.
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Chapter 2
Cognitive Function and Hypoglycaemia
2.1 Brain metabolism
The human brain normally depends entirely on glucose for its energy. Confirmation of
this is given by the respiratory quotient (RQ), the ratio of CO2 produced to O2
consumed. This approaches 1.0 when carbohydrate oxidation is the sole fuel, and for
the brain the RQ has been experimentally calculated as 0.97 [1], with a small proportion
of glucose ending up in other chemicals including the neurotransmitters GABA,
acetylcholine, aspartate and glutamate [2]. The glycogen content of the brain is
sufficient for only 4-5 minutes of normal energy use [3]. Potential fuels other than
glucose include ketone bodies, lactate and amino acids, although the contribution that
these make to brain metabolism in the acute phase is thought to be minimal [3]. Acute
hypoglycaemia therefore causes immediate energy deficiency in the brain, rescued only
by correction of the blood glucose level. This energy deficiency is assumed to be the
cause of cerebral dysfunction, of which one manifestation is cognitive impairment.
The blood-brain barrier prevents simple diffusion of water-soluble molecules such as
glucose, which cross instead by facilitated diffusion via the glucose transporters GLUT1
to GLUT5. Transport of glucose has been considered insulin-independent on the basis
of studies showing no increase with hyperinsulinacmia [4,5,6] although recent evidence
has indicated that physiological insulin concentrations increase brain glucose uptake by
comparison with sub-physiological concentrations [7].
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2.2 Cognitive impairment during hypoglycaemia
2.2.1 Confirmation of cognitive dysfunction during hypoglycaemia
Fletcher & Campbell provided perhaps the earliest report of cognitive dysfunction [8],
describing instances of accidental hypoglycaemia associated with the newly-discovered
insulin therapy. The authors described loss of fine motor function, dysarthria and
confusion, and also noted that the blood glucose level at which these changes occurred
varied from patient to patient. Numerous descriptions of hypoglycaemic cognitive
dysfunction followed, although the first known attempt to study this formally was not
until 1975 [9]. This study reported impaired motor coordination and word recall, and
slower (but not less accurate) performance on a reasoning task. Holmes and colleagues
expanded on this work in the 1980s, studying both diabetic and non-diabetic subjects,
and finding that relatively mild hypoglycaemia (3.0 to 3.4 mmol/1) resulted in
impairment of several different aspects of cognitive function, including reaction time,
mathematical computation, and verbal fluency [10,11,12,13].
The literature in this area expanded rapidly over the next decade, with many aspects of
cognitive function being studied during hypoglycaemia. Results of studies that have
examined cognitive function during moderate hypoglycaemia are summarized in Table
2.1 (excluding studies in which glycaemic thresholds were estimated, discussed in
section 2.3). This subject has been comprehensively reviewed by Deary [14,15], but
broadly speaking, the following cognitive functions have consistently been shown to be
impaired by moderate hypoglycaemia (2.0 to 3.4 mmol/1): visual and auditory reaction
time, mathematical computation, verbal fluency, and number recall. Other aspects of
cerebral function, such as fine motor control, have also shown impairment, though
there is some debate as to whether these meet the generally understood meaning of
'cognitive function'.





Finger tapping 3.05 [16] 2.0 [17]
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Table 2.1. Summary of studies reporting performance on cognitive
function tests as impaired and unimpaired at various blood glucose levels.
'Impaired' generally means a statistically significant (P<0.05) reduction in
score; 'unimpaired' generally means failure to achieve the same.
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2.2.2 The meaning of cognitive function testing
When a hypoglycaemia study is devised, the choice of cognitive function test is limited
by a number of practical requirements. It must be possible to perform the test in a
recumbent position with one hand; the test must yield an objective, numerical score; and
usually, the test duration must be no more than a few minutes. The duration of the test
is particularly important in studies that seek to determine glycaemic thresholds for
cognitive dysfunction, as testing at multiple time points is required. As Table 2.1 shows,
four of the most commonly-used tests are choice reaction time, Trail-Making B, Digit
Symbol Substitution and the Stroop ink colour tasks. There are at least two problems
when it comes to interpreting performance on these tasks.
Firstly, for these and most other tests, there is no agreed account of the cognitive
abilities which are engaged. For example, in Trail-Making B subjects are required to
connect letters and numbers in the sequence l-A-2-B-3-C-etc. from a 5x5 grid in which
they have been randomly distributed. Consideration of the task suggests that working
memory (remembering which letter or number comes next), visual scanning (finding
that letter or number) and hand-eye coordination (joining letters and numbers in a 'trail')
must all be involved. These abilities seem to be separate, but this is little more than
intuition, and there is no guarantee that they utilize different cerebral pathways.
Furthermore, if Trail-Making B performance is impaired during hypoglycaemia, we
cannot say whether this is because of effects on all, some, or only one of these cognitive
abilities. It is possible that performance decrements are due to a very non-specific effect
such as global cognitive deterioration, or even difficulty paying attention; moderate
hypoglycaemia has been demonstrated to impair performance on tests considered to
measure attention in both diabetic [37] and non-diabetic subjects [38].
Secondly, for most of the commonly-used tests, what is measured is cognitive speed.
Reaction time, the Stroop tasks and Trail Making are measured as completion time.
Digit Symbol Substitution and finger-tapping are measured as the number of
substitutions or taps completed in a set time. Thus, most studies that have reported
cognitive impairment during hypoglycaemia have actually shown slowing of cognitive
function. Omitting this detail ignores the potential trade-off between speed and
accuracy or absolute ability, and may overstate the real-life importance of the
hypoglycaemic effect. Holmes et al reported that subjects completed fewer
mathematical computations and Stroop tasks during hypoglycaemia, but achieved the
same proportion of correct answers (10,11]- In studies of attention during
hypoglycaemia, completion time rather than accuracy was impaired [37,38], and studies
using heterogeneous test batteries have reported greater deterioration on timed than
non-timed tests [21,34].
Two strategies have been adopted to attempt to sidestep the uncertain meaning ofmost
cognitive tests. The first involves narrowing the experimental scope to measurement of
fundamental brain processes during hypoglycaemia. Many researchers have studied the
effects of hypoglycaemia on the P300 wave, which is a brain evoked potential that is
detected approximately 300 milliseconds after presentation of an auditory or visual
stimulus. Delay or attenuation of the P300 wave is associated with poorer cognitive
performance, and has been reported during hypoglycaemia in numerous studies
[39,40,41,42,43,44,45]. Aspects of auditory information processing, including volume
and temporal discrimination but not pitch discrimination, are impaired in both diabetic
and non-diabetic subjects [32,46]. Similarly, aspects of visual information processing,
including inspection time, visual change detection and movement detection but not
visual acuity, are impaired in diabetic and non-diabetic subjects [29,31,47], However,
the difficulty here is in the real-life relevance of these results. Activities in daily life
result are complex and are achieved by the integration of multiple cerebral processes.
There is no evidence that a statistically significant increase in visual inspection time
under laboratory conditions may be translated into (for example) a meaningful
deterioration in driving ability, and thus the ecological validity of these cognitive tests is
questionable [48].
The second strategy is to broaden the cognitive function tests, to the point that a
minimum of extrapolation to daily activities is required. Mathematical computation is,
as mentioned above, impaired during hypoglycaemia [14,15]. Another ability that is
important in daily life, and has been studied during hypoglycaemia, is driving. Cox et al
performed two studies in subjects with type 1 diabetes using a driving simulator, which
is not a perfect replica but is a much closer approximation than measurements of
reaction time and visual inspection speed [49,50]. Overall driving performance was
impaired by mild hypoglycaemia (3.6 mmol/1 in the earlier study and ~3.0 mmol/1 in
the latter), with a tendency to veer off course, drive too fast and brake inappropriately.
There is some evidence that motor vehicle accident rates are higher for diabetic drivers
than for non-diabetic drivers [51], and although the literature is not consistent on this
subject [52,53], this does support a real-life correlation for laboratory hypoglycaemia
studies.
2.2.3 Experimental design and methodology
A major problem with the body of research on hypoglycaemic cognitive function is the
difficulty of comparing results from different studies. There are many instances where
different studies appear to show conflicting results — for example, performance on a
particular cognitive test being impaired during hypoglycaemia in one study but not in
another. Much of the disagreement is likely to have resulted from deficiencies and
differences in experimental methods, as discussed by Heller & Macdonald [54], which
include:
Degree of hypoglycaemia. The target blood glucose has varied widely, between 1.5 and 3.6
mmol/1.
Blood sampling. Arterial blood glucose measurement is the direct measure of glucose
supply to tissues, but arterial cannulation is a relatively difficult and painful procedure.
Venous blood glucose is much easier to measure, but is not perfectly correlated with
arterial glucose, as the proportion of glucose taken into tissues increases with
hypoglycaemia. Many studies have used arterialized venous blood sampling, where
venous blood is taken from a hand that is placed within a heated box to increase blood
flow and create a partial arteriovenous shunt [55], This reduces, but does not negate,
differences between arterial and venous sampling.
Measurement of glucose concentration. Glucose concentration may be measured in whole
blood or in plasma. Plasma glucose concentrations are typically 10-20% higher than the
equivalent whole blood concentrations [56],
Method of induction of hypoglycaemia. In earlier studies, uncontrolled hypoglycaemia was
induced by bolus injection of insulin. The rate of fall of blood glucose could not be
kept constant to ensure equivalent hypoglycaemia in all subjects, nor could the effects of
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prolonged hypoglycaemia be studied. Later, researchers infused insulin at a variable rate
aiming to maintain a target blood glucose level, but the delayed effect of insulin infusion
adjustments meant that this remained inaccurate. The hyperinsulinaemic glucose clamp
has been in general use for the last 15 years [57], and involves infusion of insulin at a
high, fixed rate which is intended to saturate insulin receptors and deliver a maximal
hypoglycemic response. Simultaneously, glucose is infused at a variable rate to achieve
target blood glucose concentrations. This method allows the design of studies such that
subjects are exposed to identical hypoglycaemia and insulinaemia, and although more
complicated, is clearly preferable.
lluglycaemia control studies. Clamp studies are arduous for subjects, and over their course
subjects may suffer from fatigue or boredom. Conversely, if cognitive function tests are
repeated, then a practice effect may occur. For these reasons, it is not adequate to
compare performance during hypoglycaemia with baseline performance. Instead, the
effects of hypoglycaemia should be determined by comparing performance at equivalent
time points in hypo- and euglycaemic studies. Earlier studies did not usually include
euglycaemic control studies, and their conclusions are in consequence less robust.
Subject selection. Studies of healthy (non-diabetic subjects) may be confounded by
variables such as age, sex and race. Studies of diabetic subjects may also be confounded
by duration of diabetes and diabetic complications. Perhaps more importantly, as will
be discussed later, exposure to hypoglycaemia itself modifies subsequent responses to
hypoglycaemia, and it is extremely difficult or impossible to ensure that two different
groups of subjects have equivalent prior hypoglycaemia exposure.
Statisticalpower. Lack of statistically significant cognitive dysfunction is not evidence that
hypoglycaemia has no effect on a cognitive process, unless appropriate power
calculations are also reported. Studies in this research area have rarely or never reported
power calculations.
2.2.4 Sensitivity of different cognitive processes to hypoglycaemia
It has been suggested that performance on complex tasks involving higher cerebral
processes is impaired to a greater extent by hypoglycaemia than performance on simple
perceptual and motor tasks [14]. For example, finger tapping has frequently been
unaffected during hypoglycaemia (Table 2.1). Holmes et al reported greater
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deterioration in choice reaction time (which requires a decision) than in simple reaction
time during hypoglycaemia [121. Stevens el al reported impairment of more complex
tasks such as Digit Symbol Substitution and Trail Making during hypoglycaemia, while
simple reaction time and finger tapping were unaffected [18].
Those interpretations are not wholly persuasive: describing finger tapping as a cognitive
function test is at least questionable, and Table 2.1 demonstrates that finger tapping and
simple reaction time have been slowed in some studies during hypoglycaemia. For the
reasons outlined above, comparing results from different studies is fraught with pitfalls
due to differing methodology and subjects. Even when two cognitive tests are used
within the same study, there are difficulties in comparing them. If the performance
decrement for one test achieves statistical significance and the other does not, that does
not mean that there is a statistically significant difference between them, although this
interpretation has commonly been presented. As yet, there is no statistically robust
evidence that hypoglycaemia has a greater effect on performance on any one test than
any other.
2.2.5 Conclusions regarding cognitive function during
hypoglycaemia
Research on the effects of moderate hypoglycaemia on cognitive function has been
limited by lack of experimental consistency, small studies, inadequate statistical analysis
and uncertainties about what is being measured by cognitive tests.
The following conclusions relating to hypoglycaemia at about 2.0 to 3.0 mmol/1 are
supported:
• Hypoglycaemia results in impairment or slowing of fundamental sensory processes,
including visual and auditory change detection and critical stimulus threshold.
• Hypoglycaemia impairs mathematical computation, verbal fluency and number
recall.
• Hypoglycaemia results in slowing of performance on many tasks that appear to test
cognitive function, including visual and auditory reaction time, Trail Making B,
Digit Symbol Substitution and Stroop ink colour tasks.
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There is some evidence for the following interpretations:
• Hypoglycaemia impairs driving performance (experimental evidence is restricted to
driving simulators).
• Hypoglycaemia has more effect on complex tasks than on simple ones (the
evidence for this lacks statistical corroboration).
• Hypoglycaemia slows or impairs all cognitive functions (no test that has been used
in more than one study has been consistently unaffected by hypoglycaemia).
2.3 Glycaemic thresholds for cognitive
dysfunction
2.3.1 Methodology for estimation of glycaemic thresholds
In the studies already discussed, researchers examined whether cognitive performance
was impaired at a particular level of blood glucose. This approach does not tell us at
what level of blood glucose cognitive dysfunction begins. A different approach is to use
a stepped hypoglycaemic clamp, whereby the blood glucose concentration is lowered in
a series of steps, with cognitive function assessed at each glycaemic 'plateau' (Figure
2.1). In this way, the glycaemic threshold for cognitive dysfunction may be estimated.
There are semantic difficulties with the term 'threshold': in its metaphorical origin, the
threshold must be stepped over, and so the higher the threshold the harder it is to cross,
and the more extreme the situation represented. A 'higher glycaemic threshold' could,
quite logically, be taken to mean a lower blood glucose level. Terms such as 'higher
threshold' and 'lower threshold' will be avoided hereafter, though 'threshold' has been






















Figure 2.1. Illustration of the stepped glycaemic clamp method for
estimation of thresholds for cognitive dysfunction.
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Glycaemic thresholds for cognitive dysfunction were first calculated by Pramming et al,,
although their method of analysis was unusual and has not been repeated [19]. The
technique adopted by Schwartz et alhas persisted [58]. First, the standard deviation of
the baseline (euglycaemic) scores on cognitive tests for the entire subject group is
determined, and significant deterioration is thereafter defined as a decline greater than
two of these standard deviations. Second, for each individual subject, the point at which
their cognitive score falls below their baseline score by more than this pre-specified
amount is identified. Third, the mean actual blood glucose during that plateau of the
clamp for that individual is calculated. This blood glucose level (rather than the target)
is taken to be the glycaemic threshold for the individual.
There are flaws with this method, which have not been widely acknowledged. Firstly,
the estimated blood glucose for the onset of cognitive dysfunction must be lower than
the true blood glucose level. For example, if cognitive dysfunction is not detected at 2.8
mmol/1 but is detected at 2.4 mmol/1, the threshold must lie somewhere between these
values. Secondly, because the clamp technique does not give perfect control of blood
glucose, achieved levels are used rather than the target levels. Again, this may be
illustrated by an example, in which the true threshold for cognitive dysfunction is 2.6
mmol/1, and clamp targets include 2.4 and 2.8 mmol/1. The 2.4 mmol/1 plateau will be
the first to show cognitive dysfunction, but different subjects' thresholds may be
variously recorded as 2.3, 2.4, 2.5 mmol/1, depending on the achieved blood glucose
level. This produces apparent individual differences, which are actually experimental
artefacts. Additionally, it creates the illusion that the threshold estimate is a continuous
variable whereas it is really categorical, which has implications for statistical methods.
2.3.2 Glycaemic thresholds in non-diabetic subjects
Table 2.2 summarizes threshold estimates for cognitive dysfunction. In non-diabetic
subjects these have ranged between 2.3 and 3.1 mmol/1. Flstimates in diabetic subjects
are similar, although for reasons that will be discussed later, these are very dependent on
the patient group studied. There are no obvious outliers (i.e. cognitive function tests
that show impairment at a higher or lower blood glucose than the other tests).
Cognitive test Glycaemic threshold (mmol/1)
Non-diabetic Diabetic

































Table 2.2. Summary of studies estimating glycaemic thresholds
for cognitive dysfunction.
Despite its limitations, estimation of glycaemic thresholds has provided useful
information. Mitrakou et al calculated thresholds in non-diabetic subjects for
counterregulatory hormone release (3.6-3.8 mmol/1), autonomic symptoms (3.2
mmol/1), neuroglycopenic symptoms (2.8 mmol/1) and cognitive dysfunction (2.7
mmol/1) [66]. Importantly, these threshold estimates were compared and found to
differ with high significance (P=0.0001 for hormones vs autonomic symptoms; P^O.Ol 8
for autonomic vs neuroglycopenic symptoms; P=0.004 for autonomic symptoms vs
cognitive dysfunction). The methodological deficiencies mentioned above will tend to
reduce the significance of any comparisons; statistically significant comparisons are
therefore relatively trustworthy. Mitrakou et als study is important because it is the only
concrete evidence that in non-diabetic subjects, cognitive dysfunction occurs at a lower
blood glucose level than endocrine counterregulation and symptom generation. Similar
threshold estimates showing the same hierarchy were obtained by Fanelli et al and
Mokan et al, although there were no statistical comparisons between thresholds to
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confirm that cognitive dysfunction occurs at a lower blood glucose level than symptoms




Figure 2.2. Thresholds of responses to hypoglycaemia in non-diabetic subjects.
Based on [63,66,69].
2.3.3 Conclusions regarding glycaemic thresholds in non-diabetic
subjects
Although methods of estimation of glycaemic thresholds have some inherent flaws, all
estimates for the onset of cognitive dysfunction in non-diabetic subjects are between 2.3
and 3.1 mmol/1, with most being around 2.7-2.9 mmol/1. Although it seems intuitively
likely that complex tasks would be more susceptible to hypoglycaemia, with reference to
(for example) the effects of traumatic brain damage or alcohol intoxication, there is no
evidence that thresholds vary for different cognitive processes.
Importantly, there is a hierarchy of responses to progressive hypoglycaemia in non-
diabetic subjects. As blood glucose falls, endocrine counterregulation is the first
response, followed by symptom generation. Cognitive dysfunction occurs at a still
lower blood glucose level in non-diabetic subjects.
2.4 Speed of onset of, and recovery from,
hypoglycaemic cognitive dysfunction
Evans et al induced hypoglycaemia in non-diabetic subjects, and measured cognitive
function, symptoms and counterregulatory responses immediately and after 20 minutes
of sustained hypoglycaemia [26]. There was statistically significant impairment of
cognitive function immediately, whereas counterregulation and symptoms only achieved
significance at 20 minutes. If the possibility of type 2 statistical error is ignored, it can
be inferred that even people with normal hypoglycaemia awareness may develop
neuroglycopenia before symptoms if blood glucose falls rapidly.
Cognitive function does not recover immediately on correction of hypoglycaemia.
Several studies have reported delays of 45 to 90 minutes before recovery of reaction
time or P300 amplitude, but each had a flaw such as failure to determine statistical
significance or absence of a euglycaemic control arm [17,22,23,24,70]. Fanelli et al
reported data apparently showing residual impairment 60 minutes after hypoglycaemia,
although their statistical analyses ignored the euglycaemic control arm and simply
compared scores with baseline [71]. Evans et al reported a methodologically and
statistically robust residual impairment 20 minutes after restoration of euglycaemia [26].
More recently, Nicola Zammitt and I have shown that a delayed effect of hypoglycaemia
on choice reaction time persists as long as 75 minutes after correction of hypoglycaemia
[72].
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2.5 Cognitive adaptation to hypoglycaemia
2.5.1 Acute adaptation of cognitive function during hypoglycaemia
Several studies have reported acute adaptation of cognitive function to hypoglycaemia,
but statistical confirmation was often lacking. For example, Kerr et almeasured reaction
time repeatedly at an arterialized venous blood glucose of 2.8 mmol/1 in type 1 diabetic
subjects, and reported that reaction time was significantly prolonged after 40 minutes of
hypoglycemia, but not at 20, 65 or 90 minutes [73]. The loss of statistical significance
was taken as evidence of cerebral adaptation, although inspection of their data suggests
that reaction time was prolonged during hypoglycaemia at all times, with only the
comparison at 40 min reaching the critical P<0.05. The study may simply have been
underpowered to reliably detect hypoglycaemic cognitive decline.
More convincingly, Kerr et al lowered blood glucose to 3.5 for an hour and then to 3.0
mmol/1 for a further hour in non-diabetic subjects, and their data are approximated in
Figure 2.3 [74]. The baseline (278 ms) and peak (349 ms) reaction times were
significantly different (P<0.01). Comparisons of the peak and final (287 ms) reaction
times were not reported; comparison of the published data by the standard error
method gives P=0.004. A learning effect was not excluded by comparing the
euglycaemia reaction times (unpublished) at each time point. Even so, the data are


































Figure 2.3. Reaction time during stepped hypoglycaemia, approximated
from [74].
By contrast, Gold et al induced hypoglycaemia (arterialized venous blood glucose 2.5
mmol/1) in 24 non-diabetic subjects, and determined cognitive decrement with
reference to euglycaemic control studies. The cognitive decrement did not differ
significandy after 0 and 40 minutes of hypoglycaemia, suggesting that no adaptation
occurred during this period [24]. Evans et al found no change in cognitive function
between 0 and 60 minutes of hypoglycaemia (arterialized venous plasma glucose 2.65
mmol/1) in non-diabetic subjects, although with only eight subjects the study lacked
statistical power [26].
An impressive study by Boyle et al supports the concept of acute adaptation to
hypoglycaemia [16]. Brain glucose uptake was determined by measuring glucose
concentrations in arterial and jugular venous blood, and multiplying the difference by
the cerebral blood flow, estimated by a tracer method. In non-diabetic subjects, brain
glucose uptake and cognitive function were measured during a stepped hypoglycaemic
clamp on day 1, and again on day 4 after 56 hours of continuous hypoglycaemia at
approximately 3.0 mmol/1. The clamp plateaux were at 4.7, 4.2, 3.6, 3.0 and 2.5 mmol/1
(arterial plasma), and cognitive tests were immediate and delayed recall of a word list,
finger tapping and Stroop task performance. Brain glucose uptake was significantly
reduced at a blood glucose level of 3.6 mmol/1 and below on day 1, but there was no
significant fall in brain glucose uptake at any blood glucose level on day 4. Stroop task
performance was significantly impaired at 3.0 mmol/1 on day 1, but not until 2.5
mmol/1 on day 4, and finger tapping was impaired at 3.0 mmol/1 on day 1 but not at
any blood glucose level on day 4. The significance levels for day 1 vs day 4 cognitive
performance were reported as P=0.04 (Stroop) and P=0.004 (finger tapping), although
it is not clear if these comparisons took baseline performance on each day into account
to exclude a learning effect. However, the increased brain glucose uptake seems robust,
and the study strongly suggests that cognitive adaptation to hypoglycaemia occurs
through this mechanism.
2.5.2 Adaptation of cognitive function following recent
hypoglycaemia
Several studies have reported that hypoglycaemia reduces cognitive impairment during
subsequent hypoglycaemia. The typical design for these studies is as follows: (i) the
subject is first rendered hypoglycaemic for 1-2 hours, and after a set interval of hours or
days, hypoglycaemia is induced again and cognitive dysfunction measured; (ii) after a
fortnight or more the sequence is repeated, but with a euglycaemic first clamp; (iii)
hypoglycaemic cognitive dysfunction is compared for studies following first clamp
hypoglycaemia and first clamp euglycaemia.
Table 2.3 summarizes some of these studies. It is worth remembering that when two or
more tests are employed, the P-value for significance for any one test should be subject
to a Bonferroni correction, i.e. divided by the number of tests employed. Thus,
Mellman el als P<0.03 for attenuated cognitive impairment on the Logical Memory task
is not strictly significant, as two tests were employed and the critical value should be
P=0.05/2—0.025; on the other hand, with only nine subjects, failure to find a significant
difference for Digit Symbol Substitution may have been due to lack of statistical power
[75]. Fanelli et al avoided the problem of multiple comparisons by generating a
summary score for all cognitive function tasks, similar to the primary endpoint of
clinical trials, which was significantly preserved seven hours after antecedent
Page 49
hypoglycemia [76]. Fruehwald-Schultes et al found significant preservation of all their
cognitive measures 24 hours after antecedent hypoglycaemia [45]. Only George et al did
not report any preservation of cognitive dysfunction, but this was a small study, and it is
possible that the duration of adaptation after a single hypoglycaemic episode is less than
two days [62]. Overall, it seems likely that acute adaptation of cognitive function








































2.5 hr at 3.1
mmol/1
24 hr P300 amplitude (P<0.005)




8T1DM 2 hr at 2.8
mmol/1
2 days Choice visual
reaction time
Table 2.3. Studies reporting preservation of hypoglycaemic cognitive function after
antecedent hypoglycaemia.
2.5.3 Adaptation of cognitive function to hypoglycaemia in people
with insulin-treated diabetes
Clinical experience relates that people with tightly-controlled diabetes maintain cognitive
function during quite profound hypoglycaemia. Experimental data has been patchy, but
has tended to support this observation. Jones et al reported that in intensively-treated
type 1 diabetic subjects, a much lower blood glucose level (2.2 mmol/1) was needed to
achieve a statistically significant attenuation of the P300 evoked brain potential than in
subjects with conventionally-treated type 1 diabetes (3.5 mmol/1) and without diabetes
(3.0 mmol/1) [77]. However, there was no formal between-groups statistical test.
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In the largest study of the type, Mokan et al studied 32 type 1 diabetic subjects with
normal hypoglycaemia awareness, 11 with impaired awareness and 19 non-diabetic
controls [69]. Cognitive function tests were Trail Making A&B, Stroop tasks, simple
and choice reaction time, verbal memory and forward and backwards digit span.
Despite this comprehensive battery, cognitive scores were summarized and reported as
a single ^-score; this avoids the problem of multiple statistical comparisons, but
markedly reduces the available information, such that one has to question why so many
cognitive tests were included in the first place. A stepped glycaemic clamp was utilized,
as described in section 2.5.1. Blood glucose levels for the onset of reactions to
hypoglycaemia were generally similar in controls and diabetic subjects with normal
awareness. Compared with subjects with normal awareness, subjects with impaired
awareness had lower blood glucose levels for the onset of autonomic symptoms (2.33 vs
3.61 mmol/1, P<0.01), neuroglycopenic symptoms (2.48 vs 2.83 mmol/1, P<0.03) and
cognitive dysfunction (2.39 vs 2.69 mmol/1, P<0.01). Despite apparent cognitive
adaptation to hypoglycaemia, the blood glucose interval between the onset of symptoms
and the onset of cognitive dysfunction in aware subjects (3.61 vs 2.69 mmol/1) seems to
have been lost in subjects with impaired hypoglycaemia awareness (2.48 vs 2.39
mmol/1). However, this was not subject to statistical corroboration.
Weinger et al conducted a similar but smaller study, with 8 subjects with relatively well-
controlled diabetes, 9 with relatively poorly-controlled diabetes, and 10 controls [21].
No significant between-group differences in the blood glucose levels for cognitive
dysfunction were observed, though significant differences were detected for autonomic
symptoms and counterregulatory hormones. The latter study had substantially fewer
subjects than in Mokan et al, which may explain the different results. Also, at least one
of their tests was clearly too easy: the word recall test measured recall of just three
words after five minutes.
If people with relatively tightly-controlled diabetes show less cognitive dysfunction
during hypoglycaemia, a plausible explanation is cerebral adaptation secondary to
frequent prior hypoglycaemia. A possible mechanism is increased blood-brain glucose
transport. Studies in rats have reported upregulation of cerebral GLUT1 transporters
after chronic hypoglycaemia (of several days' duration), although no changes were seen
with acute hypoglycaemia [78,79], In a complementary study to that cited in section
2.5.1, Boyle et al measured brain glucose uptake at 3.0 mmol/1 (arterial plasma glucose)
in non-diabetic subjects and subjects with well-, averagely- and poorly-controlled
diabetes. Brain glucose uptake was preserved in subjects with well-controlled diabetes,
who by inference may have had frequent prior exposure to hypoglycaemia, but fell by
around 20% in other diabetic and non-diabetic subjects [80]. Studies using positron-
emitting glucose tracers to measure brain glucose uptake have not replicated these
findings [81,82], and indeed, one recent study reported a decrease in cerebral glucose
utilization during hypoglycaemia in hypoglycaemia-unaware subjects [83]. It is hard to
reconcile these very different findings; there is evidence that brain glucose estimates by
PET and arteriovenous difference techniques may diverge, but no gold standard against
which they may be compared to determine which studies are more reliable [84].
2.5.4 Evidence for adaptation of cognitive function to
hypoglycaemia from interventional studies
It would be unethical to intentionally cause multiple episodes of hypoglycaemia, in order
to find out whether subjects develop resistance to its cognitive effects. However, the
reverse approach of strictly avoiding hypoglycaemia is ethical, though labour intensive.
In two separate studies, Fanelli et al studied subjects with type 1 diabetes and impaired
awareness of hypoglycaemia, and also non-diabetic control subjects [65,67], The
magnitude of, and blood glucose levels for, the symptomatic, hormonal and cognitive
effects of hypoglycaemia were determined using the stepped glycaemic clamp technique.
At baseline, all of these responses were diminished and occurred at much lower blood
glucose levels in the diabetic subjects than in the non-diabetic subjects. After three
months of intensive diabetes control during which the principal aim was complete
avoidance of any hypoglycaemia, the differences between diabetic and non-diabetic
subjects were minimal. In particular, diabetic subjects showed cognitive dysfunction at
higher blood glucose levels than before the intervention, presumably reflecting reverse
adaptation [65,67],
Mitrakou et al obtained similar results in an elegant, opportunistic study in patients with
insulinomas, who suffer recurrent or chronic hypoglycaemia prior to surgical cure.
Using a similar stepped glycaemic clamp, it was shown that prior to surgery patients
could maintain cognitive performance at blood glucose levels as low as 2.3 mmol/1, and
that this effect was entirely abolished after surgical resection (Figure 2.4) [64].
H Insulinoma patients before surgery
1H Insulinoma patients after surgery
Normal controls
4.3 3.7 3.0 2.3
Figure 2.4. Cognitive function during progressive hypoglycaemia in
normal subjects, and subjects before and after removal of insulinomas.
Higher ^-scores represent worse cognitive function. Based on (but not
reproduced from) graph in Mitrakou et al [64],
2.5.5 Clinical significance of adaptation of cognitive function to
hypoglycaemia
People with insulin-treated diabetes commonly develop impaired awareness of
hypoglycaemia, as discussed previously in section 1.6. This manifests as a lowering of
the blood glucose levels at which symptomatic and hormonal responses are initiated
[85,86,87,88]. If the glucose levels for cognitive function were to remain unchanged,
then cognitive impairment would develop before symptomatic awareness of
hypoglycacmia; this hypothetical re-ordering of the normal hierarchy is shown in Figure
2.5. In conjunction with impaired counterregulation, this re-ordering could underlie the
higher incidence of severe hypoglycaemia that is associated with strict glycaemic control
and diabetes of long duration [89]. In effect, it would mean that the diabetic person
would already be confused due to neuroglycopenia by the time they realised they were
hypoglycaemic — perhaps too confused to be able to successfully treat themselves.
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Figure 2.5. Hypothetical change in blood glucose levels in impaired
hypoglycaemia awareness.
As discussed previously, there is good evidence that the brain does adapt to recurrent
hypoglycaemia. However, in the three studies where glycaemic thresholds were
measured in diabetic subjects with impaired hypoglycaemia awareness, statistically-























the symptomatic and counterregulatory responses [64,67,69], It therefore appears that
cerebral adaptation to recurrent hypoglycaemia cannot match the decline in
symptomatic and counterregulatory defences, with the result that the first manifestation
of hypoglycaemia in the unaware patient is confusion.
2.5.6 Conclusions regarding cerebral adaptation to hypoglycaemia
The results of interventional studies showing longitudinal changes in glycaemic
thresholds are particularly persuasive [16,64,65,67], and overall it seems clear that
cerebral adaptation to recurrent hypoglycaemia is a real phenomenon. The evidence so
far cited indicates that adaptation does not occur during 60 minutes [24,26], may occur
during 90 minutes [73], probably occurs during 150 min [74], and does occur during 56
hours [16] of hypoglycaemia. Also, following two to three hours of hypoglycaemia,
cognitive adaptation to subsequent hypoglycaemia may occur within two hours [75],
does occur within seven hours [76] and lasts between 24 and 48 hours [45,62], These
results suggest that a very prolonged hypoglycaemic stimulus is not required, but the
adaptive process itself may take some time. The mechanism of adaptation may be an
increase in brain glucose uptake capacity [16,80]. By contrast, studies in rats indicate
that several days of hypoglycaemia are required to induce changes in brain glucose
transport via upregulation of the GLUT1 transporter [78,79,90], and if this is also true
of humans, there may be another mechanism for acute adaptation such as increased
production of alternative brain fuels. However, neither the existence nor the nature of a
second adaptive mechanism is clear.
Nonetheless, impaired awareness of hypoglycaemia is clearly associated with severe
disabling hypoglycaemia [89], and cognitive adaptation is not sufficient to protect
against this. This appears to be because the autonomic symptoms are lost or diminished
to a much greater extent [64,67].
2.6 Support of cognitive function during
hypoglycaemia
Under normal circumstances, the brain obtains almost all its metabolic energy from
oxidation of glucose, so hypoglycaemia causes an acute energy deficiency. The brain is
also capable of generating energy from lactate, ketones and alanine, and intravenous
infusions of these substances attenuate cognitive dysfunction during hypoglycaemia
[61,68,91,92], However, it is not clear how this could be useful in clinical practice, as
intravenous infusion is not a practical intervention in daily life, and the presence of the
first two in physiological circumstances is a result of dangerous metabolic derangement.
More interest has been focused on interventions to increase cerebral glucose utilization.
Administration of acetazolamide has been shown to increase cerebral blood flow (CBF),
resulting in attenuated symptomatic and counterregulatory hormonal responses to
hypoglycaemia [44]. No effect was seen on cognitive function as measured by P300
latency, although this does not rule out beneficial effects on other cognitive measures,
and more work with acetazolamide may be merited. Kerr et al administered caffeine
during or prior to hypoglycaemia, resulting in reduced CBF [93,94]. They documented
heightened symptomatic awareness of hypoglycaemia with neutral or detrimental effects
on cognitive function, suggesting that caffeine simply resulted in more severe
neuroglycopenia for a given blood glucose level, and it is therefore unlikely that caffeine
can be of value as a therapeutic option.
Insulin promotes uptake of glucose into tissues, and it is logical to question whether
hyperinsulinaemia might improve brain function during hypoglycaemia, through effects
on glucose transport rather than blood flow. Brain glucose uptake was considered
insulin-independent, but has been re-examined in recent years using positron emission
tomography and magnetic resonance spectroscopy. Two studies reported no effect of
hyperinsulinaemia on brain glucose utilization [4,5]. Another study reported a small
increase in glucose uptake with physiological, compared with sub-physiological, plasma
insulin concentrations, but this finding may not be relevant to diabetes, where
hypoglycaemia is associated with hyperinsulinaemia [7]. Regarding cognitive
performance, two studies found no effect of hyperinsulinaemia [33,63]. Another
reported some improvement during euglycaemia with a very high insulin infusion rate
(15 mU kg"1 min'), but only at one time-point, raising the possibility of type 1 statistical
error [95].
The GABA-inhibitor modafinil is a stimulant usually used to treat narcolepsy. Smith et
al administered modafinil prior to experimental hypoglycaemia, and reported that it was
associated with a reduction in the number of incorrect scores on the Stroop colour-
word task (P=0.005), and an improvement in the accuracy of a decision reaction time
task (P=0.04) [96]. These are not the standard measures for these tasks and were not
obviously pre-specified, raising the possibility of a type 1 statistical error due to multiple
comparisons. The same group examined modulation of cerebral K-ATP channels using
diazoxide and glibenclamide [59]. The estimated blood glucose threshold for
deterioration of choice reaction time was 2.5 mmol/1 following diazoxide, and 3.0
mmol/1 following glibenclamide (0=0.002 for comparison); however, no significant
effects were demonstrated against placebo, so it is unclear whether glibenclamide was
beneficial or diazoxide detrimental.
Overall, no intervention has shown clear potential to prevent cognitive deterioration
during hypoglycaemia, and the odds may be against development of such a therapy. As
illustrated in Figure 2.4, patients exposed to prolonged hypoglycaemia compensate to an
extraordinary degree, and there may be little scope for further compensation for a
fundamental deficit in fuel supply. The underlying problem in impaired hypoglycaemia
awareness is altered thresholds for symptoms and counterregulation, and strategies to
restore these may hold more therapeutic potential.
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2.7 Long-term effects of hypoglycaemia
Profound, protracted hypoglycaemia can cause permanent brain damage or death. Post¬
mortem studies [97,98,99] and neuroimaging studies [100,101,102,103,104] of
individuals who had suffered fatal hypoglycaemia have revealed areas of cortical injury,
particularly in the frontal lobes and hippocampus. Although such catastrophic
hypoglycaemia is rare, it is possible that recurrent hypoglycaemic episodes which are less
severe but nonetheless disabling may cause subclinical brain damage, leading to
cognitive impairment over time. Anecdotal reports of diabetic patients who have
developed mental difficulties have attributed this to recurrent severe hypoglycaemia
[105],
Permanent functional brain abnormalities have been associated with recurrent
hypoglycaemia, including electroencephalographic abnormalities [106,107,108].
Cerebral blood flow is redistributed during acute hypoglycaemia, with increased frontal
lobe perfusion [109], and this pattern appears to become permanent in diabetic patients
who have suffered recurrent severe hypoglycaemia [110] or impaired hypoglycaemia
awareness [111]. Structural changes associated with hypoglycaemia are less apparent.
Neuroimaging has demonstrated abnormalities associated with type 1 diabetes, including
leukoaraiosis, small periventricular lesions representing foci of ischaemia [112,113].
This has led to the concept of "diabetic encephalopathy", to which vasculopathy,
hyperglycemia and hypoglycaemia may contribute. However, as these conditions co¬
exist, no single pathogenetic mechanism can be deduced. A recent study from our
centre found a strong association between leukoaraiosis and retinopathy but not with
hypoglycaemia, suggesting that leukoaraiosis represents a microvascular complication of
hyperglycaemia [114].
The long-term effects of severe hypoglycaemia on cognitive function are not fully
defined. A number of studies have reported intellectual disadvantage in patients with
histories of severe hypoglycaemia [115,116,117,118,119], but this association may arise
simply because less able patients manage their diabetes less effectively, and so suffer
more hypoglycaemia [119]. In a study from Edinburgh, current IQ was measured and
premorbid IQ was estimated in diabetic patients, whose history of severe hypoglycaemia
was also determined [120]. A highly significant decline in IQ was seen in patients who
had suffered at least five episodes of severe hypoglycaemia, with no significant decline
in patients with no history of severe hypoglycaemia (Figure 2.6); a study from
Nottingham using a similar design reported similar results [121]. However, there was no
significant difference in the change in IQ. A limitation is the estimation of pre-morbid
IQ, which was based on National Adult Reading Test scores. Performance on this test
correlates highly with Wechsler Adult Intelligence Scales-Revised (WAIS-R) IQ, is
resistant to the effects of organic brain damage, and so may indicate 'best ever'
intelligence [122]. Nonetheless, the correlation between NART and WAIS-R
performance is imperfect, and it is therefore possible that NART estimates of
intelligence will tend to regress closer to the mean than WAIS-R scores in the same
individuals, reducing apparent differences between patient groups. The data are
suggestive, but a prospective study design would be more robust.
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Figure 2.6. Estimated pre-morbid and current IQ in diabetic patients
with no previous severe hypoglycaemia (group A) and five or more severe
glycaemic episodes (group B). Comparison for Group A is non¬
significant, comparison for group B is significant at p<0.001. From [120].
The major prospective trial of type 1 diabetes is the Diabetes Control and
Complications Trial. Patients underwent detailed cognitive function testing at entry, and
subsequently, depending when they were enrolled, at one or more of 2, 5, 7 and 9 years
later, amounting to median follow-up of 6.5 years when the trial finished. No
association between repeated episodes of severe hypoglycaemia and cognitive decline
was demonstrated [123,124]. Follow-up data from the DCCT have now been
published, on 1144 patients undergoing detailed cognitive function testing 18 years after
the start of the trial [125]. There were no differences between patients originally
allocated to intensive or conventional insulin therapy, and no association between
frequency of severe hypoglycaemia and cognitive change. The only statistically
significant association was between poor glycaemic control (HbAlc>8.8%) and decline
in motor and psychomotor performance. This is by far the largest prospectively-
collected dataset that exists on this topic, and it provides further support for tight
glycaemic control, suggesting that it should prevent cognitive decline due to
hyperglycaemia, without causing cognitive dysfunction due to hypoglycaemia. The
DCCT population is known to be somewhat atypical of the general diabetes population,
with a low rate of severe hypoglycaemia [126]. However, a specific research question
was whether individuals with five or more episodes of severe hypoglycaemia showed
cognitive impairment, and at the end of the 18-year follow-up period, there were 66
such individuals, which provides reasonable power to detect an effect. The DCCT
findings cannot exclude the possibility that more frequent severe hypoglycaemia causes
harm. They also cannot be translated to the entire diabetic population, who often
experience hypoglycaemia in the context of psychosocial problems and erratic lifestyle
[127], and vascular disease may increase the risk of hypoglycaemic brain damage [128].
Trials randomising patients to non-intensive treatment would now be considered
unethical, and it is unlikely that there will ever be definitive answers.
2.8 Hypoglycaemia and cognitive function in
children
Acute hypoglycaemia causes cognitive impairment in children [129], but has been
studied less extensively than in adults. Matyka et al showed that, while nocturnal
hypoglycaemia was frequent in children, cognitive function was unimpaired the next
morning [130]. However, concern has been expressed about repeated exposure of the
immature brain to hypoglycaemia [131]. Retrospective studies have reported cognitive
disadvantage in later life in children with early-onset diabetes (age less than 4-5 years) by
comparison with children who developed diabetes at an older age [132,133,134].
Although one possible cause is recurrent hypoglycaemia, hyperglycaemic brain disease
or disruption of education and psychosocial development at a susceptible age could
equally explain these findings.
Several retrospective and prospective studies have reported that hypoglycaemia, rather
than some other aspect of diabetes, is correlated with educational and intellectual
disadvantage among children with diabetes [135,136,137,138,139,140]. Although these
studies were individually too small or too short to provide reliable results, and were
often prone to type 1 statistical errors, the association appears to be consistent. A
prospective Australian study has compared 90 children with type 1 diabetes with
matched non-diabetic controls shortly after diagnosis, and again after two and six years
[141]. No differences in intellectual function were observed at baseline, but by six years
a clear disadvantage in the diabetic children had emerged, particularly in verbal IQ. In
regression analysis, hypoglycaemic seizure history was a significant predictor, and
explained 3% of variance in full-scale IQ. This is not a large effect, and the major
influence of diabetes may have been hyperglycaemia or psychosocial disruption. Non-
interventional studies cannot resolve the question of whether hypoglycaemia is the cause
or the effect of lower intelligence. Nonetheless, it is probably appropriate to err on the
side of caution by attempting to avoid all severe hypoglycaemic episodes, although it is
difficult to achieve this at the same time as achieving good glycaemic control.
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2.9 Memory function during hypoglycaemia
Discussion of memory function during hypoglycaemia has been omitted in the
preceding sections, as this is a main subject of this thesis. Recently, memory has been
examined in depth in Edinburgh. Previously there was relatively little work on the
subject.
2.9.1 Older studies of memory and hypoglycaemia
Holmes et al studied 12 students with type 1 diabetes at three levels of non-arterialized
venous blood glucose: 3.3, 6.1 and 16.7 mmol/1 [10]. The memory tests used were (1)
the Key Auditory Verbal Learning Test (AVJLT), in which a list of 15 words is read out to
the subject, who attempts to repeat them immediately; the score is the number of words
recalled, and the procedure is repeated for a total of five trials with the same word list;
(2) digit span, in which progressively longer sequences of digits are read out to the
subject, who attempts to repeat them immediately; the score is the number of digits in
the longest sequence the subject is able to repeat. Performance on each test did not
differ at different blood glucose concentrations. From today's perspective this is not
surprising, as a venous blood glucose concentration of 3.3 mmol/1 (roughly equivalent
to an arterial or arterialized venous concentration of 3.6-4.0 mmol/1) is well above the
thresholds estimated for cognitive dysfunction in non-diabetic subjects (see section 2.3).
Furthermore, diabetic subjects may sustain cognitive function at lower blood glucose
levels due to adaptation resulting from previous hypoglycaemia (see section 2.5). The
study did not include a euglycaemia control study, although as the order of glycaemic
condition varied and was counterbalanced between subjects, this is a relatively minor
criticism.
Pramming et al also used digit span to measure memory function in 16 subjects with
type 1 diabetes at target venous blood glucose concentrations of 6.3, 2.9 and 1.8 mmol/1
[19]. Their method of statistical analysis was unusual. For each subject, scores on the
digit span test at the different glycaemic levels were ranked in order, and a total score at
each glycaemic level was created by summing the ranks for all subjects at that level.
This was effectively a variant of conventional rank-order statistical tests. A change in
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rank scores indicating deteriorating performance was seen with target blood glucose
levels of 2.9 and 1.8 mmol/1. A sham euglycaemia control study was included, in which
no significant changes in memory performance were reported, but the effects of
hypoglycemia were not calculated on the basis of difference between hypoglycaemia
and euglycaemia studies, and thus the data from the control arm were misused by
today's standards. Blood glucose concentrations were not well-controlled, with
sometimes large differences between achieved and target concentrations.
Harrad et al measured digit span performance at target venous blood glucose
concentrations of 2.5 and 1.5 mmol/1 in 11 subjects, of whom 5 had type 1 diabetes and
were 6 healthy [47]. No changes were seen in digit span performance. Blood glucose
control was extremely poor, such that the study only really achieved blood glucose levels
somewhere below 3 mmol/1 at each target level. Widom & Simonson tested digit span
performance and word recall in 10 non-diabetic subjects, 8 subjects with type 1 diabetes
and good glycaemic control and 9 subjects with type 1 diabetes and poor glycaemic
control [21]. The word recall test involved reading out three words to subjects, and
testing recall after five minutes. They attempted to define glycaemic thresholds for
deterioration on these and other cognitive tests. No deterioration was seen in digit span
and word recall performance despite achieving a nadir arterialized venous glucose
concentration of 2.2 mmol/1. Actual scores were not reported, but it is likely that the
word recall test was too easy to be a sensitive measure of cognitive decline.
Wirsen et al studied cognitive performance at an arterialized-venous blood glucose
concentration of 2.0 mmol/1 in 10 subjects with type 1 diabetes and 12 non-diabetic
subjects [17]. Memory tests included story recall (no citation was provided and this may
have been a bespoke test) and digit span with forwards and backwards recall.
Significant impairment on all these tests during hypoglycaemia was seen in all subjects
combined. There also seemed to be less effect of hypoglycaemia on non-diabetic
subjects for the forward digit span task. The study was well-designed apart from the
absence of a euglycaemic control session.
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In summary, the older studies of memory function reported variable results, but were
generally scientifically weak. The only study of nearly satisfactory quality showed a
deterioration in digit and story recall during hypoglycaemia [17].
2.9.2 Edinburgh studies of memory and hypoglycaemia
Sommerfield et al studied memory performance in 16 non-diabetic subjects and 16
people with type 1 diabetes during euglycaemia (4.5 mmol/1) and hypoglycaemia (2.5
mmol/1) [28,30,142], Cognitive tests used were in the following domains:
Verbal memory, the Auditory Verbal Learning Test, immediate and delayed, as described
above, and the Logical Memory Test, immediate and delayed, from the Wechsler
memory scales [143]. In the Logical Memory Test, a short story is read and points are
scored for recollection of detail and thematic elements.
Visual memory, the Visual Reproduction Test, immediate and delayed, and the Benton
Visual Retention Test [144], In both tests, progressively more complex geometric
designs are briefly shown, and must be reproduced from memory.
Working memory, the Working Digit Span and Letter/Number Sequencing tests from the
Wechsler memory scales [143], and the Validation Span and Four Term Order tests
from Kyllonen's battery [145]. The first two tests require the subject to listen to
sequences of numbers or numbers and letters, and then to recite them in numerical and
alphabetical order. The Validation Span test requires subjects to remember digits while
simultaneously solving arithmetical problems to prevent rehearsal. The Four Term
Order test is best illustrated by example: "The animals come after the furniture; the
horse comes before the dog; the desk does not come before the rug." Eight response
alternatives are displayed on a card, and the subject would score correctly by choosing
the sequence "rug-desk-horse-dog."
General cognition-, the Digit Symbol Substitution and Trail-Making B tests.
Performance on both Digit Symbol Substitution and Trail Making B declined
significantly in both groups. Table 2.4 gives performance and statistical comparisons
for euglycaemia and hypoglycaemia. Memory performance was significantly impahred
under hypoglycaemic conditions for all tests except Wechsler Visual Reproduction -
immediate, and Digit Span Forward in diabetic subjects. The average effect size (if) was
approximately 0.5, which is a large effect; particularly large effect sizes (r]2>0.6) were
seen for delayed memory and some working memory tests.
Memory Subtest Diabetic Non-Diabetic
domain Eu Hypo P rf Eu Hypo P
Immediate Logical Memory 26.8 (4.8) 21.3 (6.9) .008 .41 27.7 (5.9) 24.4 (5.0) .004 .45
verbal AVLT 39.4 (7.7) 34.0 (5.1) .002 .49 43.6 (7.0) 33.9 (7.7) .001 .53
Immediate Benton VRT 6.5 (1.7) 4.7 (1.5) .007 .42 6.3 (1.7) 5.1 (1.6) .041 .26
visual Wcchsler VRT 81.3 (7.2) 78.2 (9.5) .093 .19 85.6 (8.3) 81.7 (8.0) .059 .23
Delayed Logical Memory 13.6 (2.1) 6.1 (3.7) .0001 .83 15.1 (4.0) 8.1 (3.9) .001 .58
verbal AVLT 9.1 (1.9) 5.3 (1.9) .0001 .68 10.3 (2.1) 4.5 (1.6) <.0001 .87
Delayed Wechsler VRT 15.9 (8.7) 7.1 (7.3) .002 .52 21.5 (16.5) 7.6 (5.5) .001 .57
visual
Working Validation Span 20.7 (2.3) 14.9 (2.2) .0001 .92 22.0 (2.3) 13.4 (2.5) <.0001 .94
memory Digit Span Forward 9.6 (2.4) 8.6 (1.4) .06 .23 10.2 (2.4) 9.3 (1.7) .042 .26
Digit Span Backward 8.3 (1.9) 7.2 (1.2) .02 .33 8.8 (1.9) 6.8 (1.2) <.0001 .67
Letter/Number 11.8 (1.9) 9.7 (1.6) .0001 .57 13.1 (3.1) 10.5 (1.8) .008 .40
Sequencing
Table 2.4. Performance on memory tests during eu- and hypoglycaemia in type 1
diabetic and non-diabetic subjects in [28,30].
A remarkable effect of hypoglycaemia was seen on performance on the Four Term
Order test. Results from diabetic and non-diabetic subjects for this test were combined,
and do not appear in Table 2.4. Mean (SD) scores were euglycaemia: 12.4 (4.3),
hypoglycaemia: 3.7 (2.3), P<0.001, r)2;=0.86. Each subject attempted 24 items in the
Four Term Order test, and with eight choices for each item, the expected score from
random answering is 3.0. Thus, the scores during hypoglycaemia were reduced almost
to chance level, suggesting that working memory was obliterated [142], Working
memory correlates very strongly with other measures of general fluid intelligence [146],
and so this result suggests that complex reasoning ability should also be crippled by
moderate hypoglycaemia. However, the result should be considered in context.
Performance on the four other tests of working memory in Table 2.4 was certainly not
obliterated. The Four Term Order test is hard, even for able subjects during
euglycaemia, and the disparate results perhaps reflect the concept of cognitive 'spare
capacity'. If a test is easy under normal conditions, then there is spare capacity, and
hypoglycemia (or other interference) may first use up this spare capacity such that the
test may be completed by dint of increased concentration or mental effort. On the
other hand, if a subject is only just able to complete a test under normal conditions then
relatively minor interference may render the test impossible.
Previous studies have shown clear evidence of complex reasoning ability during
moderate hypoglycaemia. For example, McAulay et al found that non-verbal
intelligence, as assessed by Raven's Progressive Matrices, was not affected during
hypoglycaemia at 2.5 mmol/1 [38]. In Raven's Progressive Matrices, each question
presents a series of geometric shapes governed by simple rules that must be deduced.
One shape is missing, and the subject must identify the missing shape from eight
candidates. The nature of this task makes it clear that working memory must be
involved, and so working memory cannot be completely obliterated by moderate
hypoglycaemia. However, in keeping with the concept of spare capacity, it is notable
that in the study by McAulay et al, baseline (i.e. euglycaemic) performance was at a high
level (around 80% correct), and it is possible that the logical reasoning task was too easy
to be discriminative.
Working memory is a specialized form of short-term memory that is closely associated
with intelligence. The verbal and visual memory tests utilized what would more
conventionally be considered short- and long-term memory, and showed significant
deterioration. The practical relevance of these studies has limitations. Learning and
recall-testing took place during the same period of hypoglycaemia, lasting approximately
one hour. This narrow separation of learning and recall must occur relatively
infrequently in real life — intuitively, more common situations would be an extended
learning period (e.g. when studying for examinations) or a longer interval between
learning and recall (e.g. when sitting the examination, or remembering an acquaintance's
name). The examination of the effects of hypoglycaemia on different memory
processes forms the major part of this thesis, as described in Chapter 3.
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Over the previous three decades, a large body of research into the effects of
hypoglycemia on cognitive function has been created in Edinburgh. Many of the
previous studies have been described or cited in Chapters 1 & 2. The research
described in this thesis was conceived with the aim of continuing where previous
studies had left off.
3.1.1 Hypoglycaemia and memory function
Sommerfield and colleagues examined the effects of acute, moderate hypoglycaemia (2.5
mmol/1) on various aspects of memory function, as described in section 2.9.2 [1,2,3].
In these studies, both learning and recall testing took place during the same episode of
hypoglycaemia, with a maximum interval of 60 minutes. In daily life, the interval
between acquiring information and needing to remember it may be much greater, and it
is unlikely under such circumstances that both would occur during separate episodes of
hypoglycaemia.
Study 1 (in Chapter 4) examines the possibility that an episode of hypoglycaemia
occurring shortly after learning may disrupt the long-term storage of memories, i.e. that
hypoglycaemia affects the consolidation of memory. As will be discussed in that
chapter, there is evidence indicating that the hippocampus is a critical structure in the
formation of long-term memories, and that it is particularly sensitive to the acute effects
of hypoglycaemia. Functional magnetic resonance imaging is a method for examining
regional brain activation that has recently become available, and is utilized in Study 1 to
try to determine whether hippocampal dysfunction explains any memory impairment
following hypoglycaemia.
Study 2 (Chapter 5) examines the effect of (i) an episode of hypoglycaemia occurring
during learning, with recall taking place later during euglycaemia, and (ii) an episode of
hypoglycaemia occurring during recall, learning having taken place earlier during
euglycaemia. The first manipulation is intended to mimic the situation where a person
with diabetes finds themselves to be hypoglycaemic while studying (for example) —
should they review all material they have read recently, in case it has not registered?
The second manipulation is intended to mimic the discovery of hypoglycaemia during
an examination (for example) — will their recent memory for previously learned material
have been deficient?
Study 2 also includes the development of a novel test of prospective memory. Many of
the memory tests that have been utilized in hypoglycaemia studies seem to reflect the
role ofmemory in daily life poorly — it is rare that one needs to learn a list of words and
immediately recall it, for example. Also, in most memory tests, questions are explicitly
asked, whereas in daily life a more common need is to remember to do something.
3.1.2 Hypoglycaemia and non-verbal intelligence
McAulay and colleagues found no statistically significant effect of moderate
hypoglycaemia on performance on a test of abstract non-verbal intelligence (Raven's
Progressive Matrices), although attentional function was impaired [4,5]. This was
unexpected, as it has often been argued that higher-level cognitive functioning is more
sensitive to hypoglycaemia than lower-level tests with a large motor component (see
section 2.2.4). One possible explanation is that Raven's Progressive Matrices is too easy
a test for the often very intellectually able subjects who participate in research studies.
Study 3 examines this by repeating the study design with a harder version of the same
test.
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3.1.3 Speed versus Accuracy of Cognitive Function
As discussed in section 2.2.2, cognitive function tests in hypoglycaemia studies usually
measure speed of completion of tasks that are intrinsically easy. During hypoglycaemia
(or any other adverse state), one strategy may be to maintain speed at the expense of
accuracy — for example, to guess more. In previous studies (and, as it would prove, in
Studies 1 & 2 here), the number of errors made during reaction time, Trail Making and
Digit Symbol Substitution tests are too few for accuracy to be measured. To try to
answer the question of whether speed or accuracy are favoured during hypoglycaemia,
Study 3 also includes a maze task scored for both.
3.1.4 Symptoms of Hyperglycaemia
The effects of acute hyperglycaemia have received very little attention, though clinical
experience is that it causes significant symptoms and may affect mental performance.
Sommerfield et al recently produced experimental evidence for hyperglycaemic cognitive
dysfunction [6], raising the possibility that other aspects of hyperglycaemia may also
have parallels with hypoglycaemia. Study 4 is designed to identify the symptoms of
hyperglycaemia, and to examine them using factor analysis in the same way as was done
for hypoglycaemia symptoms, as described in section 1.5.
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Chapter 4
Effects of Hypoglycaemia on Memory
Consolidation
4.1 Introduction
Memory has been conceptualized as composed of three main subsystems: sensory
memory, short-term memory, and long-term memory [1], Sensory memory is the brief
retention of an auditory or visual impression after the stimulus has been removed.
Short-term memory can hold a limited number of items, with a duration measured in
seconds. Long-term memory is durable, with no quantifiable capacity limits. The
conversion of short- to long-term memory is known as consolidation. Little is known
about the neurological basis of consolidation, although it is probable that many different
areas of the brain are involved m long-term storage. However, the hippocampus and
adjacent medial temporal lobe structures appear to be critical to the formation of long-
term memory. Evidence for this comes from individuals who have sustained focal
damage to the hippocampus and have developed near-total inability to form new long-
term memories, while retaining intact short-term memory [2,3,4,5]. There have been
case reports of individuals who have developed amnesia following severe
hypoglycaemia, in whom frontal and hippocampal lesions were identified on MRI scans
[6,7]. Post-mortem examinations of individuals who have died following catastrophic
hypoglycaemia have revealed areas of necrosis in the frontal cortices and hippocampus,
with relative sparing of the hindbrain [8,9,10,11]. It appears that the frontal lobes and
hippocampal region are particularly sensitive to hypoglycaemia, and this may explain the
mechanism by which moderate hypoglycaemia disrupts aspects ofmemory.
In previous studies of memory during hypoglycaemia, stimulus presentation and recall
testing both took place during the experimental condition (hypoglycaemia or
euglycaemia) [12,13,14,15,16,17,18,19], Although these studies demonstrated memory
impairments, they could not disentangle the effects of hypoglycaemia on acquisition
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(learning), recall and consolidation. In a practical context, the possibility that
hypoglycemia impairs information acquisition and recall may not be very surprising: no
student with diabetes would wish either to study for, or to sit, an examination while
hypoglycemic. The possibility that consolidation is disrupted by hypoglycemia is
important, because it is not obvious but is potentially of considerable practical
relevance. Consolidation is the fundamental process by which new information
becomes part of our knowledge stores. Consolidation may take some time, and if it were
sensitive to hypoglycemia then it would follow that hypoglycemia could impair
memory formation for events that occurred prior to the onset of hypoglycemia.
The present study was designed to determine whether a period of hypoglycemia
immediately following the learning process can disrupt consolidation and impair
subsequent recall. To examine the mechanisms by which hypoglycemia might exert an
effect on memory, functional magnetic resonance imaging (fMRI) was used to inspect
regional brain activation during recall.
fMRI uses the blood oxygen level dependent (BOLD) signal, which exploits a natural
difference in the magnetic properties of oxy-haemoglobin and deoxy-haemoglobin [20].
When a subject is exposed to a stimulus or task, neuronal activation in related brain
regions increases, and this is followed after 10-12 seconds by local vasodilatation [21,22].
Although local oxygen use increases, the hyperaemic response more than compensates,
so that the concentration of deoxy-haemoglobin is reduced and the BOLD signal from
those regions is increased. A three-dimensional map of brain activation can thus be
generated. The speed of acquisition of fMRI allows activation maps to be generated
every few seconds, and so maps can be obtained for each task in a battery, between
which the experimental condition can be varied. Other techniques, such as positron-
emission tomography (PET), require longer periods for image acquisition, and a block
design is required, whereby an average activation map is obtained over the course of
several tasks during which the experimental condition is held constant. The advent of
fMRI has permitted study of the activation of brain structures during very specific
memory tasks. Activation of the medial temporal lobe structures (including the
hippocampus) has been consistently associated with successful encoding and retrieval of
episodic memories [23]. The pre-frontal cortex is also profoundly involved in memory
Page 81
processes, although in fMRI studies pre-frontal activation has been more consistently
associated with retrieval effort rather than successful retrieval of episodic memories [23].
4.2 Pilot Study
4.2.1 Pilot Study - Introduction
A pilot study was undertaken to develop and test an appropriate memory task for the
main study. The learning phase of the task was to be applied during the euglycaemic
phase of the glucose clamp, and the recall (test) phase in an MRI scanner following an
hour of euglycaemia or hypoglycaemia.
There were certain important restrictions imposed by the use of MRI. MRI scanning is
extremely noisy, and so it is hard to use verbal communication or auditory stimuli.
Subjects must lie prone and still in the scanner, excluding the use of a computer
keyboard. Response options are therefore generally restricted to the subject pressing
buttons with hands held at either side, and since the subject cannot look at the buttons,
only a binary response (left or right hand) is practical. Consequently, none of the
established memory tasks that had been used previously in hypoglycaemia studies could
be used, as these all required verbal or written responses, usually to verbal questions. A
further restriction was the requirement for fixed timing of the memory task, so that the
fMRI signal could be correlated with the onset of the memory retrieval effort. Previous
fMRI studies of memory have used visual recognition tasks [23]. Typically this
paradigm requires subjects to view a series of images, and later to view the same images
mixed with new images, and identify each as old or new. This only requires subjects to
look at a screen while in the MRI scanner, and identify stimuli as new or old using left
and right hand button presses. The time of presentation of each test stimulus is known,
and hence the onset ofmemory retrieval can be linked to simultaneous fMRI acquisition
by appropriate computer software.
4.2.2 Pilot Study - Methods
In the present study, two forms of visual stimuli were used: faces and words. For the
face stimuli, digitized photographs of a Caucasian student population were used, and
scaled so that the head occupied 80% of the frame. Pictures were taken without
jewellery or spectacles. For the word stimuli, words with frequencies between 20 and 30
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in the series from Kucera & Francis [24] were used. Two batteries were created, each
containing 40 faces (20 male, 20 female) followed by 50 words.
These recognition memory tasks were piloted on 12 non-diabetic volunteers,
predominantly colleagues at the Royal Infirmary of Edinburgh and the University of
Edinburgh. Pilot studies took place in empty consulting rooms in the Royal Infirmary,
in silence, with instructions provided on a computer screen. Stimuli were presented to
volunteers on a computer screen positioned at arms length, and volunteers were asked
to attempt to memorize these. To improve retention, subjects were asked to rate each
word or face for its attractiveness, although these data were not analysed.
Recognition was tested after an interval of one hour. For the face recognition task,
subjects viewed a series of 90 faces, of which 40 had been seen before (targets) and 50
were new (decoys). For the word recognition task, there were 140 stimuli, comprising
50 targets and 90 decoys. Subjects were required to identify targets by pressing a left-
hand or right-hand computer key.
Individual responses were classified as 'Correct Hits', 'Incorrect Flits' (i.e. subject stated
that they had seen the face or word previously when in fact they had not), 'Correct
Rejections' and 'Incorrect Rejections'. The numbers of responses in each category were
calculated for each subject. Flowever, none of these provides an adequate measure of
memory performance, as they may be influenced by strategy. If memory performance
were judged on 'Correct Hits' alone, then subjects responding 'Yes' every time would
score full marks. If performance were judged on 'Correct Hits' + 'Correct Rejections'
then a tendency to answer 'No' would give higher marks, as there were more decoys
than targets. Instead, stimuli correctly identified were converted into an adjusted score,
weighted for the true frequency of targets and decoys so that the chance score was 50.
The equation for this is (H/T+R/D)x50, where H is the number of correct hits, R is
correct rejections, T is targets and D is decoys.
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4.2.3 Pilot Study - Results and Conclusions
Mean corrected scores of 71% and 75% were obtained for the face and word tasks
respectively. The expected minimum score (i.e. that which would be obtained by
random answering) is 50%. These mean scores appeared to fall appropriately between
floor (50%) and ceiling (100%) limits, indicating that the visual recognition tasks were
not excessively hard or easy. There were no individual test items that were excessively
easy or hard (i.e. no words or faces that were consistently recognised or not recognised
by most subjects). Accordingly, the memory task was felt appropriate to be used in the
main study.
Page 85
4.3 Main Study - Methods
4.3.1 Ethics
The study was approved by the local research ethics committee, and all subjects
provided written and informed consent to participate.
4.3.2 Subjects
For the main study, sixteen right-handed non-diabetic adults (9 male) for whom English
was a first language were recruited. Subjects with active medical conditions or previous
histories of seizure, cerebral injury or any other contra-indication to experimental
hypoglycemia were excluded. All subjects completed the National Adult Reading Test
(NART) at the start of their first session. In the NART, the subject is presented with a
list of words that are used very infrequently in everyday spoken English, and is asked to
read them aloud. Pronunciation is scored with reference to an audio tape of correct
pronunciation. Performance on this test has been shown to correlate very highly with
best-ever Wechsler Adult Intelligence Test scores [25]. The mean score on the National
Adult Reading Test was 40, approximating to a WAIS-R Full Scale IQ score of 118.
Subject details are given in Table 4.1.




Table 4.1. Subject details. Mean and range are provided for age, BMI
and NART score; numbers male and female are given for gender.
4.3.3 Study outline and glucose clamp procedure
Subjects underwent two study sessions (hypoglycaemia and euglycaemia) separated by at
least two weeks. The study design is illustrated in Figure 4.1.
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Subjects fasted overnight and refrained from drinks containing caffeine or other
stimulants. Soluble human insulin was infused intravenously at a fixed rate according to
estimated body surface area (60 mU m2 min4), and 20% dextrose was infused at a
variable rate to achieve target blood glucose concentrations. Blood was drawn from a
vein in the non-dominant hand which had been placed within a hot blanket to arterialize
venous blood. Samples were taken every 3 to 5 minutes for measurement of whole
blood glucose using a Yellow Springs 2300 analyser.
Blood glucose concentrations were stabilized at 4.5 mmol/L for 30 minutes, and the
face and word stimuli were presented for learning. Blood glucose was then lowered to
2.5 mmol/L (hypoglycaemia condition) or maintained at 4.5 mmol/L (euglycaemia
condition) for one hour. During this hour, subjects were given other cognitive tasks to
prevent rehearsal of stimuli (these tasks form the basis of the study described in chapter
6). At the end of the experimental hour the blood glucose concentration was raised to,
or maintained at, 4.5 mmol/L and the clamp was discontinued. Subjects were given a
meal and allowed to rest for one hour to prevent any 'hangover' effect of hypoglycaemia
affecting recall results.
After the recovery hour, blood glucose was measured to ensure euglycaemia. Subjects
were then tested for recognition of the face and word stimuli, with simultaneous fMRI
acquisition.
Learning: words Recognition testing
and faces presented and fMRI scanning
Clamped hypwheamia
(2,5 mmoi(L)
Figure 4.1. Sequence of experimental procedures.
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4.3.4 Memory tests, procedure and analysis
The memory tests were the face and word recognition tests described in section 4.2.2.
During the learning phase, the face and word stimuli were presented for variable
durations of 3 to 6 seconds on a laptop computer screen at arms length, and subjects
were asked to attempt to memorize them. To improve retention, subjects rated each
word or face for its attractiveness, although these data were not analysed.
Recognition was tested while subjects were in the MRI scanner. Subjects viewed stimuli
on a screen directly above their face, with focal aids if required. Stimuli were presented
for variable durations of 3 to 6 seconds using E-prime Version 1.0 (Psychology
Software Tools Inc, Pittsburgh, USA) and IFIS 1.09 software (MRI Devices
Corporation, Waukesha, USA). Subjects were required to identify targets by pressing a
left-hand button, and decoys by pressing a right-hand button.
Corrected memory scores were calculated using the method described in section 4.2.2.
Performance was compared for euglycaemia and hypoglycaemia using repeated-
measures analysis of variance. Order of glycaemic condition and order of stimulus
battery were counterbalanced within the experimental design, and were included as
between-subjects factors. Analyses were performed using SPSS version 11.0. It was
estimated that with a sample size of 16 and two-tailed a of 0.05, the study had 80%
power to detect a difference of 0.75 s.d. and 90% power to detect a difference of 0.88
s.d.
4.3.5 Imaging acquisition and analysis
Scanning was carried out at the Brain Imaging Research Centre facilities at the Western
General Hospital, Edinburgh. The scanner was a 1.5 Tesla General Electric Signa fitted
with Echospeed gradients, using the standard head coil. Acquisition durations were 600
seconds (face paradigm) and 840 seconds (word paradigm). Contiguous gradient echo,
echoplanar images (TR 2500 ms, TE 40 ms) were collected from 30 5mm slices
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(interleaved acquisition) parallel to the anterior-posterior commissure plane. The matrix
acquired was 64 x 64 with an in-plane resolution of 3 x 3 mm. Button responses to the
memory tasks were logged simultaneously. A T1 -weighted structural scan was acquired
after fMRI acquisition. Images in each series were registered to the initial image to
correct for head motion. EPI-volumes were then co-registered to the T1-weighted
structural volume and aligned to standard coordinates, and data was smoothed with a 6
mm Gaussian kernel to allow for variability in gyral anatomy and location of activation
between subjects.
fMRI data were analysed by colleagues at the Centre for Functional Imaging Studies at
the University of Edinburgh, using the statistical parametric mapping package SPM99.
The fMRI design for the test was event-related. Events were modelled using canonical
haemodynamic response functions and six movement regressors. Events were classified
by subject responses as 'Correct Hit', 'Correct Rejection, 'Incorrect Hit', or 'Incorrect
Rejection'. For a small number of events no response was given, and these were
assigned to the relevant incorrect category. First-level fixed-effects T-contrasts were
made between the euglycaemia and hypoglycaemia conditions. The T threshold was set
at 3.09, and cluster size threshold at 10 voxels.
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4.4 Results
4.4.1 Blood glucose and timing
Blood glucose profiles are depicted in Figure 4.2. For hypoglycaemia studies, the mean
blood glucose was 4.36 (SD=0.24) mmol/L during the initial euglycaemic phase, and
2.53 (0.22) mmol/L during the experimental phase. For euglycaemia studies, equivalent
means were 4.31 (0.24) mmol/L and 4.42 (0.28) mmol/L respectively.
In hypoglycaemia studies, the mean (SD) time to lower blood glucose from 4.5 mmol/L
to a stable level of 2.5 mmol/L was 30 (7) minutes. The interval between the end of the
glucose clamp and the start of fMRI scanning was 86 (10) minutes in hypoglycaemia









Figure 4.2. Mean achieved blood glucose during initial euglycaemic phase
and experimental phase (euglycaemia or hypoglycaemia). Plots are broken
between phases due to the variable time taken to achieve hypoglycaemia.
4.4.2 Memory performance
Memory performance is shown in Table 4.2. Unadjusted data are given for 'Correct
Hits', 'Incorrect Hits', 'Correct Rejections' and 'Incorrect Rejections'. 'Adjusted Score',
as described in Section 4.2.5, was the principal performance measure. 'Correct Hits'
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minus 'Incorrect Hits' (or 'false alarms') is also reported, as this is another commonly
used measure of discriminant memory performance.
Stimulus Score Eu Hypo P
Words Correct Hits 39.2(6.4) 40.6 (6.7) 0.367
Correct Rejections 69.9 (12.8) 65.8 (17.1) 0.113
Incorrect Hits 19.8 (12.6) 20.9 (15.8) 0.553
Incorrect Rejections 10.7 (6.4) 8.1 (5.5) 0.030
CH-IH 19.4 (12.3) 19.7 (15.9) 0.915
Adjusted Score 78.0 (8.0) 77.1 (12.2) 0.701
Faces Correct Hits 24.4 (6.6) 25.4 (5.7) 0.624
Correct Rejections 36.6 (6.8) 35.1 (7.2) 0.335
Incorrect Flits 13.3 (6.8) 14.1 (7.0) 0.564
Incorrect Rejections 15.6 (6.6) 14.3 (5.5) 0.524
CH-IFI 11.1 (7.6) 11.3 (5.7) 0.914
Adjusted Score 67.2 (8.6) 66.9 (7.4) 0.895
Table 4.2. Mean (SD) performance on memory tasks following
euglycaemia (Eu) and hypoglycaemia (Hypo). Performance is reported by
six different measures for word and face tasks separately, with P-values for
comparison by repeated-measures ANOVA.
Memory performance was almost identical for euglycaemia and hypoglycaemia studies.
The adjusted face scores following euglycaemia and hypoglycaemia were 67.2 (SD 8.2)
and 66.9 (7.4) respectively (r|2=0.002, P=0.895). Equivalent adjusted word scores were
78.0 (8.0) and 77.1 (12.2) respectively (r|2=0.013, P=0.701). For both face and word
tasks, adjusted scores were significantly above the chance level of 50 (P<0.001 in both
cases).
Although post hoc analyses are unreliable, uncorrected scores were examined for evidence
of different response strategies. There were no significant differences in unadjusted
scores (e.g. 'Correct Hits' and 'Correct Rejections') between hypoglycaemia and
euglycaemia. For Incorrect Rejections in the word task, the P-value for the
euglycaemia-hypoglycaemia comparison was 0.030, which crosses the standard threshold
of 0.05, but with adjustment for multiple comparisons this is clearly non-significant.
Overall, subjects gave a 'Hit' response (whether correct or not) for approximately 43%
of word items, representing a positive bias (true proportion of targets: 35.7%), and 43%
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of face items, representing a slight negative bias (true proportion of targets: 44.4%).
The proportion of 'Hit' and 'Reject' responses were not different for euglycaernia and
hypoglycemia conditions.
The study had 90% power to detect a difference of 0.88 standard deviations, and thus it
is improbable that there is a true effect of greater magnitude than this. In fact the scores
were almost identical for hypoglycaemia and euglycaemia, suggesting that the
hypoglycemic intervention had no effect whatsoever on memory consolidation.
The responses were analysed in detail, looking for evidence that poorly designed test
batteries may have contributed to the null result. The mean scores fell appropriately
between the floor (50%) and ceiling (100%) limits, suggesting that the tests were neither
too hard nor too easy to be sensitive to hypoglycemic deterioration. Correct response
rates were then calculated for individual stimuli to determine their difficulty. This
stimulus difficulty showed a normal distribution, with most stimuli being correctly
identified on ~70% of occasions, and no very easy or very hard items. (The rationale
here is that, had a test battery been composed of half very hard and half very easy items,
then following both euglycaemia and hypoglycaemia the former would be answered
randomly and the latter correctly. Thus, hypoglycaemia could not affect performance
due to a combination of floor and ceiling effects, but the total score would be mid-way
between 50% and 100%, giving the appearance of freedom from such effects. There
was no evidence of such a problem).
4.4.3 Brain activation
Statistical parametric mapping (SPM) is the process by which fMRI data are analysed to
identify regions of the brain that show significantly different activation for different
experimental conditions (hypoglycaemia vs euglycaemia in this case). Voxels ('volume
cells') are the smallest volume for which activation can be measured, i.e. the resolution
of the scanning process, 3x3x3 mm in this case. Because an exceptionally large number
of voxels are imaged within the brain, type 1 statistical error is certain without
appropriate correction. If a P-threshold of 0.05 were set for each voxel, the comparison
of euglvcaemia vs hypoglycaemia would pass this threshold due to random chance alone
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in thousands of voxels. Such false positives are filtered out in two ways. Firstly, single
voxels are ignored; only clusters of contiguous voxels achieving significance are
considered. Secondly, P-values for statistical significance are adjusted for multiple
comparisons.
SPM outputs are presented in Figures 4.4 — 4.12. Fig 4.3 is a schematic output that
illustrates the layout of Figures 4.4 — 4.12. In each case, the output displays the position
and size of clusters of at least 10 adjacent voxels that achieve basic statistical
significance. The locations of clusters are given as X Y Z coordinates in the table, and
depicted in each of the 'glass brain' diagrams. Statistical significance is calculated at
both voxel and cluster level, and reported uncorrected and corrected for the entire brain
volume. These are fixed-effects analyses, which would normally be preliminary analyses.
Figures 4.4 and 4.5 show comparisons for hypoglycaemia vs euglycaemia for all face
stimuli correcdy identified, whether as hits or rejections. A cluster low in the right
occipital cortex, adjacent to the cerebellum, shows reduced activation after
hypoglycemia (P=0.046). Figures 4.6 and 4.7 show comparisons for all face stimuli
correctly identified as hits. The same right occipital cortex cluster shows reduced
activation after hypoglycaemia (P=0.016). A cluster in the left frontal cortex tends to
increased activation after hypoglycaemia, but does not achieve significance (P=0.08).
Figure 4.8 shows comparisons for hypoglycaemia vs euglycaemia for all face stimuli,
irrespective of response. A cluster in the midline, close to the calcarine sulcus, shows
increased activation after hypoglycaemia (P=0.027)
Comparisons for hypoglycaemia vs euglycaemia for word stimuli are shown in Figures
4.9 and 4.10 (all word stimuli correctly identified as hits or rejections) and Figures 4.11
and 4.12 (all word stimuli correctly identified as hits). There are no significant
differences.
Thus, significant differences for hypoglycaemia vs cuglycaemia were seen in two areas:
low in the right occipital cortex, and in the posterior midline. Neither area is known to
be associated with memory. Fixed-effects analyses exclude inter-individual variation,
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and so do not permit inferences to be made about the effects of hypoglycaemia in the
population. The statistical significance levels are borderline using the liberal fixed-
effects model, and in the absence of any behavioural (memory performance) results
requiring functional correlation, a more conservative random-effects analysis was not
performed [26]. It was concluded that the fMRI data do not show evidence of altered
brain activation during the recognition memory task following hypoglycaemia.
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Figure 4.3 Statistical Parametric Mapping
Illustration/Explanation of Subsequent Figures
Statistics: volume summary (p-values corrected for entire volume)
set-level cluster-level voxel-level
^ corrected kct 0r uncorrected P corrected T (ZJ ^ uncorrected
Aty,£.\iiiiii/
0.129 74 0.003 0.038 5. 06 ( 5.05) 0. 000 2 -68 24
0.304 56 0.009 0.745 4.20 < 4.19) 0. 000 -26 66 6
0.885 4 .07 ( 4.07) 0. 000 -34 62 6
0.607 40 0.023 0.921 4.03 ( 4.02) 0. 000 -16 -82 -16
0.999 12 0.185 0.922 4 . 03 ( 4.02) 0.000 -72 -32 -18
0. 924 25 0.064 0.982 3.89 ( 3.89) 0.000 20 -88 24
0.995 16 0.129 0.993 3.83 ( 3.82) 0. 000 -28 18 -24
1. 000 11 0.203 0.995 3.81 ( 3.81) 0. 000 -20 -16 -34
0.998 14 0.154 1.000 3.69 ( 3.69) 0.000 -24 -90 -4
0. 995 16 0.129 1.000 3.61 { 3.61) 0. 000 -32 -76 -16
0. 998 14 0.154 1.000 3.60 ( 3.60) 0. 000 -56 8 -20
0.997 15 0.141 1.000 3.56 ( 3.56) 0.000 -6 50 30
1. 000 11 0.203 1.000 3. 56 ( 3.56) 0. 000 28 -36 -18
0. 999 12 0.185 1.000 3. 55 ( 3.55) 0. 000 -22 12 48
0.938 24 0.068 1.000 3.53 ( 3.53) 0.000 -54 22 -22
0. 960 22 0.080 1. 000 3. 38 ( 3.38) 0. 000 -8 46 14
1. 000 11 0.203 1.000 3. 37 ( 3.37) 0.000 32 14 36
1.000 3 .22 ( 3.22) 0. 001 40 14 38






















Figure 4.4 Statistical Parametric Mapping
Faces: Hypoglycaemia Correct > Euglycaemia Correct















Analysis is restricted to faces
correctly identified, either as
new or old.







Height threshold T = 3.09
Extent threshold k = 10 voxels













































































































































Figure 4.5 Statistical Parametric Mapping
Faces: Flypoglycaemia Correct < Euglycaemia Correct
('Correct hits' plus 'correct rejections')
COMMENT:
Analysis is restricted to faces
correctly identified, either as
new or old.






This is centred on 20 -88 -20,
and is identified by the black
arrow in the figures to the left.
SPMresults:./rrtmeyer/Hypo/Ana!ysis/Faces
Height threshold T = 3.09
Extent threshold k = 10 voxels
Statistics.' volume summary (p-values corrected for entire volume)
set-level cluster-level voxel -level
x,y,z {mm}
P c ^ corrected kE p uncorrected ^ corrected T ^ uncorrected
0.686 8 0. 046 96 0.001 0.050 4 . 99 ( 4.98) 0.000 20 -88 -20
0. 892 27 0.055 0.414 4.44 ( 4.44) 0. 000 40 -32 -30
0. 924 25 0.064 0.815 4.14 ( 4.14) 0. 000 34 -78 -22
0.701 36 0.030 0.993 3.83 ( 3.83) 0.000 32 -62 44
0. 909 26 0.059 0.993 3.83 ( 3.82) 0.000 -44 -64 -26
1.000 11 0.203 0.997 3.77 ( 3.77) 0. 000 46 6 50
1. 000 11 0.203 1. 000 3.36 ( 3.35) 0.000 -68 -32 16
1. 000 10 0.224 1.000 3.35 ( 3.35) 0. 000 64 -2 -4
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Figure 4.6 Statistical Parametric Mapping
Faces: Hypoglycaemia Correct Hits > Euglycaemia
Correct Hits
SPMresults :./mmeyer/Hypo/Anaiysis/Faces
Height threshold T = 3.09
Extent threshold k = 10 voxels
COMMENT:
Analysis is restricted to faces
correctly identified as old.






Statistics: volume summary (p-values corrected for entire volume)
set-level cluster-level voxel--level
x,y,z{mm}
P c ^ corrected kE p uncorrected corrected T <ZJ ^ uncorrected
0.131 13 0.277 58 0.008 0.124 4 .78 ( 4.77) 0. 000 4 -68 22
0.080 84 0.002 0.346 4.50 ( 4.49) 0.000 -26 66 6
0.666 4 .26 < 4.25) 0 . 000 -34 62 6
0. 540 43 0.019 0.886 4.07 ( 4.07) 0. 000 -16 -82 -16
0. 969 21 0 .086 0.924 4.02 ( 4.02) 0. 000 -30 20 -26
0.950 23 0.074 0.946 3. 99 ( 3.98) 0. 000 20 -88 24
0.924 25 0.064 0. 980 3.90 ( 3.89) 0. 000 -20 12 46
0.748 34 0.034 0.996 3.80 ( 3.79) 0. 000 -50 -76 40
0. 992 17 0.119 0. 998 3.77 < 3.76) 0. 000 -32 -76 -16
0.977 20 0.093 1.000 3.65 ( 3.65) 0 . 000 40 14 38
0.793 32 0.039 1.000 3.63 ( 3.63) 0.000 -10 42 14
1.000 11 0.203 1.000 3.58 ( 3.57) 0. 000 -32 36 4
1. 000 11 0.203 1.000 3.48 < 3.48) 0. 000 -52 22 -20
1. 000 10 0.224 1. 000 3.37 ( 3.36) 0. 000 52 44 -16
table shows at most local maxima > 8.0mm apart per cluster
Height threshold: T = 3.09, p = 0.001 (1.000 corrected) Degrees of freedom = [1.0, 3399.1]
Extent threshold: k = 10 voxels, p = 0.224 (1.000 corrected) Smoothness FWHM = 7.8 7.8 8.0 {mm} = 3.9 3.9 4.0 {voxels}
Expected voxels per cluster, <k> = 7.262 Search volume: S = 2205272 mmA3 = 275659 voxels = 4226 2 resels
Expected number of clusters, <c> = 9.09 Voxel size: [2.0, 2.0, 2 0] mm (1 resel = 61.41 voxels)
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Figure 4.7 Statistical Parametric Mapping





Analysis is restricted to faces
correctly identified as old.






This is centred on 20 -88 -20,
and is identified by the black
arrow in the figures to the left.
SPMresults: /mmeyer/Hypo/Analysis/'Faces
Height threshold T = 3.09
Extent threshold k = 10 voxels
Statistics: volume summary (p-values corrected for entire volume)
set-level cluster-level voxel -level
x,y,z{mm}
P c P corrected *E P uncorrected P corrected T <A> P uncorrected
0.801 7 0. 016 120 0.000 0.072 4.91 < 4.90) 0.000 20 -88 -20
0. 587 4 . 32 ( 4.31) 0 . 000 34 -78 -22
0.793 32 0.039 0.299 4.55 ( 4.54) 0. 000 40 -32 -30
0.607 40 0.023 0.841 4.12 < 4.11) 0. 000 -46 -64 -26
0.892 27 0.055 0.910 4 . 04 ( 4.04) 0. 000 -24 -56 -24
0.382 51 0.012 0.947 3. 99 ( 3.98) 0.000 32 -62 44
0. 999 12 0.185 1.000 3.62 ( 3.62) 0.000 -10 -42 -4
1. 000 10 0.224 1. 000 3.43 ( 3.43) 0. 000 -70 -46 0
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Figure 4.8 Statistical Parametric Mapping
Faces: Flypoglycaemia > Euglycaemia
(Irrespective of response or response accuracy)
COMMENT:
Analysis is restricted to all
faces irrespective of response.






This is centred on 4 -68 22,
and is identified by the black
arrow in the figures to the left.
SPMresults 1/mmeyer/Hypo/Analysis/Faces
Height threshold T = 3.09
Extent threshold k = 10 voxels





















































































































Figure 4.9 Statistical Parametric Mapping
Words: Hypoglycaemia Correct > Euglycaemia Correct
('Correct hits' plus 'correct rejections')
COMMENT:
Analysis is restricted to
words correctly identified,
either as old or new.







Height threshold T = 3.09
Extent threshold k = to voxefs
spm<t5694>
Statistics: volume summary (p-values corrected for entire volume)
set-level cluster-level voxel-level
p C ^ corrected LU ^ uncorrected P corrected T P uncorrected
0.980 4 0.969 22 0.094 0. 672 4.22 ( 4.22) 0.000 72
0.950 24 0.082 0. 998 3.73 ( 3.73) 0. 000 38
0.996 16 0.148 1. 000 3.65 ( 3.65) 0.000 54
1.000 11 0.225 1. 000 3.29 ( 3.29) 0.001 -58
Figure 4.10 Statistical Parametric Mapping
Words: Hypoglycaemia Correct < Euglycaemia Correct
('Correct hits' plus 'correct rejections'
SPM<T5694>
COMMENT:
Analysis is restricted to
words correctly identified,
either as old or new.







Height threshold T = 3.09
Extent threshold k = 10 voxels
Statistics: volume summary (p-values corrected for entire volume)
set-level cluster-level voxel -level
x,y,z{mm})
corrected *E P uncorrected ^ corrected T <z=> uncorrected
0.128 80 0.004 0.444 4.39 ( 4.39) 0.000 30 12 56
0. 829 32 0.048 0.676 4.22 < 4.22) 0.000 32 -76 58
0.976 21 0.101 0.805 4.12 ( 4.12) 0. 000 0 -22 -32
0. 950 24 0.082 0. 949 3.95 ( 3.95) 0. 000 -54 20 -44
1.000 10 0.247 0. 999 3.70 ( 3.69) 0.000 40 4 40
0. 982 20 0.109 1.000 3.66 ( 3.66) 0. 000 42 -8 -36
0. 899 28 0.062 1. 000 3. 65 ( 3.65) 0. 000 36 -74 26
0. 998 14 0.174 1. 000 3.60 ( 3.60) 0. 00 0 62 22 -18
1. 000 11 0.225 1.000 3.48 ( 3.48) 0. 000 62 -38 -8
1. 000 10 0.247 1. 000 3.46 ( 3.46) 0. 000 -30 -2 56
0.982 20 0.109 1. 000 3.45 ( 3.44) 0. 000 -30 12 62
0.990 18 0.126 1. 000 3.43 ( 3.42) 0. 000 -34 -22 64
1. 000 10 0.247 1. 000 3.38 ( 3.38) 0. 000 -24 -82 -38
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Figure 4.11 Statistical Parametric Mapping
Words: Hypoglycaemia Correct Hits > Euglycaemia
Correct Hits
COMMENT:
Analysis is restricted to
words correctly identified as
old.







Height threshold T = 3.09
Extent threshold k = 10 voxels
Statistics: volume summary (p-values corrected for entire volume)
set-level cluster-level voxel-level
p C P corrected kE ^ uncorrected ^ corrected T (ZJ P uncorrected
. 980 4 0. 578 44 0.023 0. 664 4.23 { 4.23) 0. 000
0.990 18 0.126 0.936 3.97 ( 3.97) 0. 000
0.960 23 0.088 1.000 3.60 ( 3.60) 0. 000
0. 993 17 0.137 1.000 3.45 { 3.45) 0. 000







Figure 4.12 Statistical Parametric Mapping




Analysis is restricted to
words correctly identified as
old.







Height threshold T = 3.09
Extent threshold k = 10 voxels
Statistics: volume summary (p-values corrected for entire volume)
set-level cluster-level voxel'-level
x,y,z{mm}
P c p corrected *E P uncorrected ^ corrected T (ZJ " uncorrected
0.802 7 0.146 77 0.004 0.273 4 .55 ( 4.54) 0.000 30 14 56
0. 960 23 0.088 0.861 4.07 ( 4.07) 0. 000 0 -22 -32
0. 987 19 0.117 0.912 4 . 01 ( 4.01) 0.000 32 -76 56
0. 620 42 0.026 0.987 3.84 ( 3.84) 0. 000 -32 -22 64
0. 999 12 0.206 1. 000 3.66 ( 3.65) 0.000 -30 -2 56
1.000 11 0.225 1. 000 3.52 ( 3.52) 0. 000 -54 20 -44
0. 899 28 0.062 1. 000 3.46 ( 3.46) 0.000 -30 12 60
4.5 Discussion
4.5.1 Discussion - results and interpretation of present study
In the present study, one hour of hypoglycaemia at 2.5 mmol/L occurring between the
learning and recognition phases of a memory test did not affect memory performance.
It is possible that hypoglycaemia has no effect on consolidation, but at least five
alternative explanations can be proposed. In this sense, the null findings are helpful to
further research.
First, the study may have been underpowered to detect an effect of hypoglycaemia on
memory. Advance sample size estimates were limited by a lack of previous data. A
sample size of 16 was selected because previous hypoglycaemia studies that have yielded
positive results have generally been of a similar or smaller size. There are significant
additional logistic and financial issues associated with fMRI studies, which would have
made it difficult to complete a larger study; 16 subjects is quite a large number for an
fMRI study. Our advance power calculation indicated that the study should have good
power to detect a difference of 0.75-0.88 standard deviations on any measure. This is a
'large' effect, according to Cohen's conventions [27]; if the effects of hypoglycaemia
were more modest, then the study would be underpowered. However, although not a
statistically rigorous observation, it is notable that performance in the present study was
almost identical following euglycaemia and hypoglycaemia, which does not support the
possibility of an effect failing to achieve significance.
Second, the consolidation process may have been complete by the time hypoglycaemia
was achieved (20-40 minutes after stimulus exposure). Unfortunately, despite extensive
research, there is no clear account of the duration of the consolidation process. Diverse
interventions have been shown to affect recall of memories that were acquired minutes
or hours beforehand, including drug administration [28,29,30] and traumatic concussion
[31]. There is also a very large body of evidence for the improving effects of sleep,
immediately or overnight, on memory consolidation [32,33]. These studies suggest that
consolidation takes place during the minutes or hours after stimulus exposure. On the
other hand, studies of patients with hippocampal lesions have shown a temporal
gradient for amnesia over years [34,35,36], suggesting a chronic transfer of memory
from hippocampal to other (perhaps cortical) sites. This has been supported by a recent
fMRI study in which recognition-associated brain activation was measured 1, 2, 30 and
90 days after stimulus exposure, and was found to progressively decrease in the
hippocampus and increase in the ventral medial prefrontal region [32]. Thus,
consolidation appears to be a chronic and heterogeneous process. It is possible that
there is a very early phase of consolidation (e.g. less than 20 minutes after learning)
which is susceptible to acute, reversible, metabolic derangement. If so then a different
result might be expected if hypoglycaemia could be induced instantaneously, but this
would not be relevant to the daily life of people with diabetes, in whom hypoglycaemia
develops more slowly, and often over hours [37],
Third, the level of hypoglycaemia induced (2.5 mmol/L) may have been insufficient.
There is some evidence that different cognitive processes are differentially sensitive to
hypoglycaemia [38], and although it is known that the entire memory process from
learning to recall is affected by hypoglycaemia at 2.5 mmol/L [17,18,19], more profound
hypoglycaemia may be necessary to disrupt consolidation. Anterograde amnesia is well
recognised after electro-convulsive therapy, epileptic seizure, general anaesthesia and
alcohol intoxication [39,40,41,42,43] in addition to traumatic injury and other
pharmaceutical interventions as cited above, suggesting that any cause of major cerebral
dysfunction may have an amnesic effect.
Fourth, it is possible that the brain may work harder, or differently by recruitment of
other brain regions, to achieve the same result during hypoglycaemia. However, the
functional imaging data revealed only two brain areas with apparently different
activation for the hypoglycaemia and euglycaemia conditions. These brain regions are
not known to be associated with memory, and a liberal fixed-effects analysis yielded
only borderline statistical significance. We conclude that the functional imaging showed
no significant effect of hypoglycaemia.
Fifth, the present study measured recognition of stimuli, whereas most other studies of
memory during hypoglycaemia have measured recall (retrieval of information). Testing
of recognition was necessary for a number of reasons relating to the use of fMRI, but it
is possible that less robust memory encoding is sufficient for recognition, and hence
that recognition would be less disrupted by hypoglycaemia. However, in other studies, a
recognition task has been adequate to show both changes in memory performance and
fMRI brain activation following an intervention to affect consolidation [32], More
generally, visual recognition tasks have formed an important part of functional imaging
studies of memory [23]. The recognition material (i.e. the particular faces and words)
used in the present study was novel, but subjects were clearly able to identify stimuli
with above chance accuracy, and there was no evidence of floor or ceding effects at
either the test or the item level (see section 4.3.3), suggesting that the test should have
been sensitive to memory dysfunction if this had occurred.
The present study was intended to study a possible consequence of insulin-induced
hypoglycaemia, which is a common occurrence for people with insulin-treated diabetes.
Ideally, diabetic subjects would have been studied, but to do this would have
necessitated continuing the euglycaemic clamp during the MRI scanning to prevent
hypo- or hyperglycaemia, which could affect memory performance. Medical infusion
devices cannot be taken into MRI rooms because of the powerful magnetic field, and so
infusions must be managed remotely from an adjacent room using very long tubing.
Such facilities were not available at the site where this study was performed. The use of
non-diabetic subjects may limit the applicability of the results to diabetes. However, as
discussed in section 2.5.3, recurrent hypoglycaemia in diabetes appears to induce an
adaptive process such that cognitive function is relatively preserved during
hypoglycaemia in people with diabetes. It therefore seems unlikely that memory
impairment would have been seen in the present study had diabetic subjects been
studied.
4.5.2 Discussion - recent studies of memory consolidation
In a recently-published study, Jauch-Chara et al examined the effects of hypoglycaemia
on memory consolidation overnight in 16 type 1 diabetic and 16 non-diabetic subjects
[44]. Forty noun pairs were learned; during testing, the first word of each pair was
presented and the subject required to name the second word. At the start of each study
in the late evening, learning and testing of the same 40 word-pairs was repeated until a
minimum of 60% were recalled correctly, after which subjects slept overnight. Shortly
after the onset of stage 2 sleep, an insulin infusion was commenced: on experimental
nights, a steady fall in plasma glucose was induced over about an hour to a nadir of 2.2
mmol/1 (non-arterialized venous measurement). Recall was then retested in the
morning. The study was repeated on control nights, when plasma glucose was
maintained above 3.86 mmol/1. Overall there was a small but statistically significant
improvement overnight across all studies, consistent with the known effects of sleep on
consolidation, but the improvement was greater on control nights than on
hypoglycemia nights. The number of word pairs recalled after control nights was
about 5% higher than after hypoglycaemia nights. The results suggest that overnight
hypoglycemia disrupted consolidation ofmemories formed during the evening.
If one discounts issues of statistical power and concludes that the effect of
hypoglycaemia was nil in the present study, then why would an effect of hypoglycaemia
have been seen in the study by Jauch-Chara et aft They studied type 1 diabetic as well as
non-diabetic subjects, but as the effect of hypoglycaemia was greatest in non-diabetic
subjects this is unlikely to be the explanation. It also seems unlikely that recall of words
should be inherently more sensitive to hypoglycaemia than recognition of words. The
overall difficulty of the tests was very similar with scores of 75-80% correct in both
studies. In the study by Jauch-Chara et al, the hypoglycemic nadir was only slightly
lower than in the present study (2.2 vs. 2.5 mmol/L), and total hypoglycemic exposure
was less as the nadir was reached after a slow fall of 60 minutes, compared to an hour at
2.5 mmol/L in the present study. The interval between learning and hypoglycaemia was
not reported by Jauch-Chara et al, but was probably at least an hour longer than in the
present study; it is unlikely that a longer interval would cause greater impairment. The
most plausible explanation is that memory consolidation is more susceptible during
sleep.
Another recent study of consolidation is worthy of consideration. Takashima et al
studied 24 healthy volunteers using a very similar memory recognition task to that of the
present study [32]. Subjects viewed images of landscapes with and without buildings,
before and after a three hour rest period during which sleep was encouraged. About 30
minutes after the second session of stimulus exposure, recognition was tested with
simultaneous fMRI scanning (a similar methodology to the present study). There was
no significant correlation between duration of REM/stage 1 sleep and memory
performance. There was a significant correlation for stage 2 sleep, applying equally to
stimuli viewed before and after sleep, suggesting that the sleep may simply have
refreshed subjects for the recognition testing. There was a significant correlation for
slow-wave (deep) sleep, of greater magnitude (with statistical significance) for stimuli
viewed before sleep, suggesting that deep sleep had a positive effect on memory
consolidation.
From these two recent studies, suggestions for future research may be derived. First,
the need for an appropriate sample size is re-emphasized. Jauch-Chara et al did not
report a significant effect of hypoglycaemia in their subsets of 16 diabetic and 16 non-
diabetic subjects, but in all 32 subjects combined. Second, both studies assessed
consolidation during sleep, which appears to be a time of active re-processing of
memory [45], and therefore perhaps a time of increased susceptibility to interventions
such as hypoglycaemia.
4.5.3 Discussion - other functional brain imaging studies during
hypoglycaemia
Other researchers have managed to examine functional brain imaging during
hypoglycaemia. Rosenthal et al used fMRI to examine the effects of hypoglycaemia (2.5
mmol/L) on brain activation during cognitive tasks (finger tapping and reaction time) in
healthy subjects [46]. During hypoglycaemia there was increased activation in the
parietal association area, and decreased activation in the visual cortex, cerebellum,
hippocampus and pre-motor cortex by comparison with euglycaemia. The
hippocampus was the only one of these areas that was not activated by the cognitive
tasks. Teves et al used positron emitting tomography (PET) to measure cerebral blood
flow (CBF) during passive euglycaemia and hypoglycaemia (3.0 mmol/L) in healthy
subjects [47]. Global CBF fell by 6-8% during hypoglycaemia, with relatively increased
CBF in the thalamus, medial prefrontal cortex and right orbital prefrontal cortex, and a
26% relative decrease in CBF in the hippocampus. An earlier Edinburgh study in
diabetic subjects using single photon emission computed tomography (SPECT)
reported increased CBF in the frontal cortices and right thalamus during hypoglycaemia,
with decreases in the right cingulate and putamen [48].
It is impossible to amalgamate these studies to obtain a coherent account of changes in
activation throughout the brain. However, the hippocampus stood out as having
reduced fMRI activation or CBF during hypoglycaemia in the studies by Rosenthal et al
and Teves et al [46,47]. Given the sensitivity of the hippocampus to hypoglycaemic
damage [8,9,10], it seems plausible that hippocampal dysfunction during moderate
hypoglycaemia contributes to memory impairment.
4.5.4 Discussion - summary
In summary, one hour of hypoglycaemia at 2.5 mmol/1 after stimulus exposure did not
affect subsequent recognition performance, and did not alter brain activation patterns
during recognition. A large effect of moderate hypoglycaemia on memory consolidation
can be excluded, and thus the study provides some limited reassurance relevant to
diabetic daily life. In retrospect, the study was underpowered to detect an effect of
hypoglycaemia on memory comparable to effects seen in other studies, and future
studies should probably aim to recruit 30 or more subjects. It is possible that inducing
hypoglycaemia during sleep, varying the degree and duration of hypoglycaemia, or the
interval between stimulus exposure and testing, would yield different results. It is also
possible that moderate hypoglycaemia could disrupt performance on other memory
tasks (e.g. recall rather than recognition) which may better represent the role of memory
in everyday life; this is the hypothesis of the next chapter.
Acknowledgements
I thank Andrea Greve, Elvina Gountouna, Adam McNamara, Martin Meyer and Enrico
Simonotto of the Centre for Functional Imaging Studies, University of Edinburgh, for
their assistance with the fMRI scanning and analysis.
4.6 References
1. Baddeley AD. Human Memory: Theory and Practice, 2nd ed. Hove, UK: The
Psychology Press, 1996.
2. Scoville WB, Milner B. Loss of recent memory after hippocampal lesions. J Neurol
Neurosurg Psychiatry 1957; 20: 11-21.
3. Cohen NJ, Squire LR. Preserved learning and retention of pattern-analyzing skills
in amnesia: Dissociation of knowing how and knowing that. Science 1980; 210: 207-
210.
4. Gabrieli JDE, Cohen NJ, Corkin S. The impaired learning of semantic knowledge
following bilateral medial temporal-lobe resection. Train Cogn 1988; 7: 525-539.
5. Kroll NEA, Markowitsch HJ, Knight RT, von Cramon DY. Retrieval of old
memories: the temporofrontal hypothesis. Train 1997; 120: 1377-1399.
6. Chalmers JC, Risk MTA, Kean DM, Grant R, Ashworth B, Campbell IW. Severe
amnesia after hypoglycemia. Clinical, psychometric, and magnetic resonance
imaging correlations. Diabetes Care 1991; 14: 922-925.
7. Holemans X, Dupuis M, Misson N, Vanderijst J-F. Reversible amnesia in type 1
diabetic patient and bilateral hippocampal lesions on magnetic resonance imaging
(MRI). DiabetMed 2001; 18: 761-764.
8. Auer RN, Wieloch T, Olsson Y, Siesjo BK. The distribution of hypoglycaemic
brain damage. A-da Neuropathol (Terl) 1984; 64: 177-191.
9. Fujioka M, Okuchi K, Hiramatsu KI, Sakai T, Sagakuchi S, Ishii Y. Specific
changes in human brain after hypoglycemic injury. Stroke 1997; 28: 584-587.
10. Patrick AW, Campbell IW. Fatal hypoglycaemia in insulin-treated diabetes mellitus:
clinical features and neuropathological changes. DiabetMed 1990; 7: 349-354.
11. Strachan MW, Abraha FID, Sherwood RA, Lammie GA, Deary I}, Ewing FME,
Perros P, Frier BM. Evaluation of serum markers of neuronal damage following
severe hypoglycaemia in adults with insulin-treated diabetes mellitus. Diabetes Metab
Res Rev 1999; 15: 5-12.
12. Holmes CS, Hayford JT, Gonzalez JL, Weydert JA. A survey of cognitive
functioning at different glucose levels in diabetic persons. Diabetes Care 1983; 6:
180-185.
13. Pramming S, Thorsteinsson B, Theilgaard A, Pinner EM, Binder C. Cognitive
function during hypoglycaemia in type 1 diabetes mellitus. TrMedJ 1986; 292: 647-
650.
14. Harrad RA, Cockram CS, Plumb AP, Stone S, Fenwick P, Sonksen PFI. The effect
of hypoglycaemia on visual function: a clinical and electrophysiological study. Clin
Sci (Lond) 1985; 69: 673-679.
15. Widom B, Simonson DC. Glycemic control and neuropsychologic function during
hypoglycemia in patients with insulin-dependent diabetes mellitus. Ann Intern Med
1990;112:904-912.
16. Wirsen A, Talhroth G, Lindgren M, Agardh C-D. Neuropsychological performance
differs between type 1 diabetic and normal men during insulin-induced
hypoglycaemia. DiabetMed 1992; 9: 156-165.
17. Sommerfield AJ, Deary IJ, McAulay V, Frier BM. Moderate hypoglycemia impairs
multiple memory functions in healthy adults. Neuropsychology 2003; 17: 125-132.
Page 111
18. Sommerfield AJ, Deary IJ, McAulay V, Frier BM. Short-term, delayed, and
working memory are impaired during hypoglycemia in individuals with type 1
diabetes. Diabetes Care 2003; 26: 390-396.
19. Deary IJ, Sommerfield AJ, McAulay V, Frier BM. Moderate hypoglycaemia
obliterates working memory in humans with and without insulin treated diabetes. J
NeurolNeurosurg Psychiatry 2003; 74: 278-279.
20. Ogawa S, Lee TM, Kay AR, Tank DW. Brain magnetic resonance imaging with
contrast dependent on blood oxygenation. ProcNatlAcad Sci USA 1990; 87: 9868-
9872.
21. Blamire AM, Ogawa S, Ugurbil K, Rothman D, McCarthy G, Ellerman JM, Hyder
F, Rattner Z, Shulman RG. Dynamic mapping of the human visual cortex by high¬
speed magnetic resonance imaging. Proc NatlAcad Sci USA 1992; 89: 11069-11073.
22. Bandettini PA. MRI studies of brain activation: dynamic characteristics. In
FunctionalMRI of the Brain. Berkeley: Society of Magnetic Resonance in Medicine,
1993:144-151.
23. Gabrieli ]DE. Functional neuroimaging of episodic memory. In Cabeza R,
Kingstone A, eds: Handbook ofFunctionalNeuroimaging ofCognition. Cambridge, Mass:
MIT Press, 2001: 253-291.
24. Kucera FI, Francis WN. Computational Analysis of Present-Day American English.
Providence, RI: Brown University Press, 1967.
25. Crawford JR. Estimation of premorbid IQ: a review of recent developments. In
Crawford JR, Parker DM, eds: Developments in Clinical and Experimental
Neuropsychology. New York: Plenum, 1989: 55-74.
26. Worlsley KJ, Liao CH, Aston }, Petre V, Duncan GH, Morales F, Evans AC. A
general statistical analysis for fMRI data. Neuroimage 2002; 15: 1-15.
27. Cohen J. Statistical power analysis for the behavioral sciences. Hillsdale, NJ: Erlbaum,
1992.
28. Harmer CJ, Bhagwagar Z, Cowen PJ, Goodwin GM. Acute administration of
citalopram facilitates memory consolidation in healthy volunteers. Psychopharmacol
2002;163:106-110.
29. Colrain IM, Mangan GL, Pellett OL, Bates TC. Effects of post-learning smoking
on memory consolidation. Psychopharmacol 1992; 108: 448-451.
30. McGaugh JL. Dissociating learning and performance: drug and hormone
enhancement ofmemory storage. Brain Res Bull 1989; 23: 339-345.
31. Yarnell PR, Lynch S. Retrograde memory immediately after concussion. Eancet
1970; 863-865.
32. Takashima A, Petersson KM, Rutters F, Tendolkar I, Jensen O, Zwarts MJ,
McNaughton BL, Fernandez G. Declarative memory consolidation in humans: a
prospective functional magnetic resonance imaging study. Proc NatlAcad Sci USA
2006;103:756-761.
33. Stickgold R. Sleep-dependent memory consolidation. Nature 2005; 437: 1272-1277.
34. Milner B, Corkin S, Teuber FIL. Further analysis of the hippocampal amnesic
syndrome: 14-year follow-up study of FIM. Neuropsychology 1968; 6: 215-234.
35. Rempel-Clower NL, Zola SM, Squire LR, Amaral DG. Three cases of enduring
memory impairment after bilateral damage limited to the hippocampal formation. J
Neurosci 1996; 16: 5233-5255.
36. Haist F, Bowden Gore J, Mao FI. Consolidation of human memory over decades
revealed by functional magnetic resonance imaging. Nat Neurosci 2001; 4: 1139-
1145.
Page 112
37. Bode BW, Schwartz S, Stubbs HA, Block JE. Glycemic characteristics in
continuously monitored patients with type 1 and type 2 diabetes: normative values.
Diabetes Care 2005; 28: 2361-2366.
38. Holmes CS, Koepke KM, Thomson 11G. Simple versus complex performance
impairments at three blood glucose levels. Psychoneuroendocrinol 1986; 11: 353-357.
39. Squire LR, Slater PC, Miller PL. Retrograde amnesia and bilateral electroconvulsive
therapy. Long-term follow-up. Arch Gen Psychiatry 1981; 38: 89-95.
40. Weiner RD. Retrograde amnesia with electroconvulsive therapy: characteristics and
implications. Arch Gen Psychiatry 2000; 57: 591-592.
41. Eich E, Reeves JL, Katz RL. Anesthesia, amnesia, and the memory/awareness
distinction. AnesthAnalg 1985; 64: 1143-1148.
42. Shaw GK. Alcohol and the nervous system. Clin EndocrinolMetab 1978; 7: 385-404.
43. Butler CR, Graham KS, Hodges JR, Kapur N, Wardlaw JM, Zeman AZ. The
syndrome of transient epileptic amnesia. Ann Neurol 2007; 61: 587-598.
44. Jauch-Chara K, Hallschmid M, Gais S, Schmid SM, Oltmans KM, Colmorgen C,
Born J, Schultes B. Hypoglycemia during sleep impairs consolidation of declarative
memory in type 1 diabetic and healthy humans. Diabetes Care 2007; 30: 2040-2045.
45. Gais S, Born J. Declarative memory consolidation: mechanisms acting during
human sleep. Learning <& Memory 2004; 11: 679-685.
46. Rosenthal JM, Amiel SA, Yaguez L, Bullmore E, Hopkins D, Evans M, Pernet A,
Reid H, Giampietro V, Andrew CM, Suckling J, Simmons A, Williams SCR. The
effect of acute hypoglycemia on brain function and activation. A functional
magnetic resonance imaging study. Diabetes 2001; 50: 1618-1626.
47. Teves D, Videen TO, Cryer PE, Powers WJ. Activation of human medial
prefrontal cortex during autonomic responses to hypoglycemia. Proc Natl Acad Sci
USA 2004; 101: 6217-6221.
48. MacLeod KM, Gold AE, Ebmeier KP, Hepburn DA, Deary IJ, Goodwin GM,
Frier BM. The effects of acute hypoglycemia on relative cerebral blood flow
distribution in patients with type I (insulin-dependent) diabetes and impaired
hypoglycemia awareness. Metabolism 1996; 45: 974-980.
Chapter 5
Effects of Hypoglycaemia on Learning, Recall
and Prospective Memory
5.1 Introduction
In all previous studies of the effects of hypoglycaemia on memory function (with the
exception of the study described in Chapter 4), both the acquisition (learning) and recall
of material took place during hypoglycaemia. Deterioration in memory performance
during hypoglycaemia may have resulted from impairment of learning, consolidation
(transfer of information from short- to long-term memory), recall, or any combination
of these. The present study was designed to investigate whether these processes are
independently sensitive to hypoglycaemia by separating the acquisition and recall phases
ofmemory tasks so that only one occurred during hypoglycaemia.
Conventional laboratory memory tests tend to involve tasks such as learning lists of
words, prose passages, and geometrical shapes. Such tests may not reflect the memory
demands of daily living, which require coordination ofmultiple cognitive processes such
as planning and vigilance, and therefore may not have ecological relevance [1,2]. Recall
of retrospective events has been distinguished from prospective memory (remembering
intended actions, or "remembering to remember"), and tests of prospective memory
may have greater ecological validity [3]. Titov and Knight developed a novel test of
prospective memory in which subjects memorized a shopping list and then viewed a
video of a pedestrian journey around an urban shopping area, reporting items to be
purchased when specified shops appeared [4]. This video-based memory task had good
test-retest reliability. It also had good criterion validity: it correlated well with
performance on the same task when subjects actually walked through the shopping area.
Comparative scores were obtained for 35 subjects, yielding a correlation of r=0.71,
P<0.001, and no significant effect of study type (video vs. in vivo) in ANOVA. A similar
video task was created for the present study to explore the effects of hypoglycaemia on
prospective memory in a practical setting.
Evidence has accumulated to show that recurrent exposure to hypoglycaemia in people
with type 1 diabetes results in cerebral adaptation, such that cognitive performance is
relatively preserved during hypoglycaemia [5,6,7,8,9,10]. Repeated exposure to
hypoglycaemia can also result in impaired hypoglycaemia awareness, and a shared
mechanism for the two phenomena has been proposed [11]. Thus, in studies of people
with type 1 diabetes, it is important that subjects with impaired hypoglycaemia
awareness (which may be a surrogate marker of cerebral adaptation to hypoglycaemia)
are considered separately from those with normal hypoglycaemia awareness.
The aims of the present study were: (1) to assess the effects of acute hypoglycaemia on
different memory processes (acquisition and recall) for conventional memory tasks; (2)
to assess the effects of acute hypoglycaemia on a novel prospective memory task; (3) to




The study protocol was approved by the Lothian medical research ethics committee,
and all subjects gave informed consent for participation.
5.2.1 Subjects
Subjects were required to have a diagnosis of type 1 diabetes, age between 18-40 years, a
body mass index (BMI) between 20-30 kg m 2, and HbAlc values between 7 and 10%.
They were ineligible if they had any significant current medical condition or contra¬
indication to experimental hypoglycaemia. Female patients were eligible only if a
pregnancy test was negative.
Potential subjects were asked to grade their hypoglycaemia awareness on a scale from 1
to 7 [12], and hypoglycaemia history was also discussed. People who chose 1-2 and
reported no history of severe hypoglycaemia or significant change in their warning
symptoms were categorized as having normal hypoglycaemia awareness (NHA). People
who chose 3-7 and reported diminution of hypoglycaemic symptoms and episodes of
unrecognised hypoglycaemia were categorized as having impaired hypoglycaemia
awareness (IHA) [12]. People whose self-rated awareness appeared inconsistent with
their hypoglycaemia history were ineligible, on the grounds that their awareness status
was uncertain.
In total, 36 subjects were recruited (20 NHA, 16 IHA); characteristics are given in table
5.1. Microvascular complications were defined as any clinical diagnosis of diabetic
retinopathy, neuropathy or nephropathy, the latter also requiring urine
albumin:creatinine ratio persistently above the local reference maximum or serum
creatinine >150 pmol/1. The IHA group had significantly longer duration of diabetes
(t=3.937, df=34, P<0.001) and more microvascular complications ()(2 =5.994, df=l,






Male:female 12 : 8 6 : 10
Median (range) age (years) 29 (19-44) 33.5 (22-43)
Median (range) 3.8 (1.1-20) 15.5 (2-35)
diabetes duration (years)
HbAlc (%) 7.8 (1.3) 8.4 (1.8)
BMI (kg m2) 25.8 (2.2) 26.8 (3.6)
Number (%) with 1(5) 6 (38)
microvascular complications
Table 5.1. Subject characteristics. Data are mean (SD) unless
stated otherwise. Non-diabetic reference range for HbAlc 5.0-
6.5%.
5.2.2 Glucose clamp procedure
Each subject underwent one hypoglycaemic and one euglycaemic glucose clamp,
separated by at least two weeks. Subjects were not informed of the order in which these
occurred. On the evenings before studies, subjects took their normal insulin, fasted
from 22.00h (consuming only water) and omitted insulin on the morning of the study.
Subjects were encouraged to avoid hypoglycaemia during the 48 hours before planned
studies, by reducing insulin doses if necessary. Studies were postponed if subjects
detected any episode of hypoglycaemia by symptoms or routine blood testing during
this period, resulting in six postponements (two NHA, four IHA).
An antecubital vein and a dorsal hand vein were cannulated in the non-dominant arm
for infusions and blood sampling. The hand was placed within a heated blanket to
arterialize venous blood. Arterialized venous samples were drawn every 5 minutes, and
whole-blood glucose was measured using a Yellow Springs 2300 analyser. An infusion
of soluble human insulin (Actrapid, NovoNordisk) was started at 1.5 mU kg"1 min"1, and
20% glucose solution was infused at a variable rate to achieve desired blood glucose
concentrations.
The blood glucose concentration was initially stabilized at 4.5 mmol/1 (euglycacmia),
and maintained for 40 minutes. During the hypoglycaemia studies, the blood glucose
was then lowered over 20 minutes to 2.5 mmol/1 and maintained for 60 minutes, then
raised to 4.5 mmol/1 and maintained for a further 75 minutes. During the euglycaemia
studies, blood glucose was maintained at 4.5 mmol/1 throughout. The study outline is





























Two parallel versions of each test were available, which were combined to give two
batteries. The order in which subjects were exposed to these batteries and the
hypoglycaemia-euglycaemia order were counterbalanced within the NFIA and IHA
groups.
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Prospective memory. This was a novel test, based on a method developed by Titov and
Knight [4], Two videos showing the view of a pedestrian journeying around central
Edinburgh were created, and for each a 'shopping list' of 21 tasks was written on 21
cards. These were made up of Buy tasks (e.g. "Buy tennis balls at A&B Sports"), Do
tasks (e.g. "Book a table at Smith's restaurant") and Question tasks (e.g. "What is the
advertised loan rate at the Mercantile Bank?"). Subjects were asked to read the cards
twice at a normal reading pace, placing each card face down once read. Subjects then
watched the video, and scored points for answering questions or stating actions at the
relevant places. These were not brought to subjects' attention, and points were not
awarded for answers given at inappropriate times. Pilot studies indicated that the two
videos were of equivalent difficulty. Each lasted approximately 10 minutes, and were
similar in terms of numbers of shops passed (about 80). In the present study, subjects
read the cards (learning) during initial euglycaemia, and recall was tested after
approximately 40 minutes during the experimental period of induced
hypoglycaemia/euglycaemia. Thus, the experimental manipulation examined the effects
of hypoglycaemia on recall.
Conventional memory tests. For the following memory tests, acquisition and immediate
recall were tested during the experimental hour (euglycaemia or hypoglycaemia).
Delayed recall was tested 90 minutes later during euglycaemia, without further exposure
to the learned material. Thus, the experimental manipulation here examined the effects
of hypoglycaemia on acquisition (learning).
(1) Auditory Verbal Learning Test (AVLT) — immediate and delayed [13]. Fifteen
words were read aloud, and the subject asked to say them back immediately.
This was repeated with the same words four times in immediate succession, and
the immediate score was the sum of correct responses for the five trials
(maximum 75). Later, the subject was asked to recall the words, but this time
without them being read aloud, giving a delayed score (maximum 15).
(2) Logical Memory Test — immediate and delayed. In this subtest from the
Wechsler Memory Scales — Revised [14], a short story was read to the subject,
who tried to recount it immediately. Points were obtained for recollection of
specific details and story themes.
(3) Visual Reproduction — immediate and delayed, from the Wechsler Memory
Scales - Revised [14]. Each of five line drawings was shown to the subject for 10
seconds and then hidden, and the subject tried to draw the design from memory.
Reproductions were scored according to strict criteria.
5.2.4 General cognitive function tests
At the beginning of the experimental period (i.e. after achievement of stable
hypoglycemia, or at the equivalent time during euglycaemia studies), subjects
performed tests of 4-choice reaction time, Trail-Making B and the Digit Symbol
Substitution Test as measures of general cognitive processing speed.
5.2.5 Symptom scores
Subjects scored their symptoms of hypoglycaemia at baseline and during the
experimental period using the Edinburgh hypoglycaemia scale [15].
5.2.6 Statistical analysis
Scores on memory tasks were compared using repeated-measures analysis of variance
(ANOVA). Memory test score during euglycaemia versus hypoglycaemia was the
repeated measure (within-subjects factor). Hypoglycaemia awareness, order of
hypoglycaemia-euglycaemia and order of test battery were between-subjects factors.
Statistical significance was accepted at P<0.05 and rf was used to indicate effect size
(proportion of variance explained, comparable to r2 in correlation or linear regression).
Analyses were performed using SPSS 11.0.
5.3 Results
5.3.1 Blood glucose
During the hypoglycaemia condition, mean blood glucose was 2.5 (SD 0.2) mmol/1 in
the NHA group, and 2.5 (0.2) mmol/1 in the IHA group (P=0.468). During
euglycaemia, mean blood glucose was 4.5 (0.2) mmol/1 (NHA) and 4.5 (0.3) mmol/1
(P=0.643) (IHA).
5.3.2 Symptoms
Total symptom scores did not change during euglycaemia. During the hypoglycaemia
condition mean symptom scores rose in both NHA subjects (baseline 23.2 (4.4) vs.
experimental 44.1 (22.2); P<0.001) and IHA subjects (22.9 (7.0) vs. 28.8 (8.3); P=0.001).
The increment in symptom scores was significantly greater in the NHA group
(interaction between glycaemic condition and awareness status: P=0.002).
5.3.3 General cognitive function tasks
In NHA subjects, performance on all tests was poorer during hypoglycaemia compared
with euglycaemia (4-choice reaction time and Digit Symbol Substitution — P<0.001;
Trail-Making B — P<0.05). In IHA subjects, performance also deteriorated, but this was
not statistically significant for any test. The interaction between the experimental
condition and the hypoglycaemia awareness state was significant for DSST (P<0.01),
confirming a greater effect of hypoglycaemia in NHA subjects than in IHA subjects for
this task.
These data are not reported or discussed in detail in this thesis, but are examined in
detail elsewhere.
5.3.4 Memory tasks
Results are given in Table 5.2. There were no significant effects of order of exposure to
glycaemic condition or test battery.
Comparison of effect of hypogfycaemia in NHA and IHA subjects. The interaction between
glycaemic state and hypoglycaemia awareness designation (hereafter the glycaemia-
awareness interaction) was not significant for any tests. This means that there was no
significant difference in the effects of hypoglycaemia on cognitive function in the NHA
and IIIA groups. In some cases, there was a statistically significant effect of
hypoglycaemia in one group but not the other; however, in each case hypoglycaemia
was associated with poorer performance in both groups, and achievement of statistical
significance in one group but not the other may have been due to chance. In the
absence of significant glycaemia-awareness interactions, the effect of hypoglycaemia on
memory performance was determined for all subjects combined.
Prospective memory. Recall was significantly impaired in all patients combined during
hypoglycaemia (rf=0.255, P=0.004). IHA subjects performed better overall than NHA
subjects (P=0.018).
Immediate verbal memory. Immediate recall was significantly impaired during
hypoglycaemia for AVLT (r]2=0.268, P=0.003) and logical memory (rf=0.233, P=0.007)
in all subjects combined. The IHA group performed significantly better than the NPIA
group on the logical memory task (P=0.030).
Delayed verbal memory. Delayed recall was significantly impaired during hypoglycaemia for
both AVLT (r]2=0.373, P<0.001) and logical memory (r}2=0.315, P<0.001) in all subjects
combined. Again, the IHA group performed better overall on the logical memory task
(P=0.031). Hypoglycaemia had no effect on the proportion of information retained
(delayed score as a percentage of immediate score).
Visual memory. No significant effects of hypoglycaemia were seen. Mean euglycaemia
scores of 96.2 (NHA) and 88.3 (IHA) from a maximum of 104 indicated marked ceiling
effects. The NHA group scored better (P=0.016) on immediate visual memory.
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Performance on the novel test of prospective memory was impaired significantly during
the hypoglycaemia studies and, as learning always took place during euglycaemia, the
results indicate that recall had been disrupted by hypoglycaemia. The effect size of
hypoglycaemia on prospective memory scores (rf) was similar to those for the
conventional memory tests, which suggests that it is a similarly sensitive measure of
hypoglycemic memory dysfunction. The prospective memory task is also intuitively
more reflective of memory in daily life, where list-learning is rarely relevant. In the
paper upon which it was based, performance on the video task correlated well with
performance on the same task in a real-life setting [4]. The data suggest that people
with diabetes may suffer inability to act on previously-made plans, and thus effectively
to organise aspects of their daily life, as a consequence of hypoglycaemia.
Some limitations of the prospective memory task must be considered [4]. Firstly,
subjects are unable to explore the environment to obtain further cues if they suspect
that an action is to be performed at a location, but cannot fully remember it. Secondly,
they are unable to retrace their steps if an action is recalled after the location has been
passed. Thirdly, to make the task sufficiently difficult, more items are given than
subjects would attempt to remember in real life. Fourthly, subjects are unable to
prioritize items and plan their journey. These points reflect the fact that in real life,
prospective memory performance is not simply determined by accuracy of response to
cues, but is also dependent on organisational and other strategies. Thus, the effect of
hypoglycaemia on real-life prospective memory may be more or less than suggested by
the present study, depending on whether these strategies are themselves sensitive or
resistant to hypoglycaemia.
Before extrapolating to daily life in diabetes, the magnitude of the impairment associated
with hypoglycaemia must also be considered. The mean score during hypoglycaemia
was approximately 12% lower than during euglycaemia. Another measure is Cohen's d
— the difference in means divided by the pooled standard deviation — which in this case
is 0.34, or half-way between a 'small' and 'medium' effect according to Cohen's
conventions [16]. By both measures, the impairment of prospective memory due to
hypoglycemia was similar to (but slightly less than) the impairment for the AVLT and
logical memory tasks (score reduction 10-16%, Cohen's d 0.47-0.60). These
deteriorations themselves are much smaller than those reported by Sommerfield et al,
which ranged from 15% to 55% at a similar level of hypoglycaemia [17,18]; the
difference is hard to explain, but may be because both learning and recall occurred
during hypoglycaemia in that study. For comparison, performance on the non-memory
tasks reported in Chapter 6 deteriorated by 9-19% during hypoglycaemia.
It is also possible that poorer performance during hypoglycaemia was caused by
impairment of cognitive functions other than memory. The video required sustained
attention for around 10 minutes, and attention has been shown to be impaired during
hypoglycaemia [19,20], Deterioration of visual information processing may have
reduced subjects' ability to glean information from the video [21,22]. Alternatively, the
results may have resulted from a general effect on cognition, as very few cognitive
abilities that have been tested during hypoglycaemia have not shown deterioration [23].
These distinctions may be neuropsychological rather than practical: whatever the
mechanism, hypoglycaemia impaired the ability to act on information learned
previously, which in everyday life would be perceived to be a memory problem.
Thus, it may be concluded that moderate hypoglycaemia causes a statistically-significant
deterioration in performance on the prospective memory task, which mimics real life
more closely than conventional tasks. This supports the extrapolation of laboratory
data to practical advice for people with diabetes. The effect size was modest, though
comparable to that seen for other memory and cognitive tasks.
5.4.2 Verbal and visual memory
Immediate recall performance for the two verbal memory tasks (AVLT and logical
memory) was impaired significantly during hypoglycaemia, consistent with previous
studies [17,18], Delayed recall was always tested during euglycaemia, and it can be
inferred that the significant impairment in delayed recall following hypoglycaemia
resulted from a hypoglycaemic effect on learning and/or consolidation. A 'hangover'
effect of hypoglycaemia is unlikely to be responsible, as delayed recall was tested 50
minutes after restoration of euglycaemia. The only robust study to show residual
cognitive impairment demonstrated this 20 minutes after hypoglycaemia [24]; earlier
studies reported impaired cognitive function 45 to 90 minutes after hypoglycaemia
[25,26,27,28,29,30], but each had a methodological deficiency such as failure to test
statistical significance or absence of a euglycaemia control arm.
Correction of hypoglycaemia took approximately 20 minutes, the limiting factors being
the continuing insulin infusion and the maximum infusion rate of hypertonic glucose
solution. The possibility that hypoglycaemia impaired performance through an effect
on consolidation in the immediate post-learning period cannot be excluded. However,
on this basis it is also relatively unimportant to separate learning and immediate
consolidation, as hypoglycaemia in the daily life of a person with diabetes will not be
reversed more quickly. The practical conclusion that may be drawn from the verbal
memory results is that hypoglycaemia impairs the learning of information so that it may
be recalled at a later time. For example, if hypoglycaemia occurred while studying, the
student would be advised to review material that had recently been examined.
Visual memory was not impaired significantly by hypoglycaemia, but with mean scores
of 93% and 82% for immediate and delayed recall during euglycaemia, a ceiling effect
was evident. Future work on this aspect of memory should employ tasks with a larger
range of items, especially more difficult items.
5.4.3 Normal and impaired hypoglycaemia awareness
There was no evidence of a different effect of hypoglycaemia in IFIA and NHA
subjects. This may have been related to inadequate statistical power for this specific
between-subjects analysis. However, with a total of 36 subjects and a repeated-measures
design, the study was large by comparison with others in this research area. There are
some limitations of the between-group comparisons. Firstly, we cannot exclude
overlap, even though our method of assessing awareness has been shown to be a good
predictor of severe hypoglycaemia at the group level [29]. Subjects with similar levels of
awareness could receive different classification as a result of answering with confidence
or caution. Secondly, the two groups were not well matched for other characteristics
which may have confounded the effect of hypoglycaemia on memory performance,
particularly duration of diabetes, presence of microvascular complications and overall
memory performance. For these reasons, the present study cannot exclude a potential
difference between people with IHA and NHA.
An important consideration is that studies of this type, which compare group means
using a powerful within-subjects design, do not have much power to examine individual
differences in the effects of hypoglycaemia on cognition. There is, in our experience,
consistent anecdotal evidence from both clinical practice and research to suggest that
some individuals are much more susceptible to hypoglycaemia-induced cognitive
dysfunction than others. To assess this experimentally is impractical: for this type of
intensive study, an uncommonly large number of subjects would be required. However,
given the possibility of inter-individual differences, practical recommendations to people
with diabetes should not be too rigid.
5.4.4 Conclusions
In conclusion, the present study has confirmed that there is a disruptive effect of
hypoglycaemia on both the specific processes of learning and recall, which is relevant to
the behaviour of people with diabetes during daily life. The prospective memory test
appears to be a sensitive measure of memory dysfunction during hypoglycaemia which
may have greater ecological validity than conventional memory tests, and lends weight
to the extrapolation of laboratory data to practical recommendations for people with
diabetes.
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Chapter 6
The Effects of Acute Hypoglycaemia on Non¬
verbal Intelligence, and Accuracy and Speed
of Visuospatial Cognitive Function
6.1 Introduction
6.1.1 Non-verbal intelligence
In earlier Edinburgh studies, McAulay et al reported that several facets of attention
deteriorated significantly at an arterialized blood glucose level of 2.6 mmol/L in non-
diabetic [1] and type 1 diabetic subjects [2]. Nonverbal intelligence was also measured
using Raven's Progressive Matrices (RPM), and scores on this test were not significantly
impaired by hypoglycaemia at either 20 minutes or completion of the test (with no time
limit). This was unexpected, as various domains of cognitive function had consistently
been impaired at this level of hypoglycaemia previously [3]. Additionally, RPM is
acknowledged as among the best indicators of general fluid intelligence [4], and has a
substantial correlation with working memory [5], which is exquisitely sensitive to
hypoglycaemia [6]. The RPM consists of sequences of geometric designs governed by
logical rules, which must be deduced, held in working memory and applied
simultaneously to continue the sequence from a choice of answers [7], Figure 6.1 gives
an example of this type of problem.
As discussed in sections 2.2.3 and 2.2.4, it has been suggested that different mental
functions have variable sensitivity hypoglycaemia. It is possible that the higher-level
cognitive skills required for abstract problem-solving (as in the RPM) are resistant to
hypoglycaemia. However, this contradicts a widely-accepted view that higher-level skills
are more sensitive to hypoglycaemia than simple, repetitive cognitive or motor tasks [3].
Which shape on the
right completes the
pattern above?
Figure 6.1. Illustrative (easy) example of problems in Raven's
Progressive Matrices.
An alternative explanation is the possibility of a ceiling effect. It is assumed that if a
subject finds a problem easy, then they have cognitive spare capacity, and any
intervention that disturbs cognitive function must first eradicate the spare capacity
before performance is reduced. Thus, an intervention that causes mild or moderate
cognitive deterioration may not affect scores on easy tests. In McAulay et ats studies,
mean scores during euglycaemia were 82.5% in non-diabetic subjects [1] and 86.2% in
diabetic subjects [2], which are high but probably not excessively high. However, a
reasonable mean score may reflect a combination of very easy and harder problems.
The problems in the RPM are progressively more difficult, but many are rather easy, and
the subjects studied were generally of high intellectual ability. Figure 6.2 illustrates how































Figure 6.2. Hypothetical representation of the effect of hypoglycaemia on
tests with a low proportion (left graph) and a high proportion (right graph) of
easy problems. Performance on easy problems is assumed to be unaffected
by hypoglycaemia; performance on hard problems is assumed to be reduced
by 50%. Euglycaemia scores are identical for the two tests, but the test in the
right graph is insensitive to hypoglycaemic cognitive dysfunction.
Thus, a key requirement was to repeat McAulay et ats studies using similar but harder
cognitive tests. Raven's Advanced Progressive Matrices (RAPM) uses harder problems
of the same type as RPM, and was ideally suited to this function. The first primary aim
of this study was to determine whether performance on RAPM is impaired by
hypoglycaemia.
6.1.2 Speed vs Accuracy
As briefly discussed in section 2.2.2, although many experiments have been reported as
showing cognitive impairment during hypoglycaemia, for the vast majority it is more
correct to say that they have shown cognitive slowing. Table 2.1 listed the most
commonly used cognitive function tests. For Trail Making B, the Stroop ink colour
tasks and the reaction time variants, the score is the time to complete a certain number
of tasks. Finger tapping, verbal fluency and Digit Symbol Substitution are all scored as
number of tasks completed in a set time; since the individual tasks are very easy, what is
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effectively measured is again speed. In Table 2.1, only the digit and word recall scores
are not explicitly timed, and these are among the few tasks that have shown reduced
accuracy of cognition during hypoglycaemia.
In daily life, both speed and accuracy are relevant to most tasks. It would be of practical
interest to know whether hypoglycaemia primarily affects speed or accuracy of
cognition. The second primary aim of this study was to determine the effects of
hypoglycaemia on performance on a test scored for both accuracy and speed. A
computer-based maze task was used for this.
6.2 Methods
6.2.1 Experimental design and methodology
This study was embedded within the study ofmemory consolidation reported in chapter
4, and the subject details and experimental methodology are described in full there. In
brief, sixteen non-diabetic volunteers, aged 20-44 years, were studied. Each subject
underwent two hyperinsulinaemic glucose clamps, with experimental states of
euglycaemia and hypoglycaemia.
Initially, blood glucose was stabilized at 4.5 mmol/L in all cases, and at this point
subjects were exposed to the face and word lists for the study described in chapter 4.
Blood glucose levels were then either lowered to 2.5 mmol/L (hypoglycaemia) and
maintained at that level for one hour, or maintained at 4.5 mmol/L for the same length
of time. Subjects were not informed of the experimental condition. During the
experimental hour, subjects completed the cognitive function tests detailed below.
Euglycaemia was then restored, and the clamp discontinued. Events after this point
(fMRI scanning, as described in chapter 4) have no bearing on the present study.
6.2.2 Intelligence and other cognitive function tests
All subjects completed the National Adult Reading Test (NART) at the start of their
first session. In the NART, the subject is presented with a list of words that are used
very infrequently in everyday spoken English, and is asked to read them aloud.
Pronunciation is scored with reference to an audio tape of correct pronunciation.
Performance on this test has been shown to correlate very highly with best-ever
Wechsler Adult Intelligence Test scores [8],
The tests that were completed during euglycaemia-hypoglycaemia were Raven's
Advanced Progressive Matrices (RAPM) [9], the Alice Heim 5 test (AH5) [10], Trail-
Making B (TMB) and the Digit Symbol Substitution Test (DSST).
The Alice Heim 5 test (AH5) similarly requires identification and application of
simultaneous patterns to complete sequences, although these may be verbal, numerical
or geometric. Paper working is permitted for AH5 but not for RAPM. Parallel versions
of the RAPM and AH5 were created by separating odd- and even-numbered items, with
Set 1 and Set 2 of RAPM being combined; thus, two batteries were created, each
consisting of half of the RAPM questions and half of the AH5 questions. Subjects were
limited to 20 minutes for RAPM questions, and 20 minutes for API5 questions.
The TMB test was performed on an Apple Newton handheld computer with a touch-
sensitive screen. The DSST test was performed using paper and pen.
6.2.3 Maze task
This task was developed and supplied by Brian Tiplady of Penscreen Ltd. An Apple
Newton handheld computer with a 5 by 8 inch touch-sensitive screen was loaded with
several different maze designs, of which one example is shown in Figure 6.3. Each
maze had only one path without junctions or dead ends, and hence did not require any
route-finding. Subjects were given the exact instruction "Draw the route from the
entrance to the exit as quickly and as accurately as you can, staying in the white areas
and avoiding the black walls." If required, a minimum of demonstration was provided
with no guidance as to whether speed or accuracy was more important.
During each study, the subject completed mazes on five occasions: the first two during
initial euglycaemia, the third at the start and the fourth at the end of the experimental
hour, and the fifth when euglycaemia was restored after the experimental hour. On
each occasion the subject completed two mazes: one was the same across the five
occasions (allowing a learning effect) and the other varied.
Each maze task yielded the following data: completion time, accuracy (percentage of the
trail within the white areas) and number of errors (number of occasions the black walls
were touched or crossed).
Figure 6.3. Example ofmaze task.
6.2.4 Data analysis
Data were analysed using SPSS 11.0. Euglycaemia-hypoglycaemia comparisons were
made by repeated-measures analysis of variance (ANOVA). The order of euglycaemia-
hypoglycaemia and the two cognitive test batteries were counterbalanced, and included
as between-subjects factors in repeated measures ANOVA. The threshold for statistical
significance was set at P=0.05.
6.3 Results
There were no significant effects of order of glycaemic condition or test battery on any
test.
6.3.1 Intelligence and other cognitive function test results
The mean NART score was 40, approximating to a WAIS-R hull Scale IQ score of 118.
Scores on other tests are given in Table 6.1. Performance on all tests other than TMB
are given as mean number of correct answers (SD); TMB performance is reported as
completion time in seconds (SD), i.e. shorter completion time represents better
performance. Maximum possible scores were 36 for AH5, and 24 for RAPM. Effect
sizes (r]2) and P-values for euglycaemia - hypoglycaem ia comparisons are given in Table
6.1.
Performance on TMB, DSST and RAPM deteriorated significantly during
hypoglycaemia. There was a trend towards deterioration on AH5, which failed to
achieve statistical significance (P=0.057).





















Table 6.1. Mean (SD) cognitive function scores during euglycacmia
and hypoglycaemia.
The statistical power of the study was determined post hoc from these data. For 80%
power to detect a moderate effect size of 0.5 standard deviations at P<0.05, a sample
size of 41 subjects would be required for the AFI5 test. The observed power was 57%,
so in hindsight the sample size was significantly too small to be sure of detecting a
result, and the negative result for AH5 cannot be taken as evidence of no effect.
To assess whether hypoglycaemia had any effect on strategy, the numbers of RAPM and
AH5 items attempted and the proportions correctly answered were analysed. Results
are given in Table 6.2. For RAPM and AH5, both number of items attempted and




Attemped 22.0 (3.0) 20.8 (2.6) 0.189
Percent correct 85.1 (11.3) 80.7 (13.2) 0.406
AH5
Attempted 23.1 (7.3) 21.3 (6.8) 0.364
Percent correct 67.3 (16.0) 66.2 (14.3) 0.750
Table 6.2. Mean (SD) number of questions attemped and mean (SD)
percentage correct, with P for euglycaemia-hypoglycaemia comparison.
6.3.2 Maze results
Accuracy scores and completion times are shown in Table 6.3, and are provided
separately for the five different time points and for the fixed and variable mazes. Only
one P-value crosses the standard 0.05 threshold — this is for completion time of the
fixed mazes during the recovery period. It is not impossible that there should be a
hangover effect from hypoglycaemia, but this seems unlikely in the absence of any effect
during hypoglycaemia. Table 6.3 contains 20 statistical comparisons, and if any one is to
be accepted then the P threshold must be set at 0.0025. Thus, no statistically significant
effects of hypoglycaemia on either accuracy or speed are demonstrated.
Accuracy Accuracy P Time Time P
Eu Hypo Eu Hypo
Fixed maze
Baseline 1 96.1 (4.2) 97.4 (3.9) 0.393 25.4 (12.8) 29.4 (14.9) 0.382
Baseline 2 97.4 (1.9) 97.8 (2.4) 0.542 23.8 (7.1) 23.2 (6.5) 0.633
Exp start 98.3 (2.1) 97.8 (2.1) 0.596 22.1 (5.3) 24.0 (8.0) 0.231
Exp end 97.1 (2.9) 96.7 (3.0) 0.684 21.4 (6.7) 25.2 (7.8) 0.168
Recovery 96.7 (2.8) 97.4 (3.2) 0.368 21.7 (6.0) 25.8 (8.1) 0.049
Variable mazes
Baseline 1 97.2 (3.3) 97.9 (2.5) 0.345 26.3 (13.2) 24.3 (11.1) 0.613
Baseline 2 96.3 (5.6) 97.4 (2.1) 0.309 21.9 (6.2) 21.0 (6.3) 0.478
Exp start 97.0 (2.8) 97.3 (3.2) 0.687 22.7 (10.2) 24.4 (6.8) 0.609
Exp end 97.6 (2.9) 97.0 (3.4) 0.567 20.9 (6.2) 22.2 (5.4) 0.481
Recovery 97.5 (2.7) 96.2 (5.2) 0.344 19.6 (6.5) -20.1 (4.8) 0.404
Table 6.3. Accuracy (SD) and completion time (SD) scores for ma2e task.
Accuracy is % of trail within boundaries, time is in seconds. P for
euglycaemia-hypoglycaemia comparisons.
It is possible that the maze task suffered from a ceiling effect, although this cannot be
determined from data in the present study. Mean maze accuracy scores during
euglycaemia were approximately 97%, but this does not have the same meaning as a
97% correct score on a test like RAPM. This score indicates that 97% of the length of
the trail was drawn within the boundaries, which may or may not be a good
achievement. (Staying on the road 97% of the time could not be considered good
driving!). Population norms are not available for comparison with the performance of
the high-ability subjects in the present study.
6.4 Discussion
Hypoglycemia impaired performance on Raven's Advanced Progressive Matrices in the
present study. These results are at odds with findings from the earlier studies by
McAulay et al using the simpler Raven's Progressive Matrices [1,2]. From those earlier
studies, the scores after 20 minutes (which are directly comparable to scores in the
present study) were 80.7% in non-diabetic and 83.5% in diabetic subjects during
euglycaemia, and no significant decline was seen during hypoglycaemia. In the present
study, the mean score on Raven's Advanced Progressive Matrices during euglycaemia
was very similar at 79%, but performance declined with clear statistical significance
during hypoglycaemia. The effect size of hypoglycaemia on RAPM was substantial,
amounting to approximately three-quarters of a standard deviation. A plausible
explanation for these disparate results is that in intelligent subjects, a ceiling effect
rendered the RPM relatively insensitive to the effects of hypoglycaemia.
Mean scores on the Alice Pleim 5 test fell from 43% during euglycaemia to 39% during
hypoglycaemia, but this failed to achieve statistical significance. In retrospect, the study
was underpowered, but other possible contributory factors are of interest. The AH5 is
harder than RPM or RAPM, and there may have been a floor effect. Alternatively, the
different results for RAPM and API5 may reflect a difference in their administration:
paper working is permitted for the AFI5, but not for the RAPM. Holding and applying
the AH5 rules entirely in working memory is demanding, and a demanding working
memory task has been shown to be exceptionally sensitive to moderate hypoglycaemia
ra¬
in combination, these results indicate that moderate hypoglycaemia can impair general
fluid intelligence, but it is necessary to use a test appropriate to the ability level of the
participants. Research volunteers tend to be more able than the population they are
intended to represent, and the ceiling effect may be common in hypoglycaemia studies.
Care should be taken to avoid both ceiling and floor effects, and, while general
consensus on cognitive testing is desirable, a single battery of cognitive tests for all
subjects may be inappropriate [11].
The RAPM and AH5 results did not indicate whether speed or accuracy of cognition is
primarily affected during hypoglycaemia. The maze task was scored for both accuracy
and speed, and so might have demonstrated a tendency for one to be sacrificed to
preserve the other under adverse conditions. However, there was no evidence of
hypoglycaemic deterioration on any measure of performance on this task. The cognitive
demands imposed by the maze task are clearly different from those imposed by RAPM:
intuitively, the maze task engages hand-eye coordination and fine motor control,
whereas 11APM requires the simultaneous development and testing of abstract rules,
with a heavy load on working memory and visuo-spatial representation. It is possible
that these differences explain why the latter was sensitive to hypoglycaemia and the
former was not. However, a more recent study has clearly demonstrated that equivalent
hypoglycaemia induces significant impairment in performance on various similar
psychomotor tasks in non-diabetic adults [12]. It is more likely that the maze task (like
11PM) was too easy to be discriminatory, and the question of speed versus accuracy
remains unanswered.
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People with diabetes are commonly exposed to fluctuations in blood glucose into the
hypo- and hyperglycaemic ranges. The symptoms of hypoglycaemia have been
described in detail, and their generation has been studied using different approaches [1].
The statistical technique of factor analysis has been used to identify discrete groups, or
domains, of symptoms, which co-segregate; that is, symptoms which tend to be
reported by the same people. This technique has been applied to symptoms reported
during experimental hypoglycaemia [2], or derived from population surveys [3,4]. The
potential value of this analysis is that symptom groups identified may represent
underlying physiological processes. In the case of hypoglycaemia symptoms, two clear
groups apparently representing neuropjycopenic and autonomic symptoms emerged from
factor analysis [1,4], which suggests that the symptoms may be generated by separate
physiological mechanisms. This is consistent with studies of experimentally-induced
hypoglycaemia with different forms of pharmacological blockade [5,6], and studies in
people with diabetes and impaired hypoglycaemia awareness [7,8,9,10], in whom
autonomic but not neuroglycopenic symptoms are diminished or lost.
Symptoms of hyperglycaemia are often present at the time of diagnosis of diabetes, and
the classical osmotic symptoms include thirst, polyuria and nocturia [11], However,
there are few experimental studies of the symptoms of hyperglycaemia. When acute
hyperglycaemia was induced by a hyperinsulinaemic glucose clamp technique, only one
symptom (the need to urinate) was positively associated with this state [12]. A recent
Edinburgh study examined mood (rather than symptoms) during hyperglycaemia in
subjects with type 2 diabetes, again using a hyperinsulinaemic glucose clamp, and
reported that hyperglycaemia was associated with reduced energetic arousal and
increased sadness and anxiety [13]. In a pair of earlier studies, many subjects reported
symptoms which correlated positively with blood glucose concentrations [14], but these
symptoms varied widely between subjects, and subsequently were found to be unstable
over time [15]. A study of all symptoms in type 2 diabetes listed thirst, dry mouth,
polyuria and polydipsia as symptoms of hyperglycaemia, but this study did not focus
specifically on acute hyperglycaemia [16]. However, it is possible that symptoms
experienced during experimentally-induced hyperglycaemia are not representative of
symptoms experienced by people with diabetes during daily life.
From clinical experience, people with insulin-treated diabetes recognize various
unpleasant symptoms that are associated with transient hyperglycaemia, which may
prompt them to measure blood glucose and modify their treatment. The perception of
the development of hyperglycaemic symptoms may assist the individual to improve
glycaemic control, and the early treatment of elevated blood glucose may prevent
progression to metabolic decompensation. The principal aims of the present study were
to determine which symptoms of hyperglycaemia are reported commonly by people
with insulin-treated diabetes, and to ascertain whether any underlying structure could be
identified to assist with the classification of the symptoms. Secondary aims were to
determine whether the intensity of, and glycaemic threshold for, symptoms of
hyperglycaemia are related to the co-existing state of hypoglycaemia awareness, the




A pilot study was performed to identify possible symptoms of hyperglycaemia. Seventy
patients with insulin-treated diabetes were asked to report, in an open-ended manner,
symptoms which they associated with a high blood glucose. Their reports were grouped
together as symptoms when identical wording was used, or when it was clear that the
same sensation was being described. A total of 25 different symptoms were reported,
17 of which were reported by more than one person (Table 7.1). In formulating the
symptom questionnaire, one additional symptom (an increase in salivation) which had
been reported by more than one subject in a previous study [14] was incorporated.
These 18 symptoms were used to compile the symptom questionnaire for the main

















Table 7.1. Symptoms associated with hyperglycaemia
reported by more than one individual in pilot study.
7.2.2 Subjects
To provide a robust solution using principal components analysis, the most cautious
estimate of the number of subjects required is 10 times the number of variables under
examination [17]. With 18 symptoms in the questionnaire, 180 subjects should suffice.
A target of 400 subjects was set to provide a large safety margin.
Approval for the study was granted by the local research ethics committee. People were
recruited during their routine attendances at diabetes outpatient clinics in the
Department of Diabetes at the Royal Infirmary of Edinburgh. Patients were eligible if
they had received full insulin therapy for at least one year, performed self-monitoring of
blood glucose (irrespective of frequency), and were capable, in the opinion of the
investigator, of answering the questionnaire. Patients using insulin at bedtime only were
excluded, but any full-time regimen (twice daily injections or more often) was permitted.
There were no restrictions on other drug therapies. All consecutive patients who met
the inclusion criteria and who consented to take part were recruited until the target of
400 had been achieved. Characteristics of the participants are shown in Table 7.2.
Written informed consent was obtained before the questionnaire was applied.
Total Type 1 Type 2
n 400 288 112
Male (%) 229 (57.3) 173 (60.1) 57 (50.9)
Median age, in years 49 (18-84) 41 (18-79) 66 (35-84)
(range)
Median duration of 14 (1-59) 15 (1-59) 12 (4-36)
diabetes, in years (range)
Median duration of insulin 11 (1-59) 15 (1-59) 4 (1-33)
therapy, in years (range)
Mean HbAlr (SD) (%) 8.6 (1.3) 8.6 (1.4) 8.7 (1.3)
Table 7.2. Characteristics of insulin-treated diabetic subjects completing
symptom questionnaire.
7.2.3 Questionnaire
Each subject completed the questionnaire once. Subjects provided estimates, based on
prior experience, of the intensity with which they usually felt each symptom during
periods of hyperglycaemia ("when your blood glucose level is high"). Hyperglycaemia
was not defined more explicitly in terms of blood glucose concentration. Estimates of
symptom intensity were recorded on a visual scale from 1 ("not at all") to 7 ("very
strongly"). The participants were asked to indicate the approximate level of blood
glucose at which they would expect to experience hyperglycaemic symptoms, based on
previous blood glucose testing, and to describe any other symptoms which they
associated with hyperglycaemia. In addition, they were asked to rate their symptomatic
awareness of hypoglycaemia on a visual scale from 1 (always aware) to 7 (never aware)
[9]. Duration of diabetes and duration of insulin therapy, details of concomitant drug
therapy, and most recent glycated haemoglobin (I IbAlc) measurements were recorded.
Glycated haemoglobin was measured by high performance liquid chromatography
(BioRad Variant 2, Hemel Hempstead, UK; local non-diabetic range 5.0-6.5%).
7.2.4 Principal components analysis
Data were analysed using SPSS 11.0 (SPSS, Chicago, IL). Correlations among the
intensity ratings of the 18 symptoms were examined using principal components
analysis. The monograph by Child provides an accessible explanation of this technique
[17]. Briefly, the procedure examines the correlations among measured variables to
determine whether there are groups of variables which occur together. This could be
done informally: it might, for example, be apparent from inspection of correlation
coefficients that there were three groups of symptoms, such that symptoms were
strongly correlated with other symptoms in the same group, but only weakly correlated
with symptoms in other groups. In this hypothetical case, the entire data set could be
reduced to three 'factors', each representing a group of variables from the original data
set. If the within-group correlations had been high, then this process would greatly
simplify the data set with only minimal loss of information. The value of this technique
in examining symptoms arises from the fact that symptom grouping may hint at
underlying physiological processes. For example, in previous studies, the symptoms of
confusion, odd behaviour, inability to concentrate, drowsiness and difficulty speaking
were highly correlated, and were interpreted as the effects of neuroglycopenia; whereas
hunger, sweating, trembling, anxiety and a pounding heart formed a separate, highly
correlated group, which was interpreted as the effects of autonomic activation [2,3,4].
Principal components analysis (PCA), sometimes referred to as factor analysis, is a
statistical tool for extracting components which simplify the data, while retaining as
much information as possible. Technically, components are computed first, and
undergo a mathematical transformation called rotation to yield more easily interpretable
'factors'. Although there is a technical difference between 'component' and 'factor', for
the sake of clarity 'factor' is used here. The variance explained by a factor indicates the
amount of information from the original data which is contained within the computed
factor. PCA initially generates the same number of components as the number of
symptoms under examination, but most explain very little variance. Only components
which usefully simplify the data are considered significant, and these are determined by
selection of those which are outliers on a plot of variance (the 'scree slope criterion')
and/or those which explain more variance than a single variable from the original data
(the 'eigenvalues greater than one criterion').
PCA factors are mathematical constructs, and their interpretation relies on factor loadings,
which are the correlations between the original symptom scores and the extracted
factors. Factors are considered to represent those symptoms with which they have
moderate to high correlations. A cut-off for the correlation coefficient of 0.3 to 0.4 is
generally applied [17]. The internal consistency of the grouping of symptoms suggested
by this method may be confirmed by computing Cronbach's Alpha statistic.
7.2.5 Other statistical methods
Mean symptom intensity scores for each subject were calculated as the arithmetical
means of the scores for each variable. Associations between these scores and other
characteristics of the participants were investigated with Spearman rank correlations,
Mann-Whitney U tests and linear regression techniques. Scatter plots were examined
for correlations to exclude artefacts from outlying cases.
7.3 Results
7.3.1 Symptom endorsements
Of the 400 respondents, 361 (90.2%) identified one or more of the 18 symptoms as
associated with hyperglycaemia. The five most commonly endorsed symptoms were
'thirst', 'dry mouth', 'not feeling right', 'need to urinate' and 'tiredness'. The absolute
endorsement frequencies (i.e. any response greater than 'not at all') and the mean scores







Thirst 4.06 (2.05) 79.5
Dry mouth 4.09 (2.09) 78.7
Not feeling right 3.80 (2.08) 75.6
Need to urinate 3.71 (2.35) 64.5
Tiredness 3.30 (2.23) 61.5
Irritability 2.80 (2.18) 48.2
Poor concentration 2.59 (1.96) 47.9
Weakness 2.36 (1.85) 43.2
Sweet/funny taste 2.53 (2.09) 41.0
Restlessness 2.30 (1.88) 40.2
Feeling tense 2.19 (1.82) 38.0
Headache 2.12 (1.81) 34.1
Blurred vision 1.81 (1.45) 29.4
Light headed 1.80 (1.53) 26.9
Nausea 1.80 (1.54) 26.6
Dizziness 1.70 (1.50) 22.4
Stomach ache 1.42 (1.17) 13.9
Increased saliva 1.34 (1-07) 11.9
Table 7.3. Mean intensity scores and absolute endorsement
rates for each symptom.
7.3.2 Principal components analysis
Two of the 18 symptoms ('stomach ache' and 'increased salivation') had absolute
endorsement levels below 20%. Weakly endorsed variables cannot be reliably
interpreted by PCA, and these symptoms were excluded from subsequent analysis. PCA
was performed on symptoms data from the 361 subjects who reported any
hyperglycemic symptoms using the remaining 16 symptoms. The first unrotated
principal component has strong loadings (0.47 or greater) from all symptoms (Table
7.4), and accounts for 37.7% of total variance. The high loadings and high internal
reliability (Cronbach's Alpha 0.89) indicate that it is a general hyperglycaemic symptoms
component. Because of this, rotation was performed using the Direct Oblimin method,
which permits factors to be correlated (non-orthogonal).
A four-factor solution was appropriate, based both on eigenvalues greater than one, and
on scree-slope inspection (Figure 7.1). Variances accounted for by each factor, and
loadings from each of the 16 symptoms, are shown in Table 7.4. Factor loadings greater
than 0.35 were considered significant. The first factor ('feeling tense', 'irritability',
'restlessness' and 'poor concentration') contains symptoms which appear to have in
common some aspect of mental agitation. The second factor ('thirst', 'dry mouth', 'need
to urinate', 'not feeling right', 'sweet or funny taste' and 'weakness') mainly represents
symptoms resulting from the osmotic effects of hyperglycaemia. The third factor
('dizziness', 'blurred vision', 'light-headedness' and 'weakness') contains symptoms
similar to those designated neurogjycopenic in previous studies of hypoglycaemic symptoms
using factor analysis [2,3,4], although neurological may be a better nomenclature in the
present context. The fourth factor has strong loadings from 'headache', 'nausea' and
'sweet or funny taste'. Headache and nausea also appeared as a factor (labelled malaise)
in hypoglycaemia studies [2,3,4].
The total variance explained by the four-factor model is 62.9%. The factors are
correlated, and so the sum of the individual variances exceeds this total. Cronbach's
Alpha was calculated as a measure of internal consistency for the general hyperglycaemia
factor and each of the four rotated factors (Table 7.4). All except the malaise factor had







Variance (%) 33.7 24.6 21.5 21.2 13.3
Cronbach Alpha .86 .79 .79 .74 .51
Symptom Componentloadings
Pattern matrix loadings
Thirst .51 -.13 -.89 .03 -.03
Dry mouth .57 -.10 -.82 .03 .14
Not feeling right .70 .01 -.41 .14 .15
Need to urinate .44 .08 .73 -.16 .05
Tiredness .62 .36 .20 .33 -.07
Irritability .65 .80 .05 -.04 .08
Poor concentration .67 .56 .09 .29 -.07
Weakness .61 .18 .40 .47 -.26
Sweet/odd taste .57 .14 .42 -.06 .43
Restlessness .63 .78 -.03 -.06 .13
Feeling tense .58 .87 -.11 -.03 -.04
Headache .51 .08 .05 .07 .73
Blurred vision .45 -.09 -.06 .76 .08
Light headedness .62 .08 -.03 .73 .14
Nausea .48 .01 .02 .17 .69
Dizziness .59 .03 -.06 .83 .07
Table 7.4. Results of principal components analysis of symptom intensity scores,
with Direct Oblimin rotation.
Factor 1 Factor 2 Factor 3 Factor 4
Mental agitation Osmotic Neurological Malaise
Feeling tense Thirst Dizziness Headache
Irritability Dry mouth Blurred vision Nausea
Restlessness Need to urinate Light headedness
Poor concentration
Table 7.5. Symptoms loading strongly onto PCA factors.
Scree Plot
Component Number
Figure 7.1. 'Scree slope' plot of eigenvalues from principal components analysis
(unrotated factors). Factors 1-4 have eigenvalues>l, and are outliers from the
shallow gradient created by factors 5-16.
7.3.3 Sub-group factor analyses
Because of the large number of participants, it was possible to repeat the PCA using
sub-groups. For comparison based on hypoglycaemia awareness, the data were divided
into those participants who gave a rating of 1 or 2 (normal awareness) and those who
gave a rating of 3 to 7 (impaired awareness) [9]. Results of this sub-group analysis are
given in Tables 7.6. Although factor ordering is different, essentially the same
symptoms loaded onto the same four factors as in the analysis of the full data set.
The same process was repeated to compare subjects classified according to glycaemic
control (FIbAlc above and below the median) and age (above and below the median).
Neither lower vs. higher HbAlc, nor lower vs. higher age, modified the PCA results (data
not shown).
Symptom
Normal awareness Impaired awareness
Rotated factor loadings Rotated factor loadings
12 3 4 12 3 4
Thirst .88 -.01 .15 -.13 -.01 .89 -.04 .00
Dry mouth .82 .01 .03 .02 .09 .82 .15 .10
Not feeling right .57 .06 -.26 .03 .36 .12 .28 -.23
Need to urinate .83 -.12 .09 .01 -.10 .68 -.01 -.19
Tiredness .23 .29 -.27 -.23 .43 .10 -.04 -.37
Irritability .05 .01 -.76 -.01 .05 .04 .10 -.78
Poor concentration .16 .34 -.46 -.26 .42 -.06 .04 -.44
Weakness .30 .28 -.22 -.55 .77 .25 -.07 .10
Sweet/odd taste .59 -.04 -.25 .23 .27 .18 .62 .21
Restlessness .04 -.07 1 ooo .15 .02 .09 .07 -.76
Feeling tense -.16 -.06 -.87 -.05 .07 .03 -.03 -.81
Headache .15 .32 -.21 .55 -.01 -.04 .83 -.02
Blurred vision -.09 .79 .09 -.03 .70 -.07 -.00 .00
Light headedness -.03 .72 -.14 .08 .78 -.08 .09 -.14
Nausea .18 .50 -.03 .42 -.17 -.00 .79 -.16
Dizziness -.04 .86 .10 -.02 .75 -.14 .04 -.22
Table 7.6. Results of principal components analysis in subjects with normal
and impaired hypoglycaemia awareness.
7.3.4 Factors associated with symptom intensity and glycaemic
threshold
A mean symptom intensity score was calculated for each participant as the mean of
scores for the 16 symptoms identified in section 7.3.1. A multiple regression model was
constructed, with mean symptom intensity as the dependent variable, and the following
as independent variables: age, duration of insulin therapy, hypoglycaemia awareness
rating, current HbAlc, sex, type of diabetes, and use of beta-adrenoceptor blocking
drugs. Non-significant independent variables were removed in stepwise fashion, with a
threshold for significance of P=0.05. Results are given in Table 7.7. There was a
significant negative association with age, and a statistically significant but small positive
association with HbAlc; the total R2 for this model was 0.197.
A total of 340 subjects (85%) were able to estimate a glycaemic threshold for the onset
of symptoms of hyperglycaemia. The mean (range) estimated threshold was 15.1 (8-30)
mmol/L. A multiple regression model with estimated glycaemic threshold as the
dependent variable and the same independent variables as before was constructed.
There were statistically significant but small associations with hypoglycaemia awareness,
age, HbAlc and sex; however, the variance explained by this model was small (total R2
0.118).
Dependent Independent R2 change Standardized P
variable variable (total R2) beta
Mean symptom Age 0.182 -0.410 <.001
intensity HbAlc 0.015 0.125 .007
(0.197)
Blood glucose Hypo awareness 0.062 0.259 <.001
threshold for onset Age 0.020 0.160 .003
of symptoms HbAlc 0.018 0.154 .005
Sex 0.018 -0.137 .012
(0.118)
Table 7.7. Results of multiple regression analyses, with (i) mean symptom
intensity and (ii) estimated glycaemic threshold for symptoms as the dependent
variables. Only associations yielding P<.05 are shown. Total IT is provided
for each model in brackets. Standardized beta coefficients are the change in
the dependent variable for each standard deviation of the independent
variable; they are utilized here because the absolute spread of age (18-84) and
HbAlc (6-13) are very different. For example, for mean symptom intensity,
age has a greater effect than FIbAlc overall, but because the spread of age is
much greater the increment in symptom intensity per year of age is less than
the increment per % of TIbAlc.
7.3.5 Other symptoms of hyperglycaemia
With open-ended questioning, 68 (17%) of subjects reported hyperglycaemic symptoms
other than the 18 included in the questionnaire. The commonest were sweating (15
subjects), muscular ache (14 subjects), a flushed or warm sensation (14 subjects) and
heavy or stiff limbs (10 subjects). Various other symptoms were each reported by fewer
than five subjects.
7.4 Discussion
In the present study, 90% of adults with insulin-treated diabetes reported experiencing
symptoms associated with hyperglycaemia. The mean estimated blood glucose level at
which hyperglycaemic symptoms develop was 15 mmol/1, though the range of estimates
was wide (8 to 30 mmol/1). In regression analyses, the mean symptom intensity was
modestly associated with age, with older respondents reporting less intense symptoms.
The estimated glycaemic threshold was weakly associated with hypoglycaemia
awareness, such that people with diminished awareness of hypoglycaemia tended to
report higher blood glucose levels for the onset of hyperglycaemic symptoms. This
association may be explained by tolerance to both hypo- and hyperglycaemic extremes
in individuals with erratic blood glucose control, or by a defect in glucose sensing
leading to a single state of impaired glycaemic awareness.
When symptoms were examined using principal components analysis, most of the co¬
variation between symptom intensity scores could be accounted for by four factors.
Based on the symptoms associated with each factor, they have been labelled here as
osmotic, neurological, mental agitation and malaise. The osmotic symptoms were the most
easily classifiable and strongly endorsed symptoms, and are the classically described
symptoms of hyperglycaemia. The 'mental agitation' and 'neurological' symptoms
together suggest some change in cerebral function due to hyperglycaemia, and there is
experimental evidence to support this. The 'neurological' symptoms (light headedness,
blurred vision and dizziness) raise the possibility of acute hyperglycaemia-induced
hypotension. To our knowledge, this has not been described; on the contrary, an acute
rise in blood pressure during hyperglycaemia is well described [18]. However, there is a
potential pitfall in the interpretation of factor analysis of symptom scores. In previous
papers on the symptoms of hypoglycaemia, factor analysis was valuable in suggesting
separate underlying physiological processes (neuroglycopenic and autonomic nervous)
[2,3,4], symptoms correlating because they are different manifestations of the same
physiological aspect of hypoglycaemia. This holds true for thirst and polyuria in the
present study, which are clearly separate symptoms attributable to the osmotic effect of
hyperglycaemia. However, symptom scores may also correlate because they are
different verbal descriptions of the same sensation. The 'neurological' symptoms could
be linguistically associated in this way, rather than because they represent another
physiological process (such as hypotension).
The caveat above notwithstanding, the factor analysis results do strongly indicate that
hyperglycaemia is associated with effects on cerebral function as well as physical
symptoms. There is experimental evidence to support this. Sommerfield et al compared
the effects of euglycaemia (4.5 mmol/1) and hyperglycaemia (16.5 mmol/1) in subjects
with type 2 diabetes [13]. During hyperglycaemia, subjects performed significantly less
well on tasks measuring information processing (choice reaction time, Trail Making B
and the Digit Symbol Substitution Test), working memory and attention. Mood was
also affected during hyperglycaemia, with questionnaire responses indicating reduced
happiness and alertness and increased tension. Physiological mechanisms for impaired
cognition during hyperglycaemia are not obvious, but may relate to cerebral fluid or
electrolyte shift. Distraction, or loss of attention, caused by the physical symptoms may
also contribute.
Hypoglycaemia-induced cognitive dysfunction has been an important area of clinical
diabetes research. Could hyperglycaemia-induced cognitive dysfunction also be
important? The data of Sommerfield et al confirm its existence, although the magnitude
of impairment at 16.5 mmol/1 was considerably less than has been seen at 2.5 mmol/1.
Sommerfield et al recorded 5 to 7% slower completion of Trail Making and Digit
Symbol Substitution tasks, whereas completion was 10 to 20% slower in the study
described in Chapter 6. However, greater cognitive impairment might be seen at higher
blood glucose concentrations, e.g. 20 mmol/1 or higher. While at first such
hyperglycaemia may seem extreme and unrepresentative, it is probably a common
occurrence. A person with diabetes achieving an HbAlc of 8.5% (about average for type
1 diabetes in the Lothian region of Scotland) has a mean blood glucose of
approximately 11 mmol/1 [19]. In such a person, hypoglycaemia at 2.5 mmol/1
represents an excursion from the mean of 8.5 mmol/1; the hyperglycaemic equivalent is
19.5 mmol/1, but as the distribution is positively skewed, hyperglycaemic excursions will
tend to be more extreme than hypoglycaemic excursions. It would be interesting to
repeat the study of Sommerfield et al at a higher blood glucose level, provided safety
could be assured and research ethics requirements satisfied.
Another issue affecting the clinical relevance of hyperglycaemia-associated cognitive
dysfunction is the possible adaptation of symptoms and cognition to repeated episodes
of hyperglycaemia. As discussed in section 2.5, people exposed to recurrent
hypoglycemia seem to show cognitive adaptation, but this is insufficient to compensate
for the loss of symptoms. Our clinical experience strongly suggests that people with
poorly-controlled diabetes develop tolerance to the hyperglycaemic state, feeling no
symptoms at blood glucose concentrations as high as 15-20 mmol/1, but developing
symptoms of hypoglycaemia at 7-10 mmol/1. There was little evidence for this in the
present study, with only a trivial association between HbAlc and estimated symptom
threshold. Such retrospective estimates may be unreliable, particularly as people with
poorly-controlled diabetes are less likely to measure blood glucose frequently. It would
be interesting to repeat studies of hyperglycaemic cognitive function in people with
well- and poorly-controlled diabetes, although obtaining statistical power for between-
groups analyses (discussed in Chapters 5 and 8) would be problematic.
People with diabetes may use symptoms to identify periods of hypo-and
hyperglycaemia. This study indicates that there are some similarities between the two,
with common symptoms including tiredness, light-headedness, restlessness, poor
concentration, headache and nausea. Symptoms of thirst, dry mouth and need to
urinate have not been associated with hypoglycaemia, and these symptoms appear to be
specific for hyperglycaemia. The autonomic symptoms of hypoglycaemia (sweating,
palpitations, shaking and hunger) were not reported as symptoms in the present study.
It would appear, therefore, that the two states may be best distinguished by the presence
of osmotic or autonomic symptoms, whereas a variety ofmental and physical symptoms
may be common to both.
It was noted incidentally that many subjects reported that symptoms of tiredness and
aching muscles were more common during early hyperglycaemia, whereas thirst and
increased urination emerged with more prolonged or severe hyperglycaemia. It is
plausible that thirst and polyuria would be delayed, as they presumably cannot develop
until there has been a sustained diuresis. Participants were not formally asked about
symptoms at different levels or durations of hyperglycaemia, and so the study design did
not permit assessment of this putative association. However, an absence of osmotic
symptoms in early hyperglycaemia would be expected to make identification of this state
more difficult. The ability to distinguish hypo- and hyperglycaemia could be further
impaired in people whose autonomic symptoms of hypoglycaemia are diminished in
association with long duration of diabetes or frequent exposure to hypoglycaemia [lj.
Previous studies have confirmed that estimation of blood glucose from symptoms is
unreliable in many patients [12,20,21],
The symptoms of hyperglycaemia identified in this study were similar to those reported
in other studies [12,14,16]. Some subjects also reported symptoms of hyperglycaemia
other than those included in the questionnaire, most commonly sweating, myalgia, a
flushed or warm sensation, and heavy or stiff limbs. These symptoms were reported
rarely, although it is possible that more frequent endorsement would have resulted from
prompted questions. Future studies should include these symptoms.
Further research in this area should include studies to determine the threshold for
hyperglycaemic symptoms under experimental conditions, with comparisons between
diabetic people with normal and impaired hypoglycaemia awareness, and strict and poor
glycaemic control. It would also be pertinent to determine: how soon symptoms
develop after the onset of hyperglycaemia; whether the duration and degree of
hyperglycaemia affect the nature and correlational structure of the symptoms
experienced; and whether the four groups of symptoms identified in the present study
are differentially affected.
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Chapter 8
Discussion and Conclusions
8.1 Discussion and Conclusions
8.1.1 The effects of hypoglycaemia on memory consolidation, and
fMRI brain activation during recall (Chapter 4)
In this study, an hour of moderate hypoglycaemia (2.5 mmol/1) between the learning
and recall phases of a memory task appeared to have no effect on the consolidation of
visual stimuli in non-diabetic volunteers. There also appeared to be no effect of
hypoglycaemia on brain activation during the testing of recognition.
Stricdy speaking, the appropriate conclusion is that no significant effect at P<0.05 was
seen in this study, which had 80% power to detect an effect of 0.75 SD. In the study
reported in Chapter 5 (which was carried out later, and could not inform the sample size
of this study), the greatest effect of hypoglycaemia was seen for delayed verbal memory
performance, with an effect equivalent to approximately 0.6 SD. Post hoc calculation
reveals that for 80% power to detect a similar effect on the word task in the present
study, a sample size of 31 would have been needed. Jauch-Chara et al recendy published
a study of the effects of hypoglycaemia on the overnight consolidation of memory [1).
The decline in memory performance associated with hypoglycaemia in their study was
approximately 0.35 SD, and using this estimate of effect size, approximately 50-80
subjects would have been needed to achieve 80% power in the present study. With
hindsight, the study was underpowered to detect an effect of hypoglycaemia on
consolidation.
On the other hand, in the present study, memory performance scores following
hypoglycaemia and euglycaemia were identical, which does not support the possibility of
an effect of hypoglycaemia failing to reach significance. If one discounts issues of
statistical power and accepts the present study as clearly negative, then the most likely
explanation for the significant results obtained by Jauch-Chara et al is that they induced
hypoglycaemia during sleep. Sleep is well-established as a time of active re-processing
ofmemory [2], and may also be a time of increased susceptibility to hypoglycaemia.
More profound hypoglycaemia within the design of the present study (e.g. 1.5-2.0
mmol/L) might yield a significant effect on memory consolidation, and this would be
interesting to do if this degree of hypoglycaemia can be achieved safely.
In conclusion, this study provides some reassurance that moderate hypoglycaemia,
which occurs frequently in the daily lives of people with insulin-treated diabetes, does
not disrupt memory of prior events. It would be valuable to repeat the sleep study of
Jauch-Chara et al for confirmation of their findings, and if possible to include functional
brain imaging during the testing phase to reassess the possibility of hippocampal
dysfunction following hypoglycaemia. It may also be interesting to repeat the design of
the present study but with more profound hypoglycaemia.
8.1.2 The effects of acute hypoglycaemia on learning, recall and
prospective memory (Chapter 5)
There were two main findings in this study. Firstly, moderate hypoglycaemia (2.5
mmol/1) was associated with poorer memory performance, irrespective of whether it
occurred during the learning phase or the recall (testing) phase. For a student with
diabetes, this indicates that hypoglycaemia would be disadvantageous whether occurring
during revision or an examination, with similar consequences in other settings.
Secondly, the novel prospective memory task showed a statistically-significant
deterioration with hypoglycaemia.
The prospective memory results are important, because the task mimics one of the true
roles of memory in daily life — remembering to do something. As briefly discussed in
section 2.2.2, the practical relevance of many cognitive function tests is unclear. One of
the most widely-used memory tests is the Rey Auditory Verbal Learning Test (AVLT),
also used in the present study, which tests subjects for their ability to recite back a list of
15 words. This mode of learning may be seen in primary schools, and may indeed
correlate well with 'general' memory performance, but its direct relevance to an adult
with diabetes is limited. Another common test is paired-associates, as used by Jauch-
Chara et al [1], in which the subject is first read pairs of nouns, and later required to
recall the second word when the first of the pair is read. It is hard to think of any
activity in daily life that resembles this task. The present study is believed to be the first
hypoglycemia study to utilize a test specifically mimicking daily life. Although it was
not trialled in the field, the authors of the paper on which it was based did do this,
obtaining a good correlation between performance on the laboratory-based video task
and performance on the same task in the streets of Dunedin, New Zealand [3].
The magnitude of the impairment associated with hypoglycaemia must be considered
when extrapolating to daily life. The performance reduction in this study was
approximately 12%, or somewhere between a 'small' and 'medium' effect by Cohen's d
statistic [4]. This effect size is similar to those seen for various cognitive tests in
Chapter 6, and in numerous other studies from this centre [5,6,7,8,9]. It is important
that clinical advice and guidelines for people with diabetes should not be dogmatic: in
many cases, hypoglycaemia may cause only a minor impairment, rather than rendering
them incapable, and the degree of impairment is likely to be related to the level of
hypoglycaemia. By contrast, in the studies by Sommerfield et al from this centre [10,11],
the reductions in memory performance were very much greater — in many cases around
50% impairment, with Cohen's d well above the level deemed a 'large' effect. In the
studies of Sommerfield et al, both learning and recall took place during the experimental
condition. It would be valuable to repeat the prospective memory task, but with
hypoglycaemia occurring across both learning and recall, to assess the maximum impact
of moderate hypoglycaemia on prospective memory.
In conclusion, this study has confirmed that both the learning and recall aspects of
memory are impaired by moderate hypoglycaemia, and the prospective memory task has
lent authority to extrapolation of laboratory experimental results to hypoglycaemia in
diabetes. The prospective memory task is more time-consuming and requires additional
equipment, but if these are surmountable then it may be preferable to use the same task
or a similar task in future hypoglycaemia-memory research. With reference to the
conclusions of Chapter 4, a particularly interesting study design would use this task to
re-assess the effects of hypoglycaemia during sleep on memory consolidation.
8.1.3 The Effects of Acute Hypoglycaemia on Non-verbal
Intelligence, and Accuracy and Speed of Visuospatial
Cognitive Function (Chapter 6)
Non-verbal intelligence (principally mathematical and visuospatial problem solving, as
assessed by the Raven's Progressive Matrices test) was not significantly impaired during
hypoglycaemia in earlier studies by McAulay et al [6,7]. This was unexpected, but may
have been due to a ceiling effect, resulting from the use of a moderately difficult test in a
very able group of subjects. In the present study, performance on the harder version of
the same test (Raven's Advanced Progressive Matrices) was impaired during
hypoglycaemia at 2.5 mmol/1 with clear statistical significance. Performance on the
Alice PIcim 5 test also deteriorated, but failed to achieve statistical significance
(P=0.057); this may well have been due to an inadequate sample size. It may be
concluded that higher-level intelligence is affected by moderate hypoglycaemia,
consistent with the previous research and theories outlined in Section 2.2.4.
This study also included a maze task, intended to examine whether hypoglycaemia is
more likely to affect speed or accuracy of cognition. Disappointingly, there was
absolutely no effect of hypoglycaemia on either performance measure, and all that may
be concluded is that the maze task is not a good test for this purpose. The unanswered
question of speed vs. accuracy is of considerable practical relevance, for example in
relation to driving.
8.1.4 Symptoms of Hyperglycaemia (Chapter 7)
This study has defined the symptoms of hyperglycaemia using a very large patient
population. The study confirmed that the osmotic symptoms of thirst, polyuria and dry
mouth are the most commonly experienced symptoms of hyperglycaemia, and the
autonomic symptoms of hypoglycaemia are not reported. Thus, the presence of one or
other set of symptoms is useful in differentiating the two conditions.
One of the other groups of hyperglycaemia symptoms comprised feeling tense,
restlessness, irritability and poor concentration. Although a label of 'mental agitation'
was applied to this group, the symptom of impaired concentration also indicates that
subjects had noticed some cognitive difficulty associated with hyperglycaemia, and the
other symptoms are likely to cause difficulties with attention. This association of
hyperglycaemia with cognitive dysfunction is supported by an experimental study
performed subsequently in this centre by Sommerfield et al., in which reaction time,
working memory and aspects of attention deteriorated during a hyperglycaemic clamp at
16.5 mmol/1 [12].
The average estimated threshold for detection of symptoms was 15.1 mmol/1.
Retrospective estimates may be inaccurate, and the mean conceals a wide range of
individual responses (8 to 30 mmol/1), but even so, this tends to confirm that reliance
on symptoms is inadequate for detection of hyperglycaemia in clinical practice. In
multivariate analysis, age appeared to be the most important factor affecting the
perception of hyperglycaemia symptoms. Older age was associated with a reduction in
symptom intensity ratings that is likely to be clinically significant as well as statistically
significant. The symptoms of hypoglycaemia have also been reported to be diminished
in intensity in older people [13]. Together, these findings show that elderly people with
diabetes are vulnerable to extremes of hypo- and hyperglycaemia because of reduced
ability to detect these changes, as well as potentially reduced ability to manage them
appropriately.
8.1.5 Statistical issues
A common theme in the studies described in Chapters 4, 5 and 6 is statistical power and
sample size calculations. This was also a criticism of some previous studies in Chapter
2.
Appropriate power and sample-size calculations are crucial for quantitative biological
research, because of the natural variability of almost any parameter that might be
measured. It is unethical to ask subjects to submit to invasive or unpleasant procedures
if the study being performed is unlikely to detect a genuine effect. In the research
literature, 'negative' studies are very often described as providing evidence of no effect
when in fact they show no evidence either way.
There are at least two reasons why research is sometimes deficient in this regard.
Firstly, power calculations are more complex than the statistical tests to which they
apply, and may be daunting for non-statisticians. Secondly, to be performed accurately,
information may be required that is not available prior to the study's completion. In
this case, estimates based on previous similar studies may be used instead, but the
relevant data are not always published. This is particularly true for repeated-measures
designs, where an essential parameter is the standard deviation of the difference
between repeated measurements; this information has never reported in published
hypoglycemia studies.
The Appendix provides the data that would be required for power and sample size
calculations for all tests used in the studies described in this thesis.
Page 166
8.2 References
1. Jauch-Chara K, Hallschmid M, Gais S, Schmid SM, Oltmans KM, Colmorgen C,
Born J, Schultes B. Hypoglycemia during sleep impairs consolidation of declarative
memory in type 1 diabetic and healthy humans. Diabetes Care 2007; 30: 2040-2045.
2. Gais S, Born }. Declarative memory consolidation: mechanisms acting during
human sleep. Eearning&Memory 2004; 11: 679-685.
3. Titov N, Knight RG. A video-based procedure for the assessment of prospective
memory. Appl Cognitive Psychol 2001; 15: 61-83.
4. Cohen ). Statistical power analysis for the behavioral sciences. Hillsdale, NJ: Erlbaum,
1992.
5. Strachan MWJ, Ewing FME, Frier BM, McCrimmon RJ, Deary IJ. Effects of acute
hypoglycemia on auditory information processing in adults with type I diabetes.
Diabetologia 2003; 46: 97-105.
6. McAulay V, Deary IJ, Ferguson SC, Frier BM. Acute hypoglycemia in humans
causes attentional dysfunction while nonverbal intelligence is preserved. Diabetes
Care 2001; 24: 1745-1750.
7. McAulay V, Deary I}, Sommerfield AJ, Frier BM. Attentional functioning is
impaired during acute hypoglycaemia in people with type 1 diabetes. Diabet Med
2006; 23: 26-31.
8. McCrimmon Rj, Deary IJ, Huntly BJP, MacLeod KM, Frier BM. Visual
information processing during controlled hypoglycaemia in humans. Brain 1996;
119: 1277-1287.
9. McCrimmon RJ, Deary I], Frier BM. Auditory information processing during acute
insulin-induced hypoglycaemia in non-diabetic human subjects. IVeuropsychologui
1997;35:1547-1553.
10. Sommerfield AJ, Deary IJ, McAulay V, Frier BM. Short-term, delayed, and
working memory are impaired during hypoglycemia in individuals with type 1
diabetes. Diabetes Care 2003; 26: 390-396.
11. Sommerfield AJ, Deary IJ, McAulay V, Frier BM. Moderate hypoglycemia impairs
multiple memory functions in healthy adults. Neuropsychology 2003; 17: 125-132.
12. Sommerfield AJ, Deary Ij, Frier BM. Acute hyperglycemia alters mood state and
impairs cognitive performance in people with type 2 diabetes. Diabetes Care 2004;
27: 2335-2340.
13. Meneilly GS, Cheung E, Tuokko H. Altered responses to hypoglycemia of healthy
elderly people. J Clin EndocrinolMetab 1994; 78: 1341-1348.
Appendix 1
Information For Statistical Power
Calculations
To assist with future studies, information regarding the within-patient variation is
provided for the cognitive function tests used in the studies described in this thesis.
In each case, the difference between hypoglycaemia and euglycaemia performance
scores is calculated for each patient. The mean of these differences is necessarily the
same as the difference between mean hypoglycaemia and euglycaemia scores. The
standard deviation is an index of the consistency of the effect of hypoglycaemia between









Mean diff SD diff
Chapter 4 Non-DM 38.7 46.3 8.7 14.2
Chapter 5 T1DM, NHA 38.3 46.3 8.0 14.0
Chapter 5 T1DM, IHA 44.0 53.6 7.4 20.7
Digit Symbol Substitution
Study Subjects
No. correct in 2
minutes -
euglycaemia
No. correct in 2
minutes -
hypoglycaemia
Mean diff SD diff
Chapter 4 Non-DM 87.7 79.4 8.9 11.5
Chapter 5 T1DM, NHA 79.8 65.6 14.1 11.3









Mean diff SD diff
Chapter 5 T1DM, NHA 612 666 54 57
Chapter 5 T1DM, IHA 647 679 32 68





hypoglycaemia Mean diff SD diff
Chapter 4 Non-DM 25.8 35.6 9.8 12.8
Chapter 5 T1DM, NHA 25.0 35.0 10 14.8






hypoglycaemia Mean diff SD diff






hypoglycaemia Mean diff SD diff
Chapter 4 Non-DM 78.0 77.1 0.9 9.2





hypoglycaemia Mean diff SD diff
Chapter 5 T1DM, NHA 10.0 8.7 1.3 2.6
Chapter 5 T1DM, IHA 10.9 9.2 1.6 2.7
iYB - in Chapter 5, only the learningphase of theAV1CT wasperformed during
hypogjycaemia/ euglycaemia. Recall was always tested during eugfycaemia.





hypoglycaemia Mean diff SD diff
Chapter 5 T1DM, NHA 13.1 11.0 2.1 3.2
Chapter 5 T1DM, IHA 15.7 13.7 2.0 4.1
NB — in Chapter 5, only the learningphase of the logical Memory Test wasperformed during
hypoglycaemia / euglycaemia. Kecall was always tested during euglycaemia.





hypoglycaemia Mean diff SD diff
Chapter 5 T1DM, NHA 82.8 77.5 5.3 16.1
Chapter 5 T1DM, IHA 81.3 85.1 3.7 14.4
NB — in Chapter 5, only the learning phase of the Visual Memory Test wasperformed during






hypoglycaemia Mean diff SD diff
Chapter 5 T1DM, NHA 11.4 10.1 1.3 3.7
Chapter 5 T1DM, IHA 15.4 13.3 2.1 2.9
NB - in Chapter 5, only the recallphase of the Prospective Memory Test wasperformed during
hypoglycaemia / euglycaemia. Teaming always occurred during euglycaemia.
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Abstract
Introduction Some aspects of memory performance are impaired during
acute hypoglycaemia. The hippocampus is critical to formation of long-term
memory, and may be particularly sensitive to hypoglycaemia. This study
examined whether moderate hypoglycaemia occurring after learning would
disrupt the consolidation process, and used functional magnetic resonance
imaging (fMRI) to identify accompanying changes in brain activation.
Methods Sixteen non-diabetic subjects each underwent two glucose clamp
studies. During euglycaemia (4.5 mmol/L), subjects tried to memorize a
series of words and a series of pictures of faces. Then, either hypoglycaemia
(2.5 mmol/L) was induced for one hour, or euglycaemia was maintained.
During subsequent uncontrolled euglycaemia, subjects' recognition of the
word and face stimuli was tested, with simultaneous tMRI to measure brain
activation during recognition.
Results Face identification scores were 67.2% after euglycaemia and 66.9%
after hypoglycaemia (p = 0.895). Word identification scores were 78.0 and
77.1% respectively (p = 0.701). Analysis of the fMRI identified two foci where
activation was altered after hypoglycaemia compared with euglycaemia, but
these were not in regions associated with memory, and were probably
statistical artefacts.
Conclusions One hourofhypoglycaemia at 2.5 mmol/L induced 20-40 min
after learning did not disrupt memory consolidation. fMRI did not show
evidence of altered brain activation after hypoglycaemia. Consolidation may
be relatively resistant to hypogiycaemia, or may have been complete before
hypoglycaemia was induced. The study was powered to detect a large effect,
and provides some reassurance that moderate hypoglycaemia does not cause
major disruption of previously learned memories in people with insulin-
treated diabetes. Copyright © 2007 John Wiley & Sons, Ltd.
Keywords diabetes; hypoglycaemia; memory; consolidation; functional imaging
Peccivwl: 3 May 2007
Accepted: 23 September 2007
Introduction
Cognitive abilities, ranging from simple motor tasks and basic sensory pro¬
cessing to complex reasoning, are adversely affected by hypoglycaemia [I],
We have demonstrated previously that episodic short-, working- and long-
term memory are significantly impaired by hypoglycaemia [2-4]. These
Copyright 2007 John Wiley & Sons, Ltd.
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results are in agreement with earlier reports, which
included some teste ofmemory among broader cognitive
test batteries, but much remains to be elucidated about
the functioning of memory during hypoglycaemia.
Memory has been conceptualized as composed of three
main subsystems: sensory memory, short-term memory,
and long-tenu memory [5]. Sensory memory is the brief
retention of an auditory or visual impression after the
stimulus has been removed. Short-term memory can hold
a limited number of items, with a duration measured in
seconds. Long-term memory is durable, with no quantifi¬
able capacity limits. The conversion of short- to long-term
memory is known as consolidation. The neurological basis
of consolidation is not well understood, but the medial
temporal lobe structures appear to be critical. Evidence
cornes from individuals who have sustained focal dam¬
age to the hippocampus and have developed near-total
inability to form new long-term memories, while retain¬
ing intact short-term memory and pre-fonned long-term
memories [6-9], Cases have been reported of individuals
who have developed amnesia following severe hypogly¬
caemia, in whom frontal and hippocampal lesions were
identified on magnetic resonance imaging (MRI) scans
[10,11]. A similar distribution of lesions was reported on
MR! scans in four patients iir a vegetative state following
severe hypoglycaemia [12], and from post-mortem exam¬
inations following fatal hypoglycaemia in a human case
report [13], and in an exper imental rat study [14]. The
frontal lobes and hippocampal region appear to be partic¬
ularly sensitive to hypoglycaemia, and this may contribute
to the disruptive effects of moderate hypoglycaemia on
aspects of memory.
In most previous studies of memory during hypogly-
caernra, both stimulus presentation and recall testing
took place during the experimental condition (hypogly¬
caemia or euglycaemia), and so these studies could not
distinguish tire effects of hypoglycaemia on acquisition
(learning), recall, and consolidation. We have recently
demonstrated that moderate hypoglycaemia impairs both
learning and recall [IS]. If hypoglycaemia also impairs
consolidation, then depending on the duration of the con¬
solidation process, it could impair recall of information
learned prior to the onset of hypoglycaemia.
The present study investigated whether a period of
hypoglyeaenria occurring immediately after exposure to
new stimuli impaired subsequent recognition. Functional
magnetic resonance imaging (fMRI) was used to examine
brain activation during tire recognition task. It was
hypothesized that activation in the hippocampus and
adjacent medial temporal lobe structures would be
reduced following hypoglycaemia. (MR! exploits a natural
difference in the magnetic properties of oxy-haemoglobin
and deoxy-haemoglobin [16], such that the blood-oxygen
level dependent signal is increased following neuronal
activation [17,18]. Previous fMRi studies have shown
that activation of the medial temporal lobe structures
(including the hippocampus) is consistently associated
with successful encoding and retrieval of episodic
memories [19-23].
Copyright' 2tXf? John Wiiey & Sons. Ltd,
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Methods
The study was approved by the local research ethics
committee, and all subjects provided informed consent.
Subjects
Sixteen right-handed non-diabetic adults (9 male) for
whom English was a first language were recruited. People
with active medical conditions or previous history of
seizure, cerebral injury, or other contra-indication to
experimental hypoglycaemia were excluded. Median age
was 25 years (range 20-44) and median bodymass index
was 22.6 kg m~2 (range 20.1-27.7).
Study outline and glucose clamp
procedure
Subjects underwent two glucose clamp studies (hypogly¬
caemia and euglycaemia), preceded by overnight fasting,
and separated by at least two weeks. Soluble human
insulin was infused intravenously at a fixed rate (60
mU/min/m2 body surface area), and 20% dextrose was
infused at a variable rate to achieve target blood-glucose
concentrations. Samples for measurement ofwhole blood
glucose were drawn every 3-5 min from a vein in the
non-dominant hand, which was placed within a heated
blanket to arterialize venous blood.
The study design is illustrated in Figure 1. During an
initial euglycaemic phase, blood-glucose concentrations
were stabilized at 4.5 mmol/L for 30 min, and the series
of faces and words were presented for learning. In
hypoglycaemia studies, the glucose infusion rate was
immediately reduced to lower blood glucose quickly
to a target of 2.5 mmol/L (deemed to be achieved
when measurements over at least 6 min were in the
range 2.3-2,7 mmol/L), maintained at this level for
60 min, and finally raised to 4.5 mmol/L, when the clamp
was discontinued. In euglycaemia studies, blood glucose
was maintained at 4.5 mmol/L for 100 min, including
40 min to match the time taken to achieve and reverse
hypoglycaemia.
After discontinuation of the clamp, subjects were given
a meal and allowed to rest for 1 h to ensure recovery of
Learning: words Recognition resting
and laces |xescnl«i Meal and IMRl scanning
figure i ■ Sequence of experimental procedures
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cognitive function. Subjects were then taken to tire MR!
suite for recognition testing and fMRI acquisition.
Memory tests, procedure and analysis
Face stimuli were digitized photographs of a Caucasian
student population, taken without jewellery or spectacles,
and scaled so that the head occupied 80% of the frame.
Word lists were made up of words with frequencies
between 20 and 30 in the seties from Kucera & Francis
[24]. Two learning batteries of 40 faces (20 male, 20
female) and 50 words were created. Tests in separate
subjects pr ior to the commencement of this study yielded
recognition rates of approximately 70% alter an interval
of 2 h.
A different learning battery was presented at each
subject's two study sessions. Stimuli were presented on a
computer screen positioned at amis length. To improve
retention, subjects were asked to rate each word or face
for its attractiveness, although these data (which are
not relevant to the current study) were not analysed.
During the next hour subjects completed tests of fluid
intelligence (Raven's Advanced Progressive Matrices and
the Alice Heim V test), to prevent rehearsal of learned
material, and to address a separate research question;
results of these have been published elsewhere [25].
Recognition was tested when subjects were in the MR1
scanner. Subjects viewed stimuli on a screen directly
above their faces, with focal aids if required. Stimuli
were presented using E-prime Version 1.0 (Psychology
Software Tools Inc. Pittsburgh, USA) and 1F1S 1.09
(MR1 Devices Corporation, Waukesha, USA). Following an
initial practice run, subjects viewed 90 faces, of which 40
had been seen before (targets) and 50were new (decoys).
Subjects identified targets and decoys by pressing left- and
right-hand buttons. Word recognition was tested with 140
words, comprising 50 targets and 90 decoys.
Performance was analysed using repeated-measures
analysis of variance. Order of glycaemic condition and
order of stimulus battery were counterbalanced within
the experimental design, and were included as between-
subjects factors. Analyses were performed using SPSS
11.0 (SPSS Inc, Chicago, USA).
Imaging acquisition and analysis
Scanning was carried out on a 1.5T GE Signa scanner
fitted with Echospeed gradients, using the standard head
coil. Acquisition periods were 540 (face paradigm) and
840 s (word paradigm); tiie first 10 s were discarded to
ensure steady-state magnetization. Contiguous gradient
echo, echoplanar images (TR 2500 ms, T.E 40 ins) were
collected from 30 5imn slices (interleaved acquisition)
parallel to the anterior-posterior commissure plane. The
matrix acquired was 64 x; 64 with an in-plane resolution
of 3 x 3 mm. Button responses to the memory tasks were
logged simultaneously, ATI-weighted structural scan was
Copyright • 2007 John Wiley & Sons, Ltd.
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acquired after fMRI acquisition. Images in each serieswere
registered to the initial image to correct for head motion.
EPF-volumes were then co-registered to the Tl-weighted
structural volume and aligned to standard coordinates,
and data was smoothed with a 6 mm Gaussian kernel
to allow for variability in gyral anatomy and location of
activation between subjects.
The fMRI design for the test was event-related. Data
were analysed using the statistical parametric mapping
package SPM99. Events were modelled using canonical
haemodynamic response functions and six movement
regressors. Events were classified by subject responses
as 'Correct Hit', 'Cottect Rejection, Incorrect Hit', or
incorrect Rejection'. For a small number of events
no response was given, and these were assigned to
the relevant incorrect category. First-level fixed-effects
T-contrasts were made between the euglycaemia and
hypoglycaemia conditions. The T threshold was set at
3.09, and cluster size threshold at 10 voxels. A fixed-
effects analysis was performed, with a view to further
analysis if this produced promising results.
Results
Blood glucose and timing
Comparisons for hypoglycaemic (H) and euglycaemic
(E) sessions were as follows. Mean (SD) blood glucose
during the initial euglycaemic phase was 4.4 (0.2)
rnmoi/L (H) versus 4.3 (0.2) mmol/L (E), p = 0.436.
Mean (SD) blood glucose during the experimental phase
was 2.5 (0.2) mmol/L (H) versus 4.4 (0.3) mmol/L (E).
In hypoglycaemia sessions, mean (SD) time to achieve
stable hypoglycaemia was 30 (7) min. Mean (SD) interval
between discontinuation of clamp and commencement of
memoty testing was 86 (10) min (H) versus 85 (15) min
(E),i> = 0.803.
Memory performance
Stimuli correctly identified were converted into a
percentage, weighted for the true frequency of targets
and decoys so that the chance score was 50%. Adjusted
face identification scores were almost identical following
euglycaemia and hypoglycaemia [67.2 (8.2) % and 66.9
(7-4) % respectively, t)2 = 0.002, p— 0.895], as were
adjusted word identification scores [78.0 (8.0) % and
77.1 (12.2) % respectively; tj2 = 0.013, p = 0.701).
There was variation in the. time intervals between
learning and attainment of hypoglycaemia, and between
learning and testing. Memory performance was re-
analysed with these intervals as covariates, but all effects
remained clearly non-significant. There were also no
significant effects for unadjusted scores (e.g. number
of correct hits). No individual memory item was very
easy (correctly identified by >13 subjects) or very hard
(correctly identified by <3 subjects).
Diabetes Memo lies Rev 2008; 24: 247-252.
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Figure 2. Brain activarion maps showing clusters achieving p < 0.05 for hypogtycaemia versus euglycaemia. Cluster A showed
significantly less activation following hypoglycaemia for faces correctly identified as targets. Chtster B showed significantly more
activation following hypoglycaemia for all faces
Post hoc calculation indicated that the study had 80%
power to detect a difference in adjusted face scores of 6.6
(0.8 euglycaemia SD). and in adjusted words scores of
6.9 (0.86 euglycaemia SD).
Brain activation
One brain area appeared to show glycaemic differences
in recognition-associated activation (Figure 2, cluster A).
This cluster is located on the border of the right occipital
cortex and cerebellum, and showed reduced activation
after hypoglycaemia for faces correctly identified as tar¬
gets. A second area (Figure 2, cluster B) in the midline
close to the cakarine sulcus showed increased activa¬
tion following hypoglycaemia for all faces, irrespective of
response.
Neither area is known to be associated with memory.
The statistical significance is borderline using the
liberal fixed-effec ts model, and in the absence of any
results requiring further exploration, a more conservative
random-effects analysis was not performed.
Discussion
No effect of hypoglycaemia on memory performance was
seen in the present study. It is possible that hypogiycaemia
has no effect on consolidation, but at least five alternative
explanations can be proposed. In this sense, the null
findings are helpful to further research.
First, the study may have been underpowered, as
advance sample size estimates were limited by a lack
of previous data. Post hoc calculations showed that the
study had good power to detect a 'large* effect, according
to Cohen's conventions [26], We previously published
a study of hypoglycemia during learning and recall of
verbal and visual material (this was carried out after
the present study and could not inform its sample size)
Copyright v 2007 John Wiley & Sons, Ltd.
[15]. The greatest effect of hypoglycaemia was seen for
delayed verbal memoty, with a 'medium' effect equivalent
to approximately 0.6 standard deviations. A post hoc
calculation reveals that for 80% power to detect a similar
effect on the word task in the present snidy, a sample
size of 31 would have been needed. However, although
not statistically rigorous, the almost identical results
following euglycaemia and hypoglycaemia do not support
the possibility of an effect failing to achieve significance.
Second, the level of hypoglycaemia induced
(2.5 mmol/L) may have been insufficient. Although it
is known that the entire memory process from learn¬
ing to recall is affected by hypoglycaemia at 2.5 mmol/L
[2,3], more profound hypoglycaemia maybenecessaty to
disrupt consolidation.
Third, hypoglycaemia may have been achieved too
late (20-40 rain after stimulus exposure) to affect
consolidation. The duration of the consolidation process
is not clearly defined. Diverse interventions have been
shown to affect memories acquired minutes or hours
beforehand, including drug administration [27-29] and
concussion [30]. There is also substantial evidence for
the improving effects of sleep, immediately or overnight,
on memory consolidation [31,32]. Other studies have
shown evidence of consolidation over much longer time
periods. Recognition-associated fivlRl brain activation
progressively decreased in the hippocampus and increased
in the pre-frontai region when measured 1, 2, 30
and 90 days after stimulus exposure [31], and patients
with focal hippocampal lesions display a temporal
gradient for amnesia over years [33-35], suggesting
transfer of memory from hippocampal to other sites,
in summary, consolidation appears to be a chronic and
heterogeneous process. There maybe an early phase (e.g.
less than 20 min after learning) which is susceptible to
acute metabolic derangement; if so, a different result
might be expected if hypoglycaemia could be induced
instantaneously, but this would not be relevant to people
Diabetes Meial) lies Rev 2008; 24: 247-252.
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with diabetes, in whom hypoglycaemia may develop over
hours [36].
Fourth, it is possible that the brainmaywork harder, or
differently by recruitment of other regions, to achieve
the same result during hypoglycemia. However, the
fMRI data revealed apparent differences in activation
for hypoglycemia and euglyeaetnia in only two brain
areas, neither of which are associated with memory, and
a liberal fixed-effects analysis yielded only borderline
statistical significance. We conclude that the functional
imaging showed no evidence of altered brain functioning
following hypoglycaemia.
Fifth, the present study measured recognition rather
than recall, because of logistical difficulties in obtaining
anything other than binary answers during MR1 scanning.
Recognition may require less robust encoding, and hence
suffer less disruption from hypoglycaemia. However,
recognition tasks have been used effectively in fMRI
memory studies [19], and a recognition task was
adequate to show changes in both memory performance
and brain activation following an intervention to affect
consolidation [31]. Thememory tasks in the present study
had not been used previously, but the results suggest drat
they were valid: scores fell appropriately between floor
(50%) and ceiling (100%) limits, with no very easy or
difficult items.
Non-diabetic subjects were studied because of the
difficulties of maintaining infusions in an MR1 room,
required for diabetic subjects to prevent unacceptable
variations in blood glucose. However, most previous
studies that have compared the cognitive effects of
hypoglycaemia in diabetic and non-diabetic subjects have
reported either similar results, or relative resistance to
cognitive dysfunction in diabetic subjects [37]. It seems
unlikely that a positive result would be obtained in
diabetic subjects but a null result in non diabetic subjects.
Jauch-Chara etai recently reported the effects of
hypoglycaemia on overnight memory consolidation [38].
Word pair recall was tested before and after sleep, on
hypoglycaemia nights {nadir blood glucose 2.2 mmol/L
induced 60 min after sleep onset) and control nights.
Performance improved after control nights, consistent
with the known effects of sleep on consolidation, but
no improvement occurred over hypoglycaemia nights.
The results suggest that hypoglycaemia did disrupt
consolidation, and it is instructive to compare that study
with the present study. First, Jauch-Chara et a1. did not
report a significant effect of hypoglycaemia in subsets
of 16 diabetic and 16 non-diabetic subjects, but in
all 32 subjects combined. This is consistent with the
sample size estimate of 31 mentioned above, and tends
to reinforce tire lack of power of the present study.
Second, consolidation while asleep may be a different
phenomenon front consolidation awake while. Sleep
appears to be a time of active re-processing of memory,
and therefore, perhaps a time of increased susceptibility
to memory interventions [39].
Other researchers have managed to study brain
activation during hypoglycaemia. Using very long tubing
Copyright O 2007 Jolui Wiley & Sons, U<l.
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to infusion pumps outside the MR! field, Rosenthal et al
examined the effects of hypoglycaemia (2.5 mmol/L)
on fMRI brain activation during finger tapping and
reaction time tasks in non-diabetic subjects [40]. By
comparison with euglycaemia, during hypoglycaemia
there was increased activation in the parietal association
area, and decreased activation in the visual cortex,
cerebellum, hippocampus, and pre-motor cortex. The
hippocampus was the only one of these areas that was not
activated by the cognitive tasks. Teves et al. used positi on
emitting tomography {PET) to measure cerebral blood
flow (CBF) during passive hypoglycaemia (3.0 mmol/L)
in non-diabetic subjects [41]. Global CBF fell by 6-8%
during hypoglycaemia, but with a relative increase in
CBF in the thalamus, medial pre-frontal cortex and right
orbital pre frontal cortex, and a 26% relative decrease in
CBF in the hippocampus. Anderson er al. reported that
occipital activation during visual stimulation was reduced
during hypoglycaemia (2.8 mmol/L) in non-diabetic
subjects [42], Wesseis etal studied activation during
a working memory test, and found increased activation
in the anterior cingulate and orbital frontal gyrus during
hypoglycaemia (~2.3 mmol/L) in subjects with advanced
diabetic retinopathy compared with subjects with no
retinopathy [43]. This was interpreted as an altered
brain response compensating for cerebral microvascular
damage, for which retinopathy is a proxy. It is impossible
to amalgamate these studies to obtain a coherent account
of changes in activation throughout the brain, but the
hippocampus stood out as having reduced fMRI activation
or CBF during hypoglycaemia in the studies by Rosenthal
er al. and Teves et al., [40,41]. Given the sensitivity of the
hippocampus to hypoglycemic damage [12-14], it seems
plausible that hippoeampal dysfunction during moderate
hypoglycaemia contributes to memory impairment.
In summary, 1 h of hypoglycaemia at 2.5 mmol/L
after stimulus exposure did not affect subsequent
recognition performance, and did not alter brain
activation patterns during recognition. A large effect
of moderate hypoglycaemia on memory consolidation
can be excluded, and thus, the study provides some
limited reassurance relevant to diabetic daily life. In
retrospect, the study was underpowered to detect an
effect of hypoglycaemia on memory comparable to effects
seen in other studies, and future studies should probably
aim to recruit 30 or more subjects. It is possible that
more profound hypoglycaemia would yield a different
result. It would be of interest in future to compare
regional brain activation responses to memory and non-
memory tasks during hypoglycaemia, and to vary the
delay before induction of hypoglycaemia, and the level of
hypoglycaemia achieved,
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Abstract
Aims-hypothesis Global memory performance is impaired
during acute hypogiyeaemta. This study assessed whether
moderate hypoglycaemia disrupts learning and recall in
isolation, and utilised a novel test of prospective memory
which may better reflect the role of memory in daily life
titan conventional tests.
Subjects and methods Thirty-six subjects with type I
diabetes participated, 20 with normal hypoglycaemia
awareness (NHA) and 16 with impaired hypoglycaemia
awareness (IMA), Each underwent a hypoglycaemic clamp
with target blood glucose 2.5 mmoi/1. Prior to hypoglycae¬
mia, subjects attempted to memorise instructions for a
prospective memory task, and recall was assessed during
hypoglycemia. Subjects then completed the learning and
immediate recall stages of three conventional memory tasks
(word recall, story recall, visual recall) during hypoglyce¬
mia. Euglycaemia was restored and delayed memory for the
conventional tasks was tested. The same procedures were
completed in euglycaemic control studies (blood glucose
4.5 mraol/1).
Results Hypoglycaemia impaired performance significantly
on the prospective memory task (/r 0.004). Hypoglycaemia
also significantly impaired both immediate and delayed
recall for the word and story recall tasks (p<0.01 in each
case). There was no significant deterioration of perfor¬
mance on the visual memory task. The effect of hypogly-
R. H. Warren - N. N, Zammiit - B. M. Frier {is)
Department of Diabetes. Royal Infmnary erf Fxlinbusgh.
51 Little France Crescent,
Edinburgh EH16 4SA, UK
e-mail: braei.tVienUlula.su'Ushs.uk
I. J. Deary
Depailitieirt of Psychology, University of Edinburgh,
Editiburgii, UK
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caemia did not differ significantly between subjects with
NilA and III A.
Conclusions/interpretation Impaired performance on the
prospective memory task during hypoglycaemia demon¬
strates that recall is disrupted by hypoglycaemia. Impaired
performance on the conventional memory tasks demon¬
strates that learning is also disrupted by hypoglycaemia.
Results of the prospective memory task support the
relevance of these findings to the everyday lives of people
with diabetes.
Keywords Cognitive function ■ Hypoglycaemia-
Hypoglycaemia awareness ■ Memory - Type 1 diabetes
Abbreviations
AVLT Auditory Verbal Learning Test
1HA impaired hypogiyeaemia awareness
NHA normal hypoglycaemia awareness
Introduction
Hypoglycaemia is a common side effect of insulin therapy
for type 1 diabetes [I]. Experimentally* induced acute
hypoglycaemia causes a deterioration in performance on a
wide range of cognitive tasks in humans [2], Memory is
one the of the most important cognitive domains with
respect to everyday Junction. Previous studies applied
memory tests as part of a larger battery of cognitive tests
during hypoglycaemia [3 -8 j, and the variability of reported
results may relate to the use of different memory tests.
Methodological variation in hypoglycaemia studies has
been reviewed elsewhere (9J; particularly pertinent issues
include sample size and statistical power, the method of
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measurement of blood glucose, and the target level for, and
the duration of, hvpogiyeaemia.
Neuropsychological research indicates that memory
comprises a number of subsystems, including sensory
memory, short-term memory and long-term memory [10],
We have studied previously the effects of hypoglycaemia
on various components of memory using consistent
experimental techniques and validated memory tasks.
Hypogtycaemia impairs the auditory and visual processing
subsystems of sensory memory, short-term memory, work¬
ing memory and delayed memory in both diabetic and non-
diabetic subjects [1116], Working memory and delayed
memory are particularly susceptible to hypoglycaemia [17].
In all previous studies, both the acquisition (learning)
and recall of material took place during hypoglycaemia.
Deterioration in memory performance during hypoglyce¬
mia may have resulted from impairment of learning,
consolidation (transfer of information from short- to long-
term memory), recall, or any combination of these. The
present study was designed to investigate whether these
processes are independently sensitive to hypoglycaemia by
separating the acquisition and recall phases of memory
tasks so that only otic occurred during hypoglycaemia.
Conventional laboratorymemory tests tend to involve tasks
such as learning lists ofwords, prose passages, and geometrical
shapes. Such tests may not reflect the memory demands of
daily living, which require coordination of multiple cognitive
processes such as planning and vigilance, and therefore may
not have ecological relevance [IS, 19], Recall of retrospective
events has been distinguished from prospective memory
(remembering intended actions, or 'remembering to remem¬
ber'), and tests of prospective memory may have greater
ecological validity [20J. Titov and Knight developed a novel
test of prospective memory in which subjects memorised a
shopping list and then viewed a video of a pedestrian journey
around an urban shopping area, reporting items to be
purchased when specified shops appeared [21 j. l itis video-
based memory task had good test-rctest reliability. It also had
good criterion validity: it correlated well with performance on
tlie same task when subjects actually walked through the
shopping area. Comparative scores were obtained tor 35
subjects, yielding a correlation of r 0.71, p<0.00l, and no
significant effect of study type (video vs in vivo) in ANOVA.
A similar video task was created for tire present study to
explore the effects ofhypoglycaemia on prospective memory
in a practical setting.
Evidence has accumulated to show that recurrent
exposure to hypoglycaemia in people with type 1 diabetes
results in cerebral adaptation, such that cognitive perfor¬
mance is relatively preserved during hypoglycaemia [22-
2?j. Repeated exposure to hypogiyeaemta can also result in
impaired hypoglycaemia awareness, and a shared mecha¬
nism for the two phenomena has been proposed [28]. Thus,
179
in studies of people with type i diabetes, it is important that
subjects with impaired hypoglycaemia awareness (which
may be a surrogate marker of cerebral adaptation to
hypoglycaemia) are considered separately from those with
normal hypoglycaemia awareness.
The aims of the present study were: (1) to assess die
effects of acute hypoglycaemia on different memory
processes (acquisition and recall) for conventional memory
tasks; (2) to assess the effects of acute hypoglycaemia on a
novel prospective memory task; and (3) to compare these
effects in people with type 1 diabetes who had either
normal or impaired hypoglycaemia awareness.
Subjects and methods
The smdy protocol was approved by the Lothian Medical
Research Ethics Committee, and all subjects gave informed
consent to participation.
Subjects
Subjects were required to have a diagnosis of type 1 diabetes,
age between 18 and 45 years, a BM1 between 20 and
30 kg/inand HbAu. values between 7 and 10%. They
were ineligible if they had any significant current medical
condition or contraindication to experimental hypoglyce¬
mia. female patiestts were eligible only if a pregnancy test
was negative.
Potential subjects were asked to grade their hypoglycaemia
awareness on a scale from I to 7 [29], and their hypoglycae¬
mia history was also discussed. People who chose a grade of
1 or 2 and reported no history of severe hypoglycaemia or
significant change in their wanting symptoms were catego¬
rised as having normal hypoglycaemia awareness (NHA).
People who chose a grade between 3 and 7 and reported
diminution of hypoglyeaemic symptoms and episodes of
unrecognised hypoglycaemia were categorised as having
impaired hypoglycaemia awareness (IMA) [29], People
whose self-rated awareness appeared inconsistent with their
hypoglycaemia history were ineligible, on the grounds that
their awareness status was uncertain.
In total, 36 subjects were recruited (20 NHA, 16 IHA);
their characteristics are given in Table 1. Microvascular
complications were defined as any clinical diagnosis of
diabetic retinopathy, neuropathy or nephropathy, the latter
also requiring a urine albumin:creatinine ratio persistently
above the local reference maximum or serum creatinine
>150 pmol/1. The IHA group had significantly longer
duration of diabetes t? '3.937. df~34, pcO.OOi) and more
microvascular complications (y* 5.994, <// I. /> 0.013).
Other comparisons were non-significant.
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Each subject underwent one hypogiycaemic and one
euglycaemic glucose clamp, separated by at least 2 weeks.
Subjects were not informed of the order in which these
occurred. On the evenings before studies, subjects took
their normal insulin, fasted from 22,00 h (consuming only
water) and omitted insulin on the morning of the study.
Subjects were encouraged to avoid hypoglycaemia during
the 4X It before the planned studies by reducing insulin
doses if necessary. Studies were postponed if subjects
detected any episode of hypoglycaemia by symptoms or
routine blood testing during this period; this resulted in six
postponements (two NliA. four IHA).
An antecubital vein and a dorsal hand vein were
eanmiluted in the non-dominant arm for infusions and
blood sampling. The hand was placed within a heated
blanket to arterialise venous blood. Arterialised venous
samples were drawn every 5 min for measurement ofwhole
blood glucose (YS1 2300 STAT analyser, Yellow Springs,
Oi l, USA ). An infusion of soluble human insulin (Actrapid;
NovoNordisk, Crawley, UK) was started at 1.5 mU kg"'
min . and 20% glucose solution was intiised at a variable
rate to achieve the desired blood glucose concentrations.
The blood glucose concentration was initially stabilised at
4.5 mmol/l {eugiycaemia), and maintained for40 min. During
the hypoglycaemia studies, the blood glucose was then
lowered over 20 min to 2.5 mmol/l and maintained for
60 min, then raised to 4.5 mntol/1 and maintained for a further
75 min. Blood glucose was maintained at 4.5 mmol/l through¬
out the euglycaem ia studies.
Memory tests
Two parallel versions of each test were available, which were
combined to give two batteries. The order in which subjects







Male, fbmate (n) 12,8 6,10
Age (years): median (range) 29 (19 44) 33,5 (22 43)
Diabetes duration (years): median (range) 3.8 (1.1 20) 15.5 (2 35)
IIbAJc (%)a 7.841.3 8.441.8
BM1 (kg/nr) 25.842.2 26.843.6
Subjects with microvascular i (5) 6 (38)
complications (%)
Data are mean 4 SD unless staled othenvise













rig. 1 Study outline. The same timing was adhered to for eugiycaemia
studies
eugiycaemia order were counterbalanced within the NHA
and IHA groups. The study outline is given in Fig. I.
Prospective memory This was a novel test, based on a
method developed by Titov and Knight [2.1]. Two videos
showing the view of a pedestrian journeying around central
Edinburgh were created, and for each a 'shopping list' of 21
tasks was written on 21 cards. These were made up of 'buy"
tasks (e.g. 'Buy tennis balls at A&B Sports'), 'do' tasks
(e.g. 'Book a table at Smith's restaurant') and 'question'
tasks (e.g. 'What is the advertised loan rate at the
Mercantile Bank?'). Subjects were asked to read the cards
twice at a normal reading pace, placing each card face
down once it had been read. Subjects then watched the
video and scored points for answering questions or stating
actions at the relevant places. These were not brought to
subjects' attention, and points were not awarded for
answers given at inappropriate times. Pilot studies indicated
that the two videos were of equivalent difficulty. Each
lasted approximately 10 min, and were similar in terms of
the number of shops passed (about 80). In the present study,
subjects read the cards (learning) during initial eugiycae¬
mia. and recall was tested after approximately 40 min
during the experimental period of induced hypoglycaemia/
eugiycaemia. Thus, the experimental manipulation exam¬
ined the effects of hypoglycaemia on recall.
Conventional memory tests For the following memory
tests, acquisition and immediate recall were tested during
the experimental hour (eugiycaemia or hypoglycaemia).
Delayed recall was tested 90 min later during eugiycaemia,
without further exposure to the learned material. Thus, the
4'i Springer
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experimental manipulation here examined the effects of
hypoglycemia on acquisition (learning).
(1) Auditory Verbal Learning lest (AVLT)immediate
and delayed [30j. Fifteen words were read to the
subject, who tried to recall the words immediately.
This was repeated a further four times, and the
immediate recall score was the sum of correct
responses for the five trials. The delayed recall score
was the number correctly recalled from a single trial,
(2) Logical Memory Test—immediate ami delayed, in
this subtest from the Wechsler Memory Scales
Revised [31], a short story was read to the subject,
who tried to recount it immediately. Points were
obtained for recollection of specific details and story
themes.
(3) Visual Reproduction immediate and delayed, from
the Weehsler Memory Scales -Revised [31 J. Each of
five line drawings was shown to the subject for 10 s
and then hidden, and the subject tried to reproduce the
drawing from memory. Reproductions were scored
according to strict criteria.
Symptom scores
Subjects scored their symptoms of hypoglyeaemia at
baseline and during the experimental period using the
Edinburgh Hvpoglycaemia Scale [32.].
Statistical analysis
Scores on memory tasks were compared using repeated-
measures ANOVA, Memory test score during euglycaemia
versus hypoglyeaemia was the repeated measure (within-
subjects factor), Hypogiycaemia awareness, order of hypo¬
glycemia euglycaemia and order of test battery were
bctwccn-subjects factors. Statistical significance was ac¬
cepted at /.><().05 and if was used to indicate effect size.




During the hypoglycemic condition, meartiSD blood
glucose was 2.5±0.2 mmol/l in the NHA group, and
2.540.2 mmol/l in the 1HA group (/>-0.468). During
euglyeaemia, mean blood glucose concentration was 4.5±
0.2 mmol/l (NHA) and 4,5±0.3 mmol/l (p 0.643) (1HA).
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Symptoms
Total symptom scores did not cltange during euglycaemia.
During the hypoglycaanic condition, mean symptom scores
rose in both the NHA group (baseline 23.2±4.4 vs experimen¬
tal 44.1 ±22.2; /X0.001) and the IHA group (22.9±7.0 vs
2S.X tS.3; p O.ftOI). The increment in symptom scores was
significantly greater in the NHA group (interaction between
glycaeinic condition and awareness status, p~0M2).
Memory tasks
Results are given in Table 2. There were no significant
effects of order of exposure to glycaemic condition or test
battery.
Comparison ofthe effect ofhypoglycemia in NHA and IHA
subjects The interaction between glycaemic state and
hypoglyeaemia awareness designation (hereafter referred
to as the glyeaemia*awareness interaction) was not
significant for any tests. This means that there was no
significant difference in the effects of hypogiycaemia on
cognitive function between the NHA and IHA groups. In
some cases, there was a statistically significant effect of
hypogiycaemia in one group but not the other; however, in
each case hypogiycaemia was associated with poorer
performance in both groups, and achievement of statistical
significance in one group but not the other may have been
due to chance. In the absence of significant glycaemta x
awareness interactions, the effect of hypogiycaemia on
memory performance was determined for all subjects
combined.
Prospective memory Recall was significantly impaired in
all patients combined during hypogiycaemia (if=11.255,
p U.004). IHA subjects performed better overall than
NHA subjects (p=fl.OI8).
immediate verbal memory Immediate recall was signifi¬
cantly impaired during hypogiycaemia for the AVLT
(tf f).268,/> 0.003) and logical memory test (j/2--0.233,
/t~0.007) in all subjects combined. The IHA group
performed significantly better than the NHA group on
the logical memory task (p- 0.030).
Delayed verbal memory Delayed recall was significantly
impaired during hypoglycemia for both AVLT (if --••0.373,
/?<0.001) and logical memory test (rf~-0 3I5./X0.001) in
all subjects combined. Again, the IHA group performed
better overall on the logical memory task (/I - 0.031).
Hypogiycaemia had no effect on the proportion of informa¬
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Usual memory No significant effects of hypoglycemia
were seen. Mean euglycacraia scores of 96.2 (NHA) and
88.3 (111A) from a maximum of 104 indicated marked
ceiling effects. The NHA group scored better (/>~0.O16) on
immediate visual memory.
Discussion
Performance on the novel test of prospective memory was
impaired significantly during the hypogiycaemia studies
and, as learning always took place during euglycaemia, the
results indicate that recall had been disrupted by hypogiy¬
caemia. f he effect size of hypogiycaemia on prospective
memory scores (if) was similar to that for the conventional
memory tests, which suggests that it is a similarly sensitive
measure of hypoglveaemic memory dysfunction. The
prospective memory task is also intuitively more reflective
ofmemory in daily life, where list-learning is rarely relevant.
In the paper upon which it was based, performance on the
video task correlated well with performance on the same task
in a real-life setting [2.1]. The data suggest that people with
diabetes may suffer inability to act on previously made
plans, and thus effectively to organise aspects of their daily
life, as a consequence of hypoglycaemia.
Some limitations of the prospective memory task must
be considered [21]. First, subjects are unable to explore the
environment to obtain further cues if they suspect that an
action is to be performed at a location, but cannot folly
remember it. Second, they are unable to retrace their steps if
an action is recalled after the location has been passed.
Third, to make the task sufficiently difficult, more items are
given than subjects would attempt to remember in real life.
Fourth, subjects are unable to prioritise items and plan their
journey. These points reflect the fact that in real life,
prospective memory performance is not simply detennined
by accuracy of response to cues, but is also dependent on
organisational tmd other strategies. Thus, the effect of
hypogiycaemia on real-life prospective memory may be
more or less than suggested by the present study, depending
on whether these strategies are themselves sensitive or
resistant to hypogiycaemia.
It is also possible that poorer performance during
hypogiycaemia was caused by impairment of cognitive
functions other than memory. The video requited sustained
attention for around 10 min, and attention has been shown
to be impaired during hypogiycaemia [33, 34]. Deteriora¬
tion of visual information processing may have reduced the
subjects' ability to glean information from the video [11,
12]. Alternatively, the results may have resulted from a
general effect on cognition, as very few cognitive abilities
that have been tested during hypogiycaemia have not
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shown deterioration [2]. These distinctions may be neuro¬
psychological rather than practical; whatever the mecha¬
nism, hypogiycaemia impaired the ability to act on
information learned previously, which in everyday life
would be perceived to be a memory problem.
Immediate recall performance for the two verbal mem¬
ory tasks (AV'LT and logical memory) was impaired
significantly during hypogiycaemia, which is consistent
with previous studies [15, 16], Delayed recall was always
tested during euglycaemia, and it can be inferred that the
significant impairment in delayed recall following hypo¬
giycaemia resulted from a hypoglycaemic effect on learning
and/or consolidation. A 'hangover" effect of hypogiycaemia
is unlikely to be responsible, as delayed recall was tested
50 min after restoration of euglycaemia. The only robust
study to show residual cogniti ve impairment demonstrated
this 20 min after hypogiycaemia [35]; earlier studies
reported impaired cognitive function 45-90 min after
hypogiycaemia [8, 36-40], but each had a methodological
deficiency, such its failure to test statistical significance or
the absence of a euglycaemia control arm.
Correction of hypogiycaemia took approximately
20 min, the limiting factors being the continuing insulin
infusion and the maximum infusion rate of hypertonic
glucose solution. The possibility that hypogiycaemia
impaired performance through an effect on consolidation
in the immediate postleaming period cannot be excluded.
However, on this basis it is also relatively unimportant to
separate learning and immediate consolidation, as hypo¬
giycaemia in the daily life of a person with diabetes will not
be reversed more quickly. The practical conclusion that
may be drawn from the verbal memory results is that
hypogiycaemia impairs the learning of information so
that it may be recalled at a later time. For example, if
hypogiycaemia occurred while studying, the student would
be advised to review material that had recently been
examined.
Visual memory was not impaired significantly by
hypogiycaemia, but with mean scores of 93 and 82% for
immediate and delayed recall, respectively, during eugly¬
caemia. a ceiling effect was evident Future work on this
aspect of memory should employ tasks with a larger range
of items, especially more difficult items.
There was no evidence of a different effect of hypogiy¬
caemia in IHA and NHA subjects. This may have been
related to inadequate statistical power for this specific
between-subject analysis. However, with a total of 36
subjects and a repeated-measures design, the study was large
by comparison with others in this research area. There are
some limitations of the between-group comparisons. First,
we cannot exclude overlap, even though our method of
assessing awareness has been shown to be a good predictor
of severe hypogiycaemia at the group level [29], Subjects
Springer
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with similar levels of awareness could receive different
classifications as a result of answering with confidence or
caution. Second, the two groups wore not well matched for
other characteristics, which may have confounded the effect
of hypoglycemia on memory performance, particularly the
duration of diabetes, the presence of microvascular com¬
plications and overall memory performance. For these
reasons, the present study cannot exclude a potential
difference between people with I HA and NHA.
An important consideration is that studies of this type,
which compare group means using a powerful within-
subject design, do not have much power to examine
individual differences in the effects of hypoglycemia on
cognition. There is, in our experience, consistent anecdotal
evidence from both clinical practice and research to suggest
that some individuals are much more susceptible to
hypuglyeaerma-induced cognitive dysfunction than others.
To assess this experimentally is impracticable: for this type
of intensive study, an uncommonly large number of
subjects would be required. However, given the possibility
of inter-individual differences, practical recommendations
to people with diabetes should not be too rigid.
In conclusion, the present study has confirmed that there
is a disruptive effect of hypoglycemia on both the specific
processes of learning and recall, which is relevant to the
behaviour of people with diabetes during daily life. The
prospective memory test appears to be a sensitive measure
of memory dysfunction during hypoglycaemia that may
have greater ecological validity than conventional memory
tests, and lends weight to the use of laboratory data to
derive practical recommendations for people with diabetes.
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Acute Hypoglycemia Impairs Nonverbal
Intelligence
Importance of avoiding ceiling effects in cognitive function testing
Roderick I Warren, ihrcp1
Kate V. Vu s. mrcp1
Andrew j. Sommerfieed, mrcr'
Acute hypoglycemia causes a pro¬gressive, reversible deterioration incognitive function that becomes de
tectable at blood glucose concentrations
below—3.0-3.4 mmol/1 (1). In an earlier
study in nondiabettc subjects, we re¬
ported that several facets of attention de¬
teriorated significantly at an arterialized
blood glucose level of 2.6 mmol/1 (2).
However, performance on Raven's Pro¬
gressive Matrices (RPM) was not signifi¬
cantly impaired at either 20 mm or
completion of the test (with no time
limit). This was unexpected, because,
previously, various domains of cognitive
function had consistently been impaired al
tins level ofhypoglycemia (1). Additionally,
the RPM is acknowledged as being among
the best indicators of general, fluid intelli¬
gence (3) and has a substantial correlation
with workingmemory (4),which is exquis¬
itely sensitive to hypoglycemia (3).
Hypoglycemia disrupts performance
on different cognitive function tests to a
variable degree, leading to speculation
that different mental functions vary in
their sensitivity to hypoglycemia. This is
complicated by a lack of a universally ac¬
cepted battery of cognitive measures and
variable experimental methodology (6,7).
We speculated that the higher-level cog¬
nitive skills required for abstract problem
solving (as in lire RPM) are resistant to the
effects of hypoglycemia. However, this
contradicted a widely held opinion that
IanJ. Deary, pud2
Brian M. Frier, mo1
higher-level skills are more sensitive to
hypoglycemia than simple, repetitive cog¬
nitive or motor tasks (1). An alternative
explanation was the possibilityof a ceiling
effect. as theRPM includes a large propor¬
tion of easy problems that involve
straightforward partem completion, and
mean scores during euglycemia and hy¬
poglycemia were 49,3 and 48.7, respec¬
tively, out of a maximum of 60. The
present study was designed to test the
ceiling effect hypothesis by substituting
two more difficult tests of general fluid
intelligence that are known to be discrim¬
inatory in highly able adults. Raven's Ad¬
vanced Progressive Matrices (RAPM) (.8)
uses harder problems than RPM, which
consist of geometric designs from which
the subject must induce logical rules,
hold the rules In working memory, and
apply them simultaneously to complete a
pattern (9). The Alice Heim 5 test (AH5)
similarly requires identification and ap¬
plication of simultaneous patterns to




volunteers were studied. Their mean
score on the National Adult Reading Test
was 40, which approximates to a Wech-
sler Adult Intelligence Scale-Revised full-
scale 1Q score of 118. Each subject
underwent two hyperinsuliiiemie glucose
clamps,with experimental states of eugly¬
cemia (arieriahied blood glucose 4.3
mmol/1) and hypoglycemia (2.3 mmol/1),
during which subjects completed the
RAPM and AH5. Parallel versions were
created by separating odd- and even-
numbered items, with sets 1 and 2 of the
RAPM being combined. Both the RAPM
and AH5 were scored after 20 min, with
maximum possible scores of 36 for AH5
and 24 for RAPM. Subjects also com¬
pleted the Trail Making B (TMB) and Digit
Symbol Substitution (DSST) tests. The or¬
derofeuglycemia-hypoglycemia and cog¬
nitive test battery was counterbalanced
and included as a between-subject factor
In repeated-measures ANOVA
RESU ITS— The scores are given in Ta¬
ble 1 as means (±SD), except TMB, which
is given as completion time in seconds. Per¬
formance on TMB, DSST, and. RAPM dete¬
riorated. significantly during hypoglycemia,
with a trend toward deterioration on AH5.
The effect size of hypoglycemia on RAPM
was substantial, amounting to approxi¬
mately three-quarters of an SD,
CONCLUSIONS- These results
suggest that our earlier findings were in¬
deed due to a ceiling effect (2) and indi¬
cate that hypoglycemia does impair
general fluid intelligence, but it is neces¬
sary to use a test appropriate to ihe ability
level of the participants. Research volun¬
teers tend to he more able than the pop¬
ulation they are intended to represent,
and the ceiling effect may be common in
studies of hypoglycemia. Care should be
taken to avoid the ceiling effect, and,
while general consensus cm cognitive test¬
ing is desirable., a single battery of cogni¬
tive tests for all subjects may be
inappropriate (7).
The different results for RAPM and
AH5 may reflect differences in the stan¬
dard administration of these tests; paper
working is permitted for the AH3 but not
for the RAPM. Holding and applying rules
entirely in working memory is demand¬
ing (8), and as we have preciously shown
that working memory is obliterated by
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Nomtrhtd 'mii iUgaax ami acute hyinrgtycemui
Table I —Cognitive function scores during cuglyeemur and hypoglycemia, plus significance
level and effect size for comparison
Test Euglycemia Hypoglycemia P
RAPM L8.9 ± 3. i 16.5 ± 3.5 0 007 0.465
AH3 15.6 7: 5.6 i.3.9 ± 5.0 0 037 0.269
1MB 38.8 ±8.2 46.3 ± .16 1 0 037 0.339
DSST 87,7 ± 12.5 79.4 ± 9,3 0.019 0.409
Data ate rneam ± SD.
moderate hypoglycemia (.3), it is likely
that this had a greater impact on RAPM
than AH3.
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Abstract
Background and aims People with insulin-treated diabetes commonly
experience symptoms of hyperglycaemia, but die nature of these symptoms
and their origins are poorly understood, 'lire aims of this study were (1) to
identify and classify the symptoms of hyperglycaemia experienced by people
with insulin-created diabetes and (2) to identify patient characteristics asso¬
ciated with intensity of. and glycaemic threshold for. glycaemic symptoms.
Methods Common hyperglycemic symptoms were identified from prelim¬
inary interviews. Eighteen symptoms were used in a questionnaire. Four
hundred participants estimated the intensities with which they experienced
these symptoms during hyperglycaemia. Principal components analysis (PCA)
was used to examine correlations between symptoms. Associations between
symptom intensity, glycaemic threshold, and other characteristics were exam¬
ined with multiple regression.
Results In total. 36.1 participants (90.2%) reported experiencing hypergly-
caemlc symptoms. PCA suggested four symptom groupings: (1) feeling tense,
irritability, restlessness, poor concentration (agitation) (2) thirst, dry mouth,
need to urinate, trot feeling right, sweet/funny taste, weakness (osmotic)
(3) dizziness, blurred vision, light-headedness, weakness (neurological)
(4) headache, nausea (malaise). Mean symptom intensitywas associated with
younger age. The median (range) estimated blood glucose threshold for symp¬
tom onset was IS (8-30) mmol/U there was a weak tendency for this thresh¬
old to be elevated in people who had impaired hypoglycemia awareness.
Conclusions People with insulin-treated diabetes commonly repotted
symptoms associated with hyperglycaemia. PCA separated these into four
groups. Osmotic symptoms appear to be specific to hyperglycaemia; symptoms
in the other groups may suggest underlying physiological mechanisms, but
are relatively non-specific. Symptoms are more intense In younger people and
may be repotted at lower blood glucose concentrations in people with normal
awareness of hypoglycaemta. Copyright >© 2003 JohnWiley & Sons, Ltd.
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Introduction
People with diabetes are commonly exposed to fluctuations in blood glucose
into hypo- and hyperglycaentic ranges. The symptoms of hypoglycemia have
Copyright 2003 Jolm Wiley & Sons, Ltd.
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been described in detail, and their generation has been
studied using different approaches [1]. These include
experimentally induced hypoglycaemia with the use of
different forms of pharmacological blockade [2,3], and
statistical analysis of symptoms that had either been
described during experimental hypoglycaemia [4] or
derived from population surveys [5,6]. The statistical
techniques of principal components analysis (PCA)
and confirmatory factor analysis have been used to
identify discrete groups, or domains, of symptoms, which
correspond to underlying physiological mechanisms, and
in adults include ncurogfycopenic, autonomic, and mahstee
groups [1,6].
Symptoms of hyperglycaemia are often present at
the time of diagnosis of diabetes, and the classical
osmotic symptoms include thirst, polyuria, and nocturia
[7]. However, there are few experimental studies
of the symptoms of hyperglycaemia. When acute
hyperglycaemia was induced by a hyperinsulinaemic
glucose clamp technique, only one symptom (the need
to urinate) was positively associated with this state [8].
However, hyperglycaemia induced by this method may
not reflect everyday experience. In another study, many-
subjects reported symptoms that correlated positively with
blood glucose concentrations [9], but these symptoms
varied widely between subjects and subsequently were
found to be unstable over time [10]. A study of all
symptoms in type 2 diabetes listed thirst, dry mouth,
polyuria, and polydipsia as symptoms of hyperglycaemia,
but this study did not focus specifically on acute
hyperglycaemia [11].
In our experience, people with insulin-treated dia¬
betes recognize various unpleasant symptoms that are
associated with transient hyperglycaemia, which may
prompt them to measure blood glucose and modify
their treatment. The perception of the development of
hyperglycaemic symptoms may assist the individual to
improve glycaetnic control, and the early treatment of ele¬
vated blood glucose may prevent progression to metabolic
decompensation. The principal aims of the present study-
were to determinewhich symptoms ofhyperglycaemia are
commonly reported by people with insulin-treated dia¬
betes, and to ascertain whether any underlying structure
could be identified to assist with the classification of the
symptoms. Secondary aims were to determine whether
the intensity of, and giycaemic threshold for, symptoms
of hyperglycaemia are related to the coexisting state of
hypoglycaemia awareness, the quality of giycaemic con¬




A pilot study was performed to identify die possible
symptoms of hyperglycaemia. Seventy patients with
Copyright C 2003 John Wiley & Sons, Ltd.
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insulin-treated diabetes were asked to report, in an open-
ended manner, symptoms that they associated with a
high blood glucose. Their reports were grouped together
as symptoms when identical wording was used or when it
was clear that the same sensation was being described. A
total of 25 different symptoms were reported, 17 of which
were reported by more than one person (Table 1). In
formulating the symptom questionnaire, one additional
symptom (an increase in salivation) that had been
reported by more than one subject in a previous study
[9] was incorporated. These 18 symptoms were used to
compile the symptom questionnaire for the main study.
Patients participating in the pilot study did not take part
in the main study.
Subjects
To provide a robust solution using principal components
analysis, the most cautious estimate of the number of
subjects required is 10 times die number of variables
under examination [12]. With 18 symptoms in the
questionnaire, 180 subjects should suffice. A target of
400 subjects was set to provide a large safety margin.
Approval for the study was granted by the local
research ethics committee. People were recruited during
their routine visits at diabetes outpatient clinics in
the Department of Diabetes at the Royal Infirmary of
Edinburgh. Patients were eligible if they had received full
insulin therapy for at least one year, had performed self-
monitoring of blood glucose (irrespective of frequency),
and were capable, in the opinion of the investigator, of
answering die questionnaire. Patients using insulin at
bedtime only were excluded, but any full-time regimen
(twice daily injections or more often) was permitted. All
consecutive patients who met the inclusion criteria and
who consented to take part were recruited until the target
of400was achieved. Characteristics of the participants are
shown hi Table 2. Written informed consent was obtained
before the questionnaire was applied.
Table 1. Symptoms associated with hyperglycaemia reported
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Table 2. Characteristics of insulin-treated diabetic subjects com¬
pleting symptom questionnaire
Total Type 1 Type 2
n 400 288 112
Male (%) 229 (57.3) 173 (60.1) 57 (50.9)
Median age, in years (range) 49(18-84) 41 (18-79) 66 (35-84)
Median duration of diabetes. 14(1-59) 15(1-59} 12(4-36)
in years (range)
Median duration of insulin 11 (1-59) 15(1-59) 4(1-33)
therapy, in years (range)
MeanHbAic (SD) (%) 8.6(1.3) 8.6(1.4) 8.7(1.3)
Questionnaire
Each subject completed the questionnaire once. Subjects
provided estimates, on the basis of prior experience, of
the intensity with which they usually felt each symptom
during periods of hyperglycaemia ('when your blood
glucose level is high'). Hyperglycaemia was not defined
more explicitly in terms of blood glucose concentration.
Estimates of symptom intensity were recorded on a visual
scale from 1 ('not at all') to 7 (Very strongly'). The
participants were asked to indicate the approximate level
ofblood glucose atwhich theywould expect to experience
hyperglycemic symptoms, on the basis of previous blood
glucose testing, and to describe any other symptoms
that they associated with hyperglycaemia. In addition,
they were asked to rate their symptomatic awareness
of hypoglycaemia on a visual scale from 1 (always
aware) to 7 (never aware) (13). Duration of diabetes and
duration of insulin therapy, details of concomitant drug
therapy, and most recent glycated haemoglobin (HbAp )
measurements were recorded. Glycated haemoglobin was
measured by high-performance liquid chromatography
(BioRad Variant 2, Hemel Hempstead, UK: local non-
diabetic range 5.0-6.5%).
Principal components analysis
Data were analysed using SPSS 11.0 (SPSS, Chicago,
1L). Correlations among the intensity ratings of the 18
symptoms were examined using principal components
analysis. We refer the interested reader to the monograph
by Child [12] for an accessible explanation of this tech
tuque. Briefly, this procedure examines the correlations
among measured variables to determine whether there
are groups of variables that occur together. This could be
done informally: it might, for example, be apparent from
inspection ofcorrelation coefficients that there were three
groups of symptoms, such that symptoms were strongly
correlated with other symptoms in the same group but
only weakly correlated with symptoms in other groups. In
this hypothetical case, the entire data set could be reduced
to three 'factors', each representing a group of variables
from the original data set. It the within-group correlations
had been high, then this process would greatly simplify
the data set with only minimal loss of information. The
value of this technique in examining symptoms arises from
Copyright \ 2003 John Wiley & Sons, Lid.
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the fact that symptom grouping may hint at underlying
physiological processes. For example, in previous studies,
the symptoms of confusion, odd behaviour, inability to
concentrate, drowsiness, and difficulty in speaking were
highly correlated and were interpreted as the effects of
neuroglycopenia; whereas hunger, sweating, trembling,
anxiety, and a pounding heart formed a separate, highly
correlated group, which was interpreted as the effects of
autonomic activation [4-6].
Principal components analysis (PCA), sometimes
referred to as factoranalysis, is a statistical tool for extract¬
ing components that simplify the data, while retaining as
much information ;rs possible. Technically, components are
computed hist and then undergo amathematical transfor¬
mation called rotation to yield more easily interpretable
•factors'. Although there is a technical difference between
'component' and 'factor', for the sake of clarity, readers
may consider component and factor to be interchange¬
able here. The variance explained by a factor indicates
the amount of information from the original data that is
contained within the computed factor. PCA initially gen¬
erates the same number of components as the number of
symptoms under examination, but most explain very little
variance. Only components that usefully simplify the data
are considered significant, and these are determined by
selection of those that are outliers on a plot of variance
(the scree-slope criterion) and/or those that explain more
variance than a single variable horn the original data (the
'eigenvalues greater than one' criterion).
PCA factors are mathematical constructs and their
interpretation relies on factor loadings, which are the
correlations between the original symptom scores and
the extracted factors. Factors are considered to represent
those symptoms with which they have moderate to high
correlations. A cutoff for the correlation coefficient of 0.3
to 0.4 is generally applied [12], although this remains
somewhat arbitrary. The internal consistency of the
grouping of symptoms suggested by this method may
be confirmed by computing Cronbach's Alpha statistic.
Other statistical methods
Mean symptom intensity scores for each subject were
calculated as the arithmetical means of the scores for
each variable. Associations between these scores and other
characteristics of the participants were investigated with
Spearman rank correlations, Mann-Whimey U tests, and
linear regression techniques. Scatter plots were examined
for correlations to exclude artefacts from outlying cases.
Results
Symptom endorsements
Of the 400 respondents, 361 (90.2%) identified one or
more of the 18 symptoms as associated with hypergly¬
caemia. The five most commonly endorsed symptoms
DiabetesMeiab Res Rev 2003; 19: 408 - 414.
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were 'thirst', 'dry mouth', "not feeling right', 'need to uri¬
nate', and 'tiredness'. The absolute endorsement frequen¬
cies (i.e. any response gieater than 'not at all'} and the
mean scores [1-7] for each symptom are given in Table 3.
Principal components analysis
Two of the 18 symptoms ('stomach ache' and 'increased
salivation') had absolute endorsement levels below
20%. Weakly endorsed variables cannot be reliably
interpreted by PCA, and these symptoms were excluded
from subsequent analysis. PCA was performed on
Table 3. Mean intensity scores and absolute endorsement rates
for each symptom
Mean Absolute
Symptom score (SD) endorsement {%)
Thirst <1.06 (2.05) 79.5
Dry mouth 4.09 (2.09) 78.7
Nat feeling right 3.80 (2.08) 75.6
Need to urinate 3.71 (2.35) 64.5
Tiredness 3.30 (2.23) 61.5
Irritability 2.80(2.18) 48.2
Poor concentration 2.59 (1.96) 47.9
Weakness 2.36(1.85) 43.2
Sweet/funny taste 2.53 (2.09) 41.0
Restlessness 2.30 (1.88) 40.2
feeling tense 2.19(1.82) 38.0
Headache 2.12(1.81) 34.1
Blurred vision 1.81 (1.45) 29.4
Light headed 1.80(1.53! 26.9
Nausea 1.80(1.54) 26.6
Dizziness 1.70(1.50) 22.4
Stomach ache 1.42(1.17) 13.9
Increased saliva 1.34(1.07) 11.9
qu
symptoms' data from the 361 subjects, who reported
any hyperglycemic symptoms, using the remaining 16
symptoms. The first unrelated principal component has
strong loadings (0.47 or greater) from all symptoms
(Table 4} and accounts for 37,7% of the total variance.
The high loadings and high internal reliability (Cronbach's
Alpha 0.89) indicate that it is a general hyperglycaemic
symptoms' component. Because of this, rotation was
performed using the Direct Oblimin method, which
permits factors to be correlated (non-orthogonal).
A four-factor solution was appropriate, based on
both eigenvalues greater than one and scree-slope
inspection. Variances accounted for by each factor
and loadings from each of the 16 symptoms are
shown in Table 4. Factor loadings greater than 0,35
were considered significant. The first factor ('feeling
tense', 'irritability', 'restlessness', and 'poor concentration')
contains symptoms that appear to have in common some
aspect of mental agitation. The second factor (thirst', 'dry
mouth', 'need to urinate', "not feeling right', 'sweet or
funny taste', mid 'weakness') mainly represents symptoms
resulting from the osmotic effects of hypergiycaemia.
The third factor ('dizziness', 'blurred vision', 'light¬
headedness', and 'weakness') contains symptoms similar
to those designated neurogiycopenk in previous studies
of hypoglycaemic symptoms using factor analysis [4-6],
although neurological may be a better nomenclature in
the present context. The fourth factor has strong loadings
from 'headache', "nausea", and 'sweet or funny taste".
Headache and nausea also appeared as a factor (labelled
malaise) in hypoglycaemia studies [4-6],
The total variance explained by the four-factor model is
62.9%. The factors are correlated, and so the sum of the
Table 4. Results of principal components analysis of symptom intensity scores, with
Direct Oblimin Rotation
Rotated factots













Symptom Component loadings Pattern matrix loadings
Thirst 0.51 -0.13 -0.89 0.03 -0.03
Dry mouth 0.57 -0.10 -0.82 0.03 0.14
Not feeling right 0.70 0.01 -0.41 0.14 0.15
Need to urinate 0.44 0.08 0.73 -0.16 0.05
Tiredness 0.62 0.36 0.20 0.33 -0.07
Irritability 0.65 0.80 0.05 -0.04 0.08
Poor concentr'n 0.67 0.56 0.09 0.29 -0.07
Weakness 0.61 0.18 0.40 0.47 -0.26
SweeVodd taste 0.57 0.14 0.42 -0.06 0.43
Restlessness 0.63 0.78 -0.03 -0.06 0.13
Feeling tense 0.58 0.87 -0.11 -0.03 -0.04
Headache 0.51 0.08 0.05 0.07 0.73
Blurred vision 0.45 -0.09 -0.06 0.76 0.08
Light-headedness 0.62 0.08 -0.03 0.73 0.14
Nausea 0.48 0.01 0.02 0.17 0.69
Dizziness 0.59 0.03 -0.06 0.83 0.07
Factor loadings greater than 0.35 are highlighted,
concentr'n, concentration.
Copyright C- 2003 John Wiley & Sons, hid. Diabetes Metab Res Rev 2003; 19: 408-414.
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individual variances exceeds this total. Cronbach's Alpha
was calculated as a measure of internal consistency for
the general hyperglycaemia factor and each of the four
rotated factors (Table 4). All except the malaise factor
had high internal consistency coefficients (>0.7).
Sub-group analyses
Because of the large number of participants, it was
possible to repeat, the PCA using sub-groups. For
comparison based on glyeaemic control, the original data
were divided into two groups of participants with HbAjc
above and below the median. For comparison based on
hypoglycaemia awareness, the data were divided into
those participants who gave a rating of I or 2 (normal
awareness) and those who gave a rating of 3 to 7
(impaired awareness) [13]. In each sub-group analysis,
essentially the same symptoms loaded onto the same four
factors as hi the analysis of the full data set. Results of
sub-group analyses are not shown.
Factors associated with symptom
intensity and estimated glycaemic
threshold
A mean symptom intensity score was calculated for each
participant as the mean of scores for the 16 symptoms.
Spearman rank correlations were calculated between
this score and the following independent variables: age,
duration of insulin therapy, hypoglycaemia awareness
rating, and current HbAic. The full data set (n = 400)
was used; participants repotting no symptoms had the
minimum mean score of 1. A strong negative association
with age (/> = -0.437, p < 0.001) and a small positive
association with HbAu (p — 0.149. p — 0.003) were
observed. Mann-Whitney U tests were used to assess the
effects of the binary variables sex, type of diabetes, and use
ofbeta-adrenoceptor blocking drugs. Subjects' gender and
use of beta-blockers were not associated with significant
differences in mean symptom score. Subjects with type 1
diabetes had higher median reported symptom intensities
than subjects with type 2 diabetes (2.41 vs 1.82, 2-tailed
z = -3.867, p < 0.001).
A total of 340 subjects (85%) were able to estimate
a glycaemic threshold for the onset of symptoms of
hyperglycaemia. The mean (range) estimated threshold
was 15.1 (8-30) mmoI/L. The estimated threshold was
examined for associations with the same independent
variables. Significant correlations were observed for
duration of insulin therapy (p — 0.157,p = 0.004) and
hypoglycaemia awareness (p = 0.204.p < 0.001). No
significant associations were observed for age, HbAic,
sex, type of diabetes, or use of beta-blockers.
Multiple regression models were constructed, with
mean symptom score and estimated glycaemic threshold
separately entered as the dependent variables. The seven
independent variables used above were entered in each
model, with stepwise removal of non-significant variables.
Results are given in Table 5. With mean symptom intensity
as tire independent variable, there was a significant
negative associationwith age and a statistically significant
but small positive association with HbAu-; the total R1 for
thismodel was 0.197.With estimated glycaetnic threshold
as the independent variable, there were statistically
significant but small associations with hypoglycaemia
awareness, age, HbA-lc, and sex; however, the variance
explained bythis model wasvery small (total ft2 = 0.118).
Other symptoms of hyperglycaemia
With open-ended questioning, 68 (17%) subjects repotted
hyperglycaemic symptoms other than the 18 included in
the questionnaire. The commonest were sweating (15
subjects), muscular ache (14 subjects), a flushed or warm
sensation (14 subjects), and heavy or stiff limbs (10
subjects). Various other symptoms were each reported by
fewer than five subjects.
Discussion
In the present study, 90% of adults with insulin-treated
diabetes reported experiencing symptoms associated with
hyperglycaemia. When symptoms were examined using
PCA, it was observed that the co-variation between
intensity scores for tiie 16 most commonly reported
symptoms could be accounted for by 4 factors. On the
Table 5. Results of multiple regression analyses
Dependent Independent ft2 change Standardized
variable variable (total ft2 > beta P
Mean score for 16 Age 0.182 -0.410 -.0.001
principal symptoms HbAu 0.015 0.125 0.007
(0.107)
Blood glucose Hypoglycaemia awareness 0.062 0.259 *0.001
threshold for onset Age 0.020 0.160 0.003
of symptoms HbAic 0,018 0.154 0.005
Sex (o = male, s = female) 0.018 -0.137 0.012
(0.118)
Only associations yielding p < 0.05 are shown.
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basis of the symptoms associated with each factor, they
have been labelled here as neurological, osmotic, mental
agitation, and malaise.
One of the most striking aspects of these results
is the similarity between symptoms of hyperglycinemia
and hypoglycaeniia. Two of the four factors are similar
to factors that were labelled 'neuroglycopenic' and
'malaise' when derived from hypoglycemic symptoms.
The first hyperglyeaemia factor, apparently representing
mental agitation, includes poor concentration (also one
of the neuroglycopenic symptoms of hypoglycaemia),
and irritability and restlessness, which are described
during hypoglycaemia in children [14,15], Clearly,
neuroglycopenia is unlikely to be the cause of symptoms
in hyperglycemia, but its generation may have a
neurological basis by the direct effect of hyperglycaeinia
on cerebral function. However, clinical experience relates
that these symptoms may also be reported by people who
are unwell with various illnesses. It may be that these
are non-specific symptoms associated with systemic upset
of any sort, segregated by factor analysis into groups
representing physical and mental malaise.
Osmotic symptoms were the most strongly endowed
symptoms of hyperglycaeinia in this study. Symptoms
of thirst, dry mouth, and need to urinate have
not been associated with hypoglycaemia, and these
symptoms appear to be specific for hyperglycaemia.
The autonomic symptoms of hypoglycaemia (sweating,
palpitations, shaking, and hunger) did not also appear as
hyperglycaemic symptoms in this study. It would appear,
therefore, that the two states may Ire best distinguished
by the presence of osmotic or autonomic symptoms,
whereas a variety of mental and physical symptoms may
be common to both. Incidentally, it was noted that many
subjects reported that symptoms of tiredness and aching
muscles were more common during early hyperglycaemia,
whereas thirst and increased urination emerged withmore
prolonged or severe hyperglycaemia. It is plausible that
osmotic symptomswould be delayed, as theymay result in
part from dehydration due to increased urine formation.
Participants were not formally asked about symptoms
at different levels or durations of hyperglycaemia, and
so die study design did not permit assessment of this
putative association. However, an absence of osmotic
symptoms in early hyperglycaeinia would be expected
to make identification of this state more difficult. The
ability to distinguish between hypo- and hyperglycaemia
could be further impaired in people whose autonomic
symptoms of hypoglycaemia are diminished in association
with long duration of diabetes or frequent exposure to
hypoglycaemia [1]. Previous studies have confirmed that
estimation of blood glucose from symptoms is unreliable
in many patients [8,16,17].
The symptoms of hyperglycaemia identified in this
study are similar to those reported in other studies
[8,9,11]. Some subjects also reported symptoms of
hyperglycaemia other than those included in the
questionnaire, most commonly sweating, myalgia, a
flushed orwarm sensation, and heavy or stiff limbs. These
Copyright • 2003 JohnWiley & Sons, Ltd.
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symptoms were reported rarely, although it is possible
that more frequent endorsement would have resulted
from prompted questions. Future studies should include
these symptoms.
Regression analyses were used to examine the influence
of various subject characteristics on mean symptom
intensity and the estimated glycaemic threshold for
the onset of symptoms. Age was modestly associated
with mean symptom intensity, with older respondents
reporting less intense symptoms. The estimated glycaemic
threshold was weakly associated with hypoglycaemia
awareness, such that people with diminished awareness
of hypoglycaemia tended to report higher glycaemic
thresholds for hyperglycaemic symptoms. This association
may be explained by tolerance to both hypo- and
hyperglycaemic extremes in individuals with erratic blood
glucose control, or by a defect in glucose sensing leading
to a single state of unpaired glycaemic awareness.
The variances explained by these models were modest,
indicating substantial individual variation and limiting
the reliability of associations.
Further research in this area should include studies
to determine the threshold for hyperglycaemic symp¬
toms under experimental conditions, with comparisons
between diabetic people with normal and impaired hypo-
glycaemia awareness, and strict and poor glycaemic
control. It would also be pertinent ro determine how
soon symptoms develop after the onset ofhyperglycaemia,
whether the duration and degree ofhyperglycaemia affect
the nature and correlational structure of die symptoms
experienced, and whether the four groups of symptoms
identified in the present study are differentially affected.
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